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ZUSAMMENFASSUNG 
 
Brustkrebs ist die häufigste Krebsart bei Frauen und verursacht die meisten krebsbedingten Todesfälle.  
Die molekularen Mechanismen dieser Krankheit sind vielschichtig und tragen zur Komplexität der 
Krankheit bei. Eine frühzeitige Diagnose und genaue Charakterisierung des Tumors verbessert die 
Prognose für die Patientin erheblich. Eine begrenzte Zahl von Brustkrebsmarkern wird bereits zur 
Diagnose, Charakterisierung und Bestimmung der vielversprechendsten Therapie herangezogen. Und 
obwohl neue Therapieansätze, wie zum Beispiel Herceptin-Antikörper, zur Verfügung stehen, besteht 
dringender Bedarf an weiteren, krebsspezifischen Markern. Ein Hauptkriterium für die Beurteilung 
eines Tumors ist das Vorhandensein des Östrogenrezeptors alpha (ERα). Patientinen mit ERα-
positiven Tumoren haben eine bessere Prognose, da diese Tumore weniger aggressiv sind und oft auf 
die Anti-Östrogen Therapie ansprechen. ERα ist ein Östrogen-induzierbarer Transkriptionsfaktor, der 
die Expression von Östrogen-sensitiven Genen moduliert. Diese Gene spielen unter normalen 
physiologischen aber auch unter pathologischen Bedingungen, wie beispielsweise Brustkrebs, eine 
Rolle. Obwohl die Regulationsmechanismen sehr komplex sind, konnten verschiedene aktivierende 
Mechanismen identifiziert werden. Die Mechanismen der Genrepression werden erst langsam 
aufgedeckt, wenngleich etwa 50 % der Östrogen-sensitiven Gene reprimiert werden.  
Das Ziel dieser Promotionsarbeit bestand in der Untersuchung der Expression und Regulation des 
BASE Genes (Brustkrebs und Speicheldrüsen exprimiertes Gen). Die Untersuchung dieses Genes war 
aus zwei Gründen interessant: Erstens, seine Expression wird durch Östrogen stark unterdrückt, was 
auf eine Beteiligung des ERα bei der Regulation hinweist. Und zweitens deutet eine vorausgehende 
Studie darauf hin, dass dieses Gen hauptsächlich in Brustkrebszellen und der Speicheldrüse exprimiert 
wird. Damit könnte BASE eventuell als neuer Brustkrebsmarker fungieren. 
Eine Haupterkenntnis dieser Arbeit ist die strikte Trennung von Expression und Regulation von 
BASE. Während der Transkriptionsfaktor FoxA1 für die Expression unentbehrlich ist, spielt dieser in 
der Regulation keine Rolle. Diese Studie zeigt weiterhin, dass das BASE Gen in Abhänigkeit von ERα 
sehr schnell durch Östrogen reprimiert wird. Die direkte Bindung von ERα an die DNS scheint dabei 
nicht notwendig zu sein. Es ist denkbar, dass ERα auch über Protein-Protein-Interaktionen zum BASE 
Promoter rekrutiert wird. Aufbauend auf den Ergebnissen dieser Arbeit werden zwei Modelle für den 
Repressionsmechanismus von Östrogen am BASE Gen vorgeschlagen.   
In Zusammenarbeit mit der Arbeitsgruppe von Prof. M. Kerin (Galway, Irland) wurden Brustgewebe-
proben auf die Expression von BASE untersucht. Etwa 50 % der Proben waren postiv für BASE 
mRNA. Obwohl sehr geringe Mengen von BASE mRNA auch in nicht Tumorproben nachgewiesen 
werden konnte, bleibt BASE weiterhin ein interessanter Kandidat für einen neuen Brustkrebsmarker, 
da das Expressionlevel in gesundem Gewebe etwa 30-fach niedriger ist als in den Tumorproben.  
In einem Nebenprojekt wurde die Aktivierung von Genen durch Östrogen am Beispiel von Cathepsin 
D untersucht. Neben dem schon sehr gut charakterisierten proximalen Promoter wurden in früheren 
Studien bereits zwei weitere Bindestellen für ERα, 9 kb und 33 kb vom Transkriptionsstart entfernt, 
identifiziert. Diese Arbeit bestätigt die Bindung von ERα und DNS Polymerase II an das 9 kb 
entfernte Motif und dessen Fähigkeit, die Stimulation durch Östrogen zu vermitteln. Ob für die 
transkriptionelle Aktivierung eine physische Interaktion zwischen dem proximalen Promoter und dem 
ERα bindenden Motif notwendig ist, wird zur Zeit noch untersucht. 
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SUMMARY 
 
In women, breast cancer is the most common cancer and accounts for most cancer deaths. The 
molecular mechanisms underlying this pathology are diverse and contribute to the complexity of the 
disease. Early diagnosis and detailed molecular characterization of tumours significantly increase the 
prognosis for the patients. A limited number of breast cancer markers are already used for diagnosis, 
characterization, and determination of the most promising therapy of breast cancer tumours. Although 
new therapeutic approaches such as herceptin antibodies are now available on the market, new 
markers that are specific for a subset of breast cancer patients are urgently needed. A major criterion in 
breast cancer diagnosis is the presence of the estrogen receptor alpha (ERα) which is associated with 
better prognosis and often sensitivity to anti-estrogen therapy. ERα is a ligand-inducible transcription 
factor that modulates expression of estrogen responsive target genes involved in both, physiological 
and pathological conditions such as breast cancer. Despite the complexity of the regulatory 
mechanisms, a variety of mechanisms resulting in transcriptional activation of target genes have been 
characterised. Although about 50 % of estrogen-responsive genes are repressed in response to estrogen 
treatment, the mechanisms underlying this regulation are just beginning to be discovered.  
This thesis aimed to study expression and regulation of the breast cancer and salivary gland expression 
gene (BASE). The evaluation of this gene was interesting for two reasons: firstly, its expression is 
strongly repressed by estrogen suggesting involvement of ERα, and secondly, previous studies 
indicate that the expression of this putative secreted protein is restricted to breast cancer cells and 
salivary gland. Therefore, BASE has the potential to function as a new breast cancer marker.  
One major finding of this study is the strong separation of expression and regulation of BASE. 
Expression of the gene is depending on the transcription factor FoxA1, which binds in a regulatory 
region about 2 kb upstream of the transcription start site. Although essential for expression, FoxA1 has 
no function in BASE regulation.  
Furthermore, this study shows that the BASE gene is rapidly repressed after estrogen-treatment and 
that ERα is required for this regulation. ERα can bind the BASE promoter in the same regulatory 
region as FoxA1, however, direct binding seems not to be a critical prerequisite. Based on the data 
obtained in this study, two molecular models for the mechanism of repression are proposed.  
Furthermore, analysis of normal and primary breast tumour samples in collaboration with M. Kerins 
group in Galway confirmed BASE expression in about 50 % of the samples. Therefore, BASE remains 
an interesting candidate as breast cancer marker.  
  
In a side project investigating the mechanism of estrogen mediated activation of target genes, the 
CTSD gene has been further characterized. Besides the well characterized proximal promoter, the 
functionality of two further ERα binding sites, located 9 kb and 33 kb upstream of the transcription 
start site, have been reported. This study confirmed binding of ERα and PolII to the 9 kb upstream 
enhancer and moreover, the ability of this site to convey estrogen-stimulation was confirmed. Whether 
the enhancer requires physical interaction with the proximal promoter to enable transcriptional 
activation remains to be further examined.  
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INTRODUCTION 
1. General introduction – estrogen receptor and disease  
Estrogens, such as 17ß-estradiol (E2), are primarily known as female hormones although they have 
many diverse functions in both men and women. They control physiological functions such as fertility, 
cell proliferation, fat and bone metabolism, cardiovascular and neuronal activity (for review see 
Norman and Litwack, 1987; Auchus and Fuqua, 1994; Mendelsohn and Karas, 1999). In addition, 
estrogens play a critical role in diseases like osteoporosis (Horowitz, 1993), breast and endometrial 
cancers (Henderson et al., 1988), arteriosclerosis (e.g. Rackley, 2004), cardiovascular disease 
(Mendelsohn et al., 1999), and Alzheimer’s disease (Honjo et al., 2001). 
Estrogens belong to the steroid hormone family. These lipophilic polycyclic hormones are derived 
from cholesterol, and also include androgens, mineralcorticoids, and glucocorticoids. In females, 
estrogens are synthesized in the granulosa cells of the mature ovary before menopause, and in adult 
men in the adrenals, testes and adipose tissue. Minor amounts of estrogens are also produced in 
skeletal muscle, skin, adipose tissue, brain, and bone (reviewed in Simpson, 2000), and are transported 
by the blood stream to their target tissues. There, the hormones either bind to membrane-associated 
receptors thereby initiating signalling cascades, or freely diffuse into the cell where they bind their 
cognate intracellular receptors, the estrogen receptors (ERα and ERβ), which then function as 
transcription factors in the nucleus. 
 
2. The nuclear receptor family  
The estrogen receptors belong to the superfamily of nuclear receptors. This family comprises 48 
family members which are divided into six evolutionary groups. Nuclear receptors function as 
transcription factors. Interestingly, despite their highly conserved structural organisation, the functions 
and mechanisms of action are very diverse. Their actions can be genomic or non-genomic, ligand-
dependent or independent, and contribute to gene activation, gene repression, or release of gene 
repression (reviewed in Germain et al., 2006). Two receptor subtypes can be distinguished. Type 1 
acts as homodimer while type 2 to acts as heterodimer after ligand binding. Type 1 comprises the 
steroid receptors for estrogens (e.g. estradiol; ERα (NR3A1) and ERβ (NR3A2)), glucocorticoids (e.g. 
cortisol; GR (NR3C3), mineralcorticoids (e.g. aldosterone; MR (NR3C2)), progestins (e.g. 
progesterone; PR (NR3C1)), and androgens (e.g. testosterone; AR (NR3C4)). Non-steroid hormone 
receptors such as vitamin D receptor (VDR (NR1I1)), thyroid hormone receptor (TR (NR1A)), 
retinoic acid receptor (RARα (NR1B1), RARβ (NR1B2), RARγ (NR1B3)), peroxisome proliferator-
activated receptor (PPAR (NR1C)) act predominantly as heterodimers with the retinoic X receptor 
(RXR (NR2B)). For a number of nuclear receptors, so-called orphan receptors, the natural ligands 
have not been identified or may not exist (for review see Mangelsdorf et al., 1995).  
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2.1 The estrogen receptors  
The effects of estrogen are mediated by its cognate receptor proteins, estrogen receptors ERα and ERβ 
(for review see McDonnell and Norris, 2002). Both subtypes recognize the same DNA motif, the 
estrogen response element (ERE), and function as ligand-inducible transcription factors. They thereby 
provide a direct link between signalling molecules and transcriptional response.  
However, depending on the nature of ligand, posttranslational modifications, cofactor interactions or 
promoter response elements ERs mediate distinct functions (for review see Pelletier, 2000; Moggs and 
Orphanides, 2001). For example, the selective estrogen receptor modulator (SERM) tamoxifen 
functions as a cell- and tissue specific agonist-antagonist for ERα on ERE-based reporter genes, but as 
a pure antagonist for ERß (Watanabe et al., 1997; Barkhem et al., 1998; Tremblay et al., 1998). The 
opposite effect has been demonstrated with Jun/Fos on AP-1 elements. When bound to the natural 
hormone estradiol, ERα activated transcription while activation via ERß was inhibited. In contrast, in 
complex with antagonists (e.g. tamoxifen) ERß functioned as a potent transactivator (Paech et al., 
1997). Moreover, when bound to estradiol, ERα and ERß can form homo- and heterodimers. And 
although ERα seems to be the functionally dominant partner in the ERalpha/beta heterodimer it is 
possible that combining the properties of the two partners gives rise to novel functions (Li et al., 
2004). Other important aspects are the different tissue distribution and levels of expression of the two 
receptors. While ERα is mainly expressed in the anterior pituitary, uterus, vagina, testis, liver and 
kidney, ERß is predominant in thyroid, skin, bladder, lungs, gastro-intestinal tract and cartilage. In 
tissues where both receptors are present (ovary, mammary gland, testis, brain) the expression pattern 
observed is cell type-specific (Pelletier, 2000). Even more complexity is added by the estrogen 
receptor related proteins (ERRα, ERRβ, and ERRγ), which are currently classified as orphan 
receptors. These receptors were identified by sequence similarity to ERα and share target genes, 
regulatory proteins and sites of action with the ERs (for review see Giguere, 2002). Altogether, the 
relative ratios of ERα, ERß, and ERRs in different cell types play an important role in modulation of 
the cellular responses to estradiol. 
 
2.1.1 The estrogen receptor alpha 
The existence of high affinity binding proteins for estrogens was first described in the 1970’s (Toft 
and Gorski, 1966; Jensen, 1966). However, it took another 20 years until the gene was identified and 
cloned (Walter et al., 1985; Green et al., 1986). The gene consists of 8 exons spanning more than 140 
kb on chromosome 6 (6q25.1). Expression of the gene is controlled by one or more of 7 promoters 
which are regulated in a cell-specific manner. For most mRNA variants the exons associated with the 
different promoters are spliced to the first coding exon and thus all code for the same full-length 
receptor (Kos et al., 2001). The 1788 bp transcript, generated by sequential splicing of all 8 exons, 
encodes a 595 amino acid protein of about 66,2 kDa, which is considered the full-length human ERα 
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protein (for review see Kos et al., 2001). Similar to other members of the nuclear receptor family, the 
estrogen receptor protein is composed of 6 domains, termed A to F (Evans, 1988; Robinson-Rechavi 
et al., 2003), that define common structural features such as a highly conserved DNA binding domain 
(DBD), a hinge region, a ligand binding domain (LBD) as well as two activation functions (AF-1 and 
AF-2) which directly recruit transcriptional cofactors (for review see Hall et al., 2001; Olefsky, 2001).  
 
 
 
 
Figure I1. The estrogen receptor alpha (adapted from Reid et al., 2002). 
A. Genomic organization of the human ERα promoter region. The location of multiple promoters 
(represented as arrows) and corresponding upstream exons (depicted as shaded boxes) are shown. The 
size of the intronic regions is given in kb. Position of 5’ start sites, or splice donor or acceptor sites, 
relative to the originally described start site, are indicated below the exon boxes. Furthermore, various 
splice variants are indicated. 
B. Genomic organization of the ERα coding region including the common acceptor splicing site and 
the 8 coding exons of the estrogen receptor alpha gene. 
C. The different domains of ERα protein are represented with their associated functions. Significant 
phosphorylation (Ser) and acetylation sites (Lys) are indicated below. Numbering corresponds to the 
position of the domains in the human receptor in amino acids.  
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2.1.2 The A and B domains 
The N-terminal domain is highly variable both in sequence and length between the nuclear receptors. 
For the ERα the A/B domain encompasses the first 180 aa. The crystal structure of the A/B domain 
has not been resolved yet. However, structural models indicate that the A domain represses ligand-
independent transactivation and transrepression through direct interaction with the E domain (C-
terminal) of the receptor (Metivier et al., 2000; Metivier et al., 2002). This interaction has been shown 
to be important for coactivator binding.  
The B domain contains one of the two activation functions (AF-1). In the presence of ligand, AF-1 
synergizes with the second transactivation function (located in the ligand binding domain, see section 
2.1.5). The cell type dependent effects of the partial agonist/antagonist hydroxytamoxifen (Tam) are 
mediated via different phosphorylation sites in AF-1 (Glaros et al., 2006). Also, in contrast to AF-2, 
AF-1 activity can be enhanced through ligand and second messenger signalling pathways, allowing the 
integration of alternative signalling pathways (e.g. reviewed in Lannigan, 2003). It has been shown 
that the AF-1 region contains phosphorylation sites for a number of kinases including MAPK, AKT 
and cyclin A/cdk2 (Kato et al., 1995; Rogatsky et al., 1999; Campbell et al., 2001).  
 
2.1.3 The DNA binding domain (C-domain) 
The C-domain spans from amino acid 181 to 263. It is highly conserved in the nuclear receptor 
superfamily and serves as DNA binding domain (DBD). It forms a helix-turn-helix motif with two 
cystein-rich zinc finger motifs (CI and CII) which interact with alternate grooves on the DNA 
(Schwabe et al., 1990; Schwabe et al., 1993). The first zinc finger identifies the palindromic estrogen 
responsive element (ERE), while the second zinc finger stabilizes the binding by additional 
(unspecific) contacts with DNA, and/or dimerization with another nuclear receptor molecule (Green et 
al., 1988; Schwabe et al., 1993). Three amino acids in the first zinc finger (P-box) determine the 
specific recognition of the ERE, with the consensus sequence A(G/A)GTCAnnnTGACC(T/C). 
Exchange of the P-box sequence EGckA to GSckA, changes the specificity of the receptor from an 
ERE to a glucocorticoid response element (GRE; Green and Chambon, 1987; Mader et al., 1989).  
 
2.1.4 The hinge region (D-domain) 
The D-domain, situated between amino acids 264 and 302, is not well conserved between members of 
the nuclear receptor superfamily and between receptors from different species (Krust et al., 1986; 
Green and Chambon, 1988; Weatherman et al., 2001). The hinge region joins the DNA binding 
domain and the ligand binding domain, allowing the receptor to change its conformation upon ligand 
binding without creating steric hindrance. The C-terminal part of the hinge region contains a part of 
the transactivation function 2 termed AF-2a, which has the potential to act autonomous in a ligand 
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independent manner. It might be required for the agonist activity of tamoxifen in AF-1 dominant cells 
(Norris et al., 1997). Furthermore, the D-domains of GR, PR and ERs harbour a nuclear localization 
signal (NLS; in human ERα amino acids 256 to 303; Picard et al., 1990) and provide part of the 
interaction interface for coactivators and -repressors (Hu and Lazar, 1999). 
 
2.1.5 The ligand binding domain (E-domain) 
The E-domain, also called the LBD, encompasses amino acids 303 to 553 and is highly conserved 
between species and well conserved between members of the nuclear receptor superfamily. This 
region harbours important features such as the ligand binding pocket (LBP), a dimerization surface 
which mediates interactions with partner LBDs, a coregulator binding surface, which binds to 
regulatory complexes, and the major part of the transcativation function 2, that is required for ligand-
dependent transactivation and coactivator recruitment (Norris et al., 1997). In absence of ligand, the 
LBD inhibits the transcriptional activity of the full-length protein through 
intramolecular/intermonomer interactions (e.g. Metivier et al., 2002).  
Crystal structure analysis revealed that binding to ligands modulates the conformation of the receptor, 
and consequently changes surface properties, thereby regulating the binding of coactivators (when 
bound to agonists) or corepressors (when bound to antagonists). More specifically, upon binding to 
E2, helix 12 (H12) folds into the LBD enclosing the ligand in a hydrophobic cleft (Brzozowski et al., 
1997; Bourguet et al., 2000). This structural change reduces receptor - heat shock protein binding and 
uncovers the dimerization interface and surfaces for binding of cofactors containing an NR-box motif 
(Nuclear receptor interaction box, consensus sequence LxxLL, where L is a leucine and x is any amino 
acid). In contrast, when bound to the antagonist tamoxifen, H12 cannot fold over the LBP but instead 
binds the coactivator binding site, thereby preventing coactivator recruitment (reviewed in Bourguet et 
al., 2000).  
 
Figure I2 Model for the structural modulation of ERα 
activity by it’s a domain (Metivier et al., 2002). 
Depending on ligand and cofactor binding A-domain 
(a), ERα helix 12, and cofactors (c, d) compete for the 
same C-terminal binding surface.  
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The relative importance of the different transactivation functions (AF-1 and AF-2) depends on 
promoter and cell context. Three different “categories” can be distinguished: 1) AF-2 permissive cells, 
like the human endometrial cancer cell line HeLa, where ERα mediated transactivation depends on 
cofactors associating with the AF-2 surface, 2) AF-1 permissive cells, such as the human liver 
carcinoma cell line HepG2, where transactivation is primarily dependent on AF-1, and 3) cells with a 
mixed AF-1/AF-2 context such as the human breast cancer cell line MDA-MB-231 or the 
osteosarcoma cell line SaOS (Flouriot et al., 2000; Denger et al., 2001). The relative contribution of 
the two transactivation functions depends on the differentiation stage of the cell. Specifically, the more 
differentiated the cell is the higher its dependence on AF-1 (Merot et al., 2004).   
 
2.1.6 The F-domain 
The F-domain is located at the C-terminal end of the receptor starting at amino acid 554. Its function is 
not fully understood, but several studies show that the F-domain has a complex role in modulation of 
the transcriptional activation of ERα in a ligand-, promoter-, and cell-specific manner Montano et al., 
1995; Nichols et al., 1998; Weatherman et al., 2001; Schwartz et al., 2002; Kim et al., 2003; Koide et 
al., 2006). For example, deletion or mutation of the F-domain results in loss of agonist activity of 
tamoxifen in MDA-MB-321 human breast cancer cells, and also the ability of E2-bound ERα to 
activate transcription via interactions with SP1 is impaired. The F-domain harbours a putative PEST 
sequence, rich in proline, glutamic acid, serine and threonine residues. Although PEST sequences have 
been implicated in rapid protein turnover, the deletion of the F-domain in ERα does not change 
receptor stability or turnover (Pakdel et al., 1993; Lonard et al., 2000). 
 
2.1.2 ERα isoforms  
A number of ERα mRNA transcript isoforms have been reported in various tissues and organisms 
(Hirata et al., 2003). However, in addition to the full length 66 kDa protein only four smaller isoforms, 
hERα46, hERα36, TERP-1 and TERP-2, have been reported in humans (Castles et al., 1993; Friend et 
al., 1995; Flouriot et al., 2000; Denger et al., 2001; Wang et al., 2006; Bryant et al., 2006). Most 
mRNA variants are generated either by multiple promoter usage or by alternative splicing.  
 
The 46 kDa truncated form has been identified in human breast cancer cells (Flouriot et al., 1998; 
Flouriot et al., 2000), osteoblasts (Denger et al., 2001; Longo et al., 2004), and endothelial cells 
(Russell et al., 2000; Li et al., 2003; Figtree et al., 2003). It can be produced by alternative splicing 
from the E and F promoters directly to coding exon 2, omitting exon 1 (Flouriot et al., 2000). 
Alternatively, it can originate from internal ribosome entry and translation from the downstream ATG 
174 in exon 2 (Barraille et al., 1999).   
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ERα46 lacks the A/B domain which harbours AF-1, and therefore, only exhibits ligand-dependent 
activities. Interestingly, the ERα46 homodimer shows higher affinity for the consensus ERE than the 
ERα66 homodimer (Denger et al., 2001; Penot et al., 2005). However, ERα can also heterodimerize 
with the full-length protein and the effect of ERα46 depends on the cell context. In a predominantly 
AF-2 context, ER46 functions as a ligand-inducible transcription factor. In contrast, it is an effective 
inhibitor for ERα66, in cells were AF-1 dominates over AF-2 (Flouriot et al., 2000; Denger et al., 
2001; Penot et al., 2005). Furthermore, full-length and truncated ERα isoforms also differ in terms of 
cofactor recruitment and chromatin remodelling of target promoters. More specifically, unliganded 
ERα66 prepares the promoter to respond to ligand, while ERα46 recruits corepressors delaying the 
hormone induced response (Metivier et al., 2004).   
 
Another naturally occurring isoform that originates from alternative splicing is ERα36 (Wang et al., 
2005b; Wang et al., 2006). Remarkably, this ERα isoform is expressed in both ERα66-positive (e.g. 
MCF7 and T47D cells) and –negative cell lines (e.g. MDA-MB-231). It lacks both transactivation 
functions but retains DBD, partial dimerization and LBD, and can therefore inhibit genomic estrogen 
signalling through competition for the DNA binding elements (EREs). However, in contrast to the 
full-length receptor, which mainly localizes in the nucleus, the 36 kDa truncated ERα is found in 
association with the plasma membrane (~50 %), in the cytosol (~40 %), and in the nucleus (~10 %). 
Like other isoforms, hERα36 has been shown to activate the MAPK/ERK pathways in response to 
estrogen, referred to as “non-genomic” or “non-classic” action. Interestingly, ERα36 can also 
stimulate this pathway in response to anti-estrogens which could be a consequence of the altered 
ligand binding domain. The stimulation of signalling pathways by ERα36 in response to estrogens and 
anti-estrogens may play an important role in development of tamoxifen-resistance in breast cancers.  
 
The pituitary-specific ~20 kDa isoforms TERP-1 and TERP-2 (truncated estrogen receptor product 1 
and 2) are derived form an estrogen inducible promoter located between coding exons 4 and 5. The 
mRNAs contain a unique 5’end and exons 5 - 8 (Friend et al., 1995). At low levels, TERP has been 
shown to enhance ERα mediated transcription on ERE containing promoters, while at higher 
concentrations it interferes with ERα and ERß cofactor binding and thereby suppresses their activity 
(Schreihofer et al., 1999; Resnick et al., 2000). The strong dependence of TERP expression on 
hormone levels and its ability to enhance and inhibit ERα dependent transcription suggests that it may 
play an important physiological role.   
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2.2 Posttranslational modifications of ERα 
The activity of the ERα has been shown to be controlled by a number of posttranslational 
modifications such as phosphorylation, acetylation, ubiquitination, SUMOylation and NEDDylation. 
The status of the modifications influences DNA and cofactor binding, as well as dimerization and 
protein stability. Modifications and effects on transcription maybe cell type and promoter specific.  
 
2.2.1 Phosphorylation 
ERα and associated cofactors can be phosphorylated by various kinases in response to estrogens, 
growth factors, cytokines, protein kinase A (PKA)-activating agents, neutrotransmitter and cyclins (for 
review see (Weigel, 1996; Moggs et al., 2001; Lannigan, 2003; Faus and Haendler, 2006). Thus, 
phosphorylation modulates both, ligand-dependent and -independent receptor activation, and thereby 
allows integration of different signalling pathways supporting a complex cross-talk network. ERα is 
phosphorylated mainly on serine residues located in the N-terminal region, where the AF-1 is situated 
(reviewed in Lannigan, 2003). However, while binding to estradiol induces phosphorylation on S118, 
S104 and S106, activation via the MAPK (mitogen activated protein kinase) pathway leads to 
phosphorylation of S118 and S167. Although both, estradiol binding and activation of the MAPK 
pathways, lead to S118 phosphorylation, the kinetics and kinases involved are different. Estradiol 
induces phosphorylation within 20 min while exposure to epidermal growth factor (EGF) results in 
rapid but transient phosphorylation. Phosphorylation of serine residues in the AF-1 domain influences 
coactivator recruitment resulting in enhanced ER-mediated transcription (reviewed in Lannigan, 
2003). For example, S118 phosphorylation has been shown to be required for recruitment of the p68 
RNA helicase and the spliceosome component (SF)3a p120, both of which interact with AF-1 and 
enhance ERα-mediated transcription.  
Phosphorylation also plays an important role in regulation of the agonistic and antagonistic effects of 
tamoxifen, a selective estrogen receptor modulator used in breast cancer therapy. Tamoxifen resistant 
tumours show increased expression of EGFR (HER-1) and ErbB2 (HER-2), members of the epidermal 
growth factor receptor family. These growth factors are involved in phosphorylation of the S167 of 
ERα which leads to increased interaction with ER-amplified in breast cancer 1 (ER:AIB1) in the 
presence of tamoxifen, and consequently, resistance to tamoxifen.  
Besides modulating ERα activity, phosphorylation also influences the stability of the receptor. For 
example, phosphorylation at S236 by PKA activates and stabilizes the receptor (Tsai et al., 2004) and 
MAPK activation decreases ICI182780-bound ERα degradation (Marsaud et al., 2003).  
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Figure I3. Pathways and 
kinases potentially involved 
in ERα phosphorylation 
 (Lannigan, 2003). 
 
 
 
 
 
 
 
 
 
2.2.2 Acetylation 
Cofactors, like p300, CBP, SRC1 and P/CAF, which possess intrinsic histone acetylase activity, are 
recruited by the activated ERα where they influence chromatin structure through histone acetylation. 
However, p300 can also directly acetylate ERα at lysine residues (K266, K268, K299, K302 and 
K303) at the boundary between the hinge region and the LBD. Acetylation can stimulate DNA binding 
and ligand-dependent activation (K266 and K268), but also diminish ligand-induced activation (K302 
and K303). Interestingly, acetylation of K303 can be prevented by phosphorylation of S305, revealing 
a cross-talk between different posttranslational modifications (reviewed in Faus et al., 2006). 
Furthermore, the activity of a number of nuclear receptor cofactors is acetylation dependent (e.g. 
NRIP, where acetylation by p300/CBP leads to its inactivation; (Vo et al., 2001)). Consequently, 
acetylation is likely to influence ERα mediated transcription, although the exact mechanisms remain 
to be elucidated.  
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2.2.3 Ubiquitination  
The estrogen receptor has a short half-life of about 4 hours, which is further reduced to 3 hours in the 
presence of its ligand estradiol (Eckert et al., 1984). The pure anti-estrogen ICI182780 (Fulvestrant®, 
Faslodex®) further decreases the ERα half-life, while the partial antagonist tamoxifen inhibits 
ubiquitination and proteosomal degradation (Wijayaratne and McDonnell, 2001). Rapid turnover of 
ERα allows for fast changes in receptor levels and thus dynamic hormone responses. Degradation of 
ERα occurs mainly via the ubiquitin/proteasome pathway (Alarid et al., 1999; Nawaz et al., 1999; El 
Khissiin and Leclercq, 1999). Inhibition of proteasome activity stabilizes ERα but renders the protein 
immobile, and blocks ligand-induced transcription (Stenoien et al., 1998; Reid et al., 2003). 
Furthermore, proteasome activity is a requirement for cyclical ERα turnover and transcriptional 
activity (Lonard et al., 2000; Reid et al., 2003). ERα binds directly to the E3 ubiquitin ligases Mdm2 
and E6AP. Interestingly, this interaction requires phosphorylation of S118 (Valley et al., 2005). 
An inverse relation between activity and stability has been shown for PR (Syvala et al., 1998) and 
RXR (Nomura et al., 1999), as well as for other coactivators (Molinari et al., 1999; Salghetti et al., 
2000), suggesting the existence of a link between transcriptional activity and degradation of the 
factors.  
 
2.2.4 Sumoylation 
Sumoylation, the covalent attachment of the small ubiquitin-like modifier (SUMO) -1, appears to be 
involved in the regulation of diverse cellular processes, including nuclear transport, signal 
transduction, and gene transcription (reviewed in Seeler and Dejean, 2003). Regulation of hormone-
induced transactivation has also been shown for other nuclear receptors, including GR and PR 
(reviewed in Faus et al., 2006). The sumoylation pathway is mechanistically similar to the ubiquitin 
pathway but involves a distinct set of enzymes. Unlike, ubiquitin, most targets are conjugated to only a 
single SUMO-1 molecule, and this modification does not target proteins for degradation, but modifies 
protein stability or activity (Seeler et al., 2003).  
Recently, ERα has been identified as a target for sumoylation by PIAS1 and PIAS3 (SUMO-E3 
ligases, Sentis et al., 2005).  ERα can be sumoylated on K266 and K268 in a strictly hormone-
dependent manner. Interestingly, these residues are also subject to acetylation resulting in stimulation 
of DNA binding and also ligand-dependent activation of the receptor. Although, PIAS1 and PIAS3 act 
as SUMO-E3 ligases they regulate ERα-mediated transcription via an unknown sumoylation-
independent mechanism (Sentis et al., 2005).  
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3. Mechanisms of ERα mediated transcriptional activation 
Genome wide transcriptome analysis have identified a large number of possible E2 target genes in a 
variety of cell types (Inoue et al., 2002; Frasor et al., 2003; Coser et al., 2003; Wang et al., 2004; Kian 
et al., 2004; Bourdeau et al., 2004). Roughly half of these genes are induced while the others are 
repressed in the presence of estrogen. Depending on the initiation step of estrogen action two modes 
can be distinguished: “nuclear-initiated” (also referred to as “classical or genomic action”) and 
“membrane-initiated” (also called “non-genomic”) events.  
 
3.1 “Classical”: cyclic transactivation through estrogen responsive elements (EREs) 
ERs can induce transcription of target genes by directly interacting with the estrogen response 
element, a palindromic sequence with the consensus A(G/A)GTCAnnnTGACC(T/C) (reviewed in 
Klinge, 2001). The formation of transcriptional complexes is a highly ordered process which involves 
sequential association and dissociation of hERα (Shang et al, 2000; Metivier et al., 2003; Reid et al., 
2003). The kinetics of ERα-mediated transcription activation was studied in detail on the pS2 
promoter (Metivier et al., 2003; Metivier et al., 2006). In the absence of ligand, ERα cycles on the 
pS2 promoter with a periodicity of 20 min, generating a permissive state for transcription, but without 
recruiting the transcriptional machinery. Upon ligand binding, the conformation of ERα changes to 
display coactivator-binding surfaces resulting in initiation of ordered recruitment of a number of 
cofactor complexes. This leads to histone acetlyation and methylation, chromatin remodeling and 
eventually the recruitment of the basal transcription machinery. However, after synchronization with 
α-amanitin, which blocks RNA polymerase II, the first cycle in the presence of hormone is 
transcriptionally unproductive but results in modification of histones (by histone acetyl transferases 
(HATs) and histone methyl transferases (HMTs)) and remodeling of the local nucleosomes (by 
SWI/SNF) to generate a transcriptional competent conformation (Metivier et al., 2003). This first 
cycle is followed by two types of productive cycles that alternate with a periodicity of about 45 min 
(Shang et al., 2000; Reid et al., 2003; Metivier et al., 2003). During these cycles, cofactors with HAT 
activity (like p300, CBP, p/CAF) and HTMs (like CARM1 and PRMT1), also general transcription 
factors (e.g. TBP, TFIIA, TFIIB), mediator (TRAP220) and eventually RNA polymerase II are 
recruited. Transcriptional initiation is followed by the clearance phase. In this phase the chromatin 
remodelling complex SWI/SNF, HDACs, NURD, heat shock protein 70 (hsp70) and ubiquitin E3-
ligases (MDM2 and E6AP; Reid et al., 2003) are recruited, resetting the promoter to allow a new cycle 
to begin. Interestingly, some factors, like TBP and TFIIA, and modifications such as dimethylation of 
histone H3 persist over two cycles. Thus, the two transcriptional productive cycles differ in the 
clearance phase and the proteins present at the beginning of the cycles. Sequential chromatin 
immunoprecipitations, which detect the simultaneous presence of two proteins at one site, have 
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identified six ERα-containing complexes. Within these complexes functions such as HAT activity can 
be provided by various proteins (e.g. p300 or Tip60), reflecting functional redundancy in the system. 
Recruitment of hsp70 and ubiquitin E3-ligases provide two mechanisms which can limit estrogen 
signalling. One mechanism involves targeting ERα for degradation concomitant with transcription 
(Reid et al., 2003; Metivier et al., 2003; Metivier et al., 2004). The other is based on disassembly of 
transcriptional complexes by molecular chaperones (Freeman and Yamamoto, 2002). Periodic 
assembly and disassembly of the transcription machinery on the pS2 promoter allows the continuous 
sampling of estradiol levels and ensures an appropriate limitation of the response to hormone 
(reviewed in Metivier et al., 2006). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure I4. Cyclical recruitment of transcription factors on the pS2 promoter in MCF-7 cells in the 
presence of estrogen (from Metivier et al., 2006). The periodic association of HATs, HDACs, HMTs 
and SWI/SNF (Brg/Brm), as well as other important complexes that contribute to ERα dynamics and 
promoter clearance are shown with arrows. Ac-H3, acetylated histone 3 (K14); Ac-H4, acetylated 
histone 4 (K16); APIS, AAA ATPase proteins independent of 20S; ERE, estrogen response element; 
HAT, histone acetyltransferase; HDAC, histone deacetylase; HMT, histone methyltransferase; Met-
H3, dimethylated histone 3 (R17); Met-H4, dimethylated histone 4 (R3); NuRD, nucleosome 
remodelling and deacetylating complex ; p68, p68 RNA helicase; TBP, TATA-binding protein. 
 
3.2 Indirect transactivation through protein-protein interaction on non-ERE elements 
ERα can also regulate gene transcription in an ERE-independent manner via protein/protein 
interactions. This is seen on AP-1 sites where liganded ERα binds and enhances the activity of 
components of the coactivator complexes recruited by Jun/Fos heterodimer (reviewed in Kushner et 
al., 2000). Two different mechanisms have been proposed for estrogen- and anti-estrogen-bound ERα. 
When stimulated by estrogen ERα uses the same protein-protein interactions (binding of p160 to AF-1 
and AF-2) on AP-1 sites as on EREs. In contrast, when bound to tamoxifen, a selective estrogen 
receptor modulator (SERM), ERα adapts a conformation which allows binding of HDAC-repressor 
complexes, enabling ERα to titrate these complexes away from the Jun/Fos coactivator complex, 
resulting in increased activation from AP-1 sites (Webb et al., 1999; Kushner et al., 2000). ERα can 
also activate transcription by interacting with SP1 on motifs consisting of SP1 binding sites and either 
a half ERE or a full ERE, or only GC-rich regions (for review see Safe, 2001).  
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3.3 “Non-genomic activity” of ERα 
In addition to transcriptional responses, estrogens also induce very rapid responses (within seconds or 
minutes) which are insensitive to transcriptional and translational inhibitors. These effects are usually 
referred to as “non-genomic” or “membrane-initiated signalling”. They can originate from interaction 
of ligand-bound ERα with cytosolic or cell membrane associated regulatory proteins of second 
messenger signalling pathways, or from membrane-bound ERα (reviewed in Wehling, 1997; Kelly 
and Levin, 2001; Kousteni et al., 2001; Razandi et al., 2004; Pedram et al., 2006). Reported non-
genomic actions of estrogens include  
(1) the rapid activation of the ERK/MAPK signal transduction pathway,  
(2) phospholipase-C (PLC) activation through Gαq resulting in PKC activation and increases in 
cytosolic Ca2+ pools,  
(3) activation of adenylate cyclase through G-protein subunit Gαs resulting in cAMP-induced gene 
transcription,  
(4) increased activities of the phosphatidylinositol-3-kinase (P13K)/Akt pathway,  
(5) stimulation of growth factor receptors,  
(6) activation of endothelial nitric oxide synthase (eNOS) which is believed to contribute to the 
cardioprotective effects of estradiol (for review see Mendelsohn et al., 1999).  
Non-genomic actions can converge and can furthermore influence the genomic actions of estradiol. 
For example, ERα and eNOS have been shown to colocalize in caveolae, specialized membrane 
domains enriched in the scaffold protein caveolin-1. It was suggested that E2 stimulates eNOS through 
regulation of the local calcium environment (Chambliss et al., 2000). In addition, activation of eNOS 
requires the PI3K/Akt pathway (Haynes et al., 2000) which is mediated through direct interaction of 
estradiol-bound ERα with the p85 regulatory subunit of PI3K. Interestingly, Akt can directly 
phosphorylate ERα, resulting in “ligand-independent” transcription of estrogen-responsive genes 
(Campbell et al., 2001). 
 
Membrane-located ERα has been reported in vascular smooth muscle, osteoblasts, and endothelial 
cells that express endogenous ERα (Song and Santen, 2006). ERα does not have a transmembrane 
domain but can be palmitoylated which allows the receptor to associate with the membrane. At 
present, it is not known whether ERα translocation to the membrane and activation occur sequentially 
or are independent of each other. In addition to the classical ERs (full-length and truncated isoforms), 
sex-steroid binding protein receptor (SBP-R; Catalano et al., 1997), as well as still unidentified 
proteins present in non-ER expressing cells such as CHO and COS 7 cells (Nethrapalli et al., 2005) 
could play a role in non-genomic effects of estrogen. However, the estrogen-induced rapid effects are 
most likely regulated through the formation of protein complexes containing ERα. A central role in 
these rapid effects has been proposed for the tyrosine kinase Src. It has been hypothesized that Src and 
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ERα associate and upon estrogen stimulation this interaction is stabilized leading to activation of Src. 
Several other potential components of these large complexes have been identified, including MNAR 
(modulator of nongenomic action of ER), p85α, Shc, G proteins and caveolin-1 (reviewed in Song et 
al., 2005). In addition, membrane growth factor receptors, such as IGF-1R (insulin-like growth factor 
receptor) and EGFR (epidermal growth factor receptor) are also activated in response to estrogen. 
Further complexity, is added by the fact that activation of signaling pathways by estrogen leads to 
phosphorylation and activation of coactivator proteins which in turn then modulate ER-mediated 
transcription (Wu et al., 2005). 
 
 
Figure I5: Different pathways of steroid mediated actions (Losel and Wehling, 2003). 
This schematic representation summarizes the mechanisms of nongenomic action that can occur 
within a generic cell - no cell type has been shown to display all effects. The modes of action include 
direct transcriptional activation by classical receptors (left), kinase pathways driven by classical 
receptors (middle part), as well as cyclic AMP, lipase and kinase pathways, including ion fluxes, 
which are driven by nonclassical receptors (right). Some signalling pathways eventually lead to 
(indirect) modulation of gene expression by modification of transcription factors. CREB, cyclic AMP 
response-element-binding protein; DAG, diacylglycerol; ERK/MAPK, extracellular-signalregulated 
kinase/mitogen-activated protein kinase; InsP3, inositol trisphosphate; MEK, MAPK and ERK kinase; 
pCREB, phosphorylated CREB; PI3K, phosphatidylinositol 3-kinase; PKA, protein kinase A; PKC, 
protein kinase C; PLC, phospholipase C (Losel et al., 2003). 
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4. Mechanism of hormone-induced gene repression 
E2-mediated transcriptional repression has only recently become an active field of research. Hence, it 
is not surprising that although equivalent numbers of genes are up- and down-regulated in the presence 
of estrogen, the underlying mechanisms of down-regulation are only beginning to be revealed. 
However, already the few genes that have been studied demonstrated a very broad and complex 
orchestra of mechanisms and tide regulations. Like gene activation, repression of gene expression can 
be achieved through direct and indirect actions in ligand-dependent and -independent manners. A 
number of mechanisms are conceivable (Fig. I6). ERα can interfere with association of other 
transcription factors (e.g factor X) at their target promoters. This can occur by preventing DNA 
binding through direct interaction between ERα and putative factor X (A, 4.1), or through allosteric 
competition, which excludes factor X from the promoter (B, 4.2). Furthermore, competition for 
cofactor binding could also result in estrogen-induced gene repression (C). DNA bound-ERα can also 
repress gene expression through recruitment of corepressors (D, 4.3). Whether ERα interacts with 
activators or repressors might further be defined by the DNA sequence or other transcription factors in 
close proximity (E, 4.4). In cases when unliganded ER enhances transcription, dismissal of ER upon 
hormone treatment can lead to reduced gene expression (F, 4.5). Moreover, the level of estrogen may 
define the availability of cofactors through stimulation of expression or degradation (G) or by 
influencing cellular localization. Regulatory networks in cells are a result of complex interactions 
involving multiple factors. Therefore, different mechanisms cannot always be separated and often 
combinations of several pathways apply. A few examples for estrogen-mediated gene repression will 
be introduced briefly in the next sections.  
Introduction 
16 
 
Figure I6. Conceivable mechanisms for estrogen induced gene repression mediated by ERα. For 
details see sections 4.1 to 4.5. 
 
4.1 Repression of GATA-1 activity by estrogen 
The transcription factor GATA-1 (ERYF1) is expressed mainly in erythroid cells and related linages 
such as mast cells and megakaryocytes, where it is involved in the regulation of the majority of 
erythroid-specific genes. Thus, GATA-1 is essential for continued survival and full maturation of 
erythroid precursor cells, and its inhibition drives cells into apoptosis (reviewed in Morceau et al., 
2004). Its transcriptional activity has been shown to be impaired by the estrogen-activated ERα which 
can directly interact with the zinc finger and N-terminus of GATA-1, preventing its DNA binding 
(Blobel et al., 1995; Blobel and Orkin, 1996). Consequently, “non-classical” ERα target genes (such 
as erythroid kruppel-like factor (EKLF, KLF1) and ß-globin) are repressed in an estrogen-dependent 
manner. This interference might account for some biological effects of estrogens on eryhropoiesis like 
the induction of anemia in mammals treated with high doses of estrogen (Fried et al., 1974) and the 
reduction of human bone marrow derived erythroid progenitor cells in the presence of estrogen 
(Blobel et al., 1995). 
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4.2 Passive repression through allosteric hindrance 
Regulation of gene expression can also be achieved through competition for binding sites. In this 
scenario, ERα binds to the promoter thereby blocking the (identical or overlapping) transcription 
factor binding site of a specific transcription factor. The factor is excluded from the promoter and the 
gene is no longer activated. This mechanism has been demonstrated for monoamine oxidase B, a key 
enzyme involved in neurotransmitter degradation. MAO-B gene expression is stimulated by ERRα 
and ERRγ, and repressed by ERα and ERß in a ligand-dependent and -independent manner (Zhang et 
al., 2006). ERRs (estrogen-related receptors) are orphan receptors closely related to the ERs with 
which they share target genes and coregulators (reviewed in Giguere, 2002). While the ERs 
preferentially bind as homodimers to EREs (AGGTCAnnnTGACC), ERRs recognize the ERRE with 
the consensus extended half-site TnAAGGTCA. At the MAO-B promoter, ERRs and ERs share 
proximal and distal binding sites. After hormone treatment, ERRα and ERRγ, which stimulate 
expression, are displaced while ERα and ERß occupancy is increased. Consequently, MAO-B 
expression is reduced. It is of note that the ERß was more effective than ERα in inhibiting MAO-B 
expression, indicating physiological consequences of the differences between the isoforms (Giguere, 
2002).  
 
4.3 Recruitment of corepressors to a half ERE in the cyclin G2 promoter by ERα 
Cyclin G2 is a primary ERα target gene in MCF7 cells. Its promoter contains a half ERE embedded 
into a GC-rich region that functions as a Sp1 binding site. While Sp1 is associated with the promoter 
regardless of hormone treatment, ERα is only recruited to the half ERE after E2 treatment. Presence of 
liganded ERα is accompanied by recruitment of an NCoR-HDAC1 complex, resulting in histone 
deacetylation, release of PolII and consequently repression of cycling G2 expression (Stossi et al., 
2006). Thus, liganded ERα exerts opposite effects on the cyclin G2 promoter in comparison to the pS2 
promoter where it leads to coactivator and PolII recruitment (e.g. Shang et al., 2000; Metivier et al., 
2003). This example emphasizes the importance of the promoter context in defining the transcriptional 
outcome.  
 
4.4 DNA sequence as allosteric effector  
The DNA itself also contains information which is interpreted through conformational adaptation of 
the DNA binding domain. The allosteric information is then transmitted via intramolecular 
interactions to the hinge region and ligand binding domain resulting in altered cofactor binding sites 
(reviewed in Lefstin and Yamamoto, 1998). Differences in ERα conformation have been observed for 
example between ERα bound to the consensus vitellogenin A2 ERE and bound to the imperfect ERE 
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of pS2 (Wood et al., 2001; Klinge et al., 2004). Thus, ERα may present a binding surface for 
activators on one gene while recruiting repressors on another gene. 
4.5 Enhancement of TNFα action on the TNFα promoter through apo-ERα  
TNFα (Tumor necrosis factor-α) recruits AP-1 and NF-κB to its own promoter. Subsequent 
association of the unliganded ERα, Hsp90 and CBP results in potentialization of the activation by 
TNFα. TNFα treatment does not induce phosphorylation of ERα S118 or S167, and the positive effect 
of ERα is not likely to be due to recruitment of p160s, SRC-1, SRC-2 (GRIP1, TIF2, NcoA2) or SRC-
3 (AIB1). Upon hormone treatment, ERα is either dismissed from the promoter or masked by GRIP1, 
whose recruitment has shown to be crucial for the repression (Cvoro et al., 2006).  
In addition, estradiol has been shown to decrease the activity of the Jun NH(2)-terminal kinase (JNK) 
resulting in reduced phosphorylation of c-Jun and JunD which diminishes the autostimulation of c-Jun 
and JunD genes. Consequently, less binding of c-Jun/c-Fox and JunD/c-Fos heterodimers to AP-1 sites 
in the TNF promoter results in decreased transactivation of the TNF gene (Srivastava et al., 1999). 
 
4.6 Crosstalk with NF-κB – an example of complexity 
The interaction between the activities exerted by ERα and NF-κB (RelA (p65), RelB and c-Rel, p50, 
p52) are a good example of the very complex cross-talk which can occur between transcription factors. 
Both factors regulate important physiological processes and can (dependent on the gene) act 
separately, synergistically or in an inhibitory manner (Kalaitzidis and Gilmore, 2005). Inactive NF-κB 
is located in the cytoplasm in complex with IκB (inhibitory protein κB). Following phosphorylation of 
IκB by IKK, which can be activated by numerous signals including chemokines and growth factors, 
NF-κB is released and translocated to the nucleus where it modulates expression of target genes. ERα 
can interfere with this pathway at different steps: 1) ERα can inhibit IKK activity (preventing 
phosphorylation of the NF-κB inhibitor), 2) it can inhibit IκB degradation (preventing release of RelA 
and p50), 3) it can block NF-κB DNA binding, 4) it can compete for coactivator binding (e.g. both 
interact with p300 and CBP), 5) and finally ERα can bind DNA bound NF-κB and prevent 
transactivation (reviewed in Kalaitzidis et al., 2005). Interestingly, while cooperation requires the ERα 
AF-1 domain, repression depends on the LBD, DBD and region D of ERα.  
More specifically, ERα has been shown to interfere with NF-κB transactivation on the cyctokine 
interleukine-6 (IL6) promoter. IL-6 is a key mediator of immune and acute phase responses. Its 
expression is induced in response to cytokines such as IL1, activators of protein kinase C (phorbol 
esters (phorbol 12-myristate 13-acetate (PMA)) and protein kinase A (forskolin), while estrogens and 
glucocorticoids exert inhibitory effects. The synergistic action of NF-κB and C/EBPb on the IL-6 
promoter is required for its expression. However, ERα can directly interact with both factors and 
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prevent their binding to the IL-6 promoter (Stein and Yang, 1995; Ray et al., 1997). This physical 
interaction depends in part on the DBD of ERα and the DNA binding and dimerization domains of 
NF-kB and C/EBP.  
In contrast, ERα and NF-κB act synergistically on the cyclin D1 promoter and promote cell cycle 
progression. Cyclin D1 gene expression is induced by a complex that contains the activated ERα, NF-
κB, and the nuclear receptor coactivator RAC3, which can interact with both transcription factors 
(Rubio et al., 2006). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure I7. Inhibition of NF-κB by ERα through several mechanisms (Kalaitzidis et al., 2005). 
Shown is the canonical NF-κB pathway in which extracellular signals lead to activation of the IKK 
complex. The IKK complex phosphorylates inhibitors of NF-κB (IκBs), which usually hold the NF-
κB complex (which consists of various homo- and heterodimeric NF-κB family members) latent in the 
cytoplasm. Phosphorylation of IκB leads to its ubiquitination and proteasome-mediated degradation 
and consequently to nuclear accumulation of the active NF-κB complex. NF-κB then binds to 
promoters in target genes and recruits coactivators to enhance transcription. ERα has been shown to 
block NF-κB activity at several steps: (a) it can inhibit IKK activity, (b) it can inhibit degradation of 
IκB, (c) it can block DNA binding by NF-κB, (d) it can bind coactivators and compete with NF-κB for 
coactivator binding, and (e) it can bind directly to NF-κB to inhibit NF-κB-mediated transcriptional 
activation.  
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5. The estrogen receptor in breast cancer 
Estrogens play an important role in normal physiology. However, high levels of exogenous estrogens 
have been shown to be directly associated with an increased risk of breast cancer (London et al., 
1992). Moreover, prolonged exposure to estrogens through early menarche, late menopause, 
nulliparity and late age at first pregnancy are related to increased risk of developing breast cancer 
(Kelsey et al., 1993). The molecular mechanisms underlying this relationship could be the stimulation 
of cellular proliferation by estrogen through modulation of expression and activity of key regulatory 
components of the cell cycle like cyclin D1 or c-myc. The high proliferation rate increases the risk of 
replication errors which may result in accumulation of harmful mutations.  
Estrogen receptors have proven to be one of the most important targets in breast cancer with more than 
70 % of primary breast cancers in women being ERα positive and showing estrogen dependent growth 
(Masood, 1992). These tumours are often susceptible to anti-estrogen treatment (e.g tamoxifen) and/or 
hormone reduction therapy using aromatase inhibitors. In contrast, ER-negative breast cancers are 
more aggressive and unresponsive to anti-estrogens. Consequently, ER-positive status is generally 
associated with better prognosis (reviewed in Ariazi et al., 2006).  
SERMS (e.g. tamoxifen (Nolvadex)) have been successfully used in breast cancer treatment. 
Tamoxifen blocks estrogen action in breast cancers while exerting estrogenic effects in bone, brain 
and cardiovascular tissues. Thus, while preventing breast cancer and osteoporosis tamoxifen increases 
the risk of endometrial cancer. Also, following an initial response, long-term treatment with tamoxifen 
often results in development of resistance.  However, most tumours, even if resistant to SERM 
treatment, retain ERα and therefore estrogen responsiveness which allows them to be targeted with 
pure anti-estrogens (e.g. Fulvestrant (ICI182780)) or aromatase inhibitors (AI, e.g Letrozole, 
Exemeestane). While Fulvestrant impairs transcriptional action and accelerates degradation of ERα, 
AIs decrease the availability of estrogen.  
Both, polychemotherapy and hormonal therapy reduce the risk of recurrence and death from breast 
cancer. However, these therapies are not equally effective in all patients and they can be associated 
with severe side effects. Early diagnosis and detailed molecular characterization of tumours 
significantly increases the prognosis for the patients by minimizing unnecessary treatments. Therefore, 
identification of markers that are indicative of metastatic potential and tumour growth is critical since 
they can be used in diagnosis, therapy, and prognosis determination for women with early stage breast 
cancer. At the moment only a limited number of such markers are being used such as ERα, PR, HER-
2 (ErbB2, neu), and BRCA1 (reviewed in Murphy et al., 2005). Depending on the expression status of 
these markers five breast cancer subtypes can be defined (Carey et al., 2006): luminal A (ER+ and/or 
PR+, HER2-), luminal B (ER+ and/or PR+, HER2+), basal-like (ER-, PR-, HER2-, cytokeratin 5/6+, 
and/or HER1 (EGFR)+), HER2+/ER- (ER-, PR-, HER+), and unclassified (negative for all 5 markers). 
Expression of ER and PR are used to select patients for hormone therapy and generally indicate a 
favourable prognosis. In contrast, HER-2 positively identifies patients with metastatic disease who 
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have a poorer prognosis manifested by shorter disease-free and overall survival. HER-2 
overexpression correlates with a lower probability to respond to hormone therapy. This might be 
attributed to activation of the MAPK and Akt pathways by HER-2 and the consequent activation of 
ERα in response to tamoxifen. However, these cancers might respond to trastuzumab, a recombinant 
monoclonal antibody against HER-2, either alone or  in combination with cytotoxic chemotherapy 
(reviewed in McKeage and Perry, 2002). Nowadays, microarray gene expression profiling is 
increasingly used for tumour classification, prognosis and therapy prediction. This has led to 
identification of sets of potential predictive genes and gene expression profiles (predictive signatures) 
and may eventually give rise to individualized treatment of patients.  
The risk to develop breast cancer can be inherited. Women who have mutations in BRCA1 or BRCA2 
genes have a lifetime risk of 50 to 80% to develop breast cancer. The arising tumours are distinct from 
sporadic cancers and each other. While BRCA1 breast tumours are typically negative for ER and PR 
expression, BRCA2 tumours are likely to express both receptors (Hedenfalk et al., 2001; Murphy et 
al., 2005).  
Treatment of the more aggressive ER-negative tumours requires other targets. In addition to HER2, 
cathepsin D (CTSD), a lysosomal protease, had been identified as putative target. Cathepsin D is 
overexpressed in about 60 % of the ER-negative breast cancer, although it was originally identified as 
an estrogen-induced gene in ER-positive breast cancer cells. Its overexpression is frequently 
associated with shorter relapse-free and overall survival, and does not correlate with either ER levels 
or HER-2 amplification, thus classifying CTSD as a potential new target. Furthermore, CTSD was 
identified as one of the rate-limiting factors for growth of micrometastases (reviewed in Rochefort et 
al., 2003). The protease exerts a dual mode of action: As an extracellular protease CTSD can free 
factors that stimulated angiogenesis such as fibrioblast growth factor (bFGF). In addition, the secreted 
proenzyme might function as a ligand for a still unidentified cell-surface receptor and trigger 
mitogenic signals. In summary, CTSD has essential roles in cancer cell proliferation, fibroblast 
outgrowth, angiogenesis and inhibition of tumour apoptosis (for review see Liaudet-Coopman et al., 
2006) and thus represents a interesting target for treatment of breast cancers overexpressing this 
protease. 
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6. Estrogen-stimulated gene activation – the impact of distal enhancers   
A very detailed analysis on the dynamics of cofactor assembly and disassembly has previously been 
performed for the pS2 gene. The promoter of this gene contains an ERE in close vicinity to the 
transcription start site. However, many genes are regulated through distal motifs (personal 
communication with Jane Thomsen, GIS Singapore). To our knowledge, no studies have been 
performed on cyclical recruitment of complexes to these distal elements. A well known estrogen 
induced gene is Cathepsin D (CTSD), encoding a lysosomal aspartyl protease. Three ERα binding 
regions have been discovered: the proximal promoter and two distal binding sites, 9 kb and 33 kb 
upstream (Krishnan et al., 1994; Augereau et al., 1994; Bourdeau et al., 2004; Carroll et al., 2006). 
Regulation of CTSD expression through its proximal promoter has been extensively studied and 
revealed a complex mode of regulation. Within the proximal region several E2-responsive motifs have 
been identified: 1) a SP1-ERE half site (-199 to -165; Krishnan et al., 1994; Krishnan et al., 1995), 
which binds an ERα/SP1 protein complex; 2) an SP1 binding site (-145 to -135; Wang et al., 1998), 
and 3) an imperfect ERE as part of the MLPE (E2 responsive major late promoter element, -119 to -
107; Augereau et al., 1994; Wang et al., 1997), which binds the ERα homodimer. Estrogen induced 
CTSD expression can be inhibited by interaction of the aryl hydrocarbon receptor (AhR) with dioxin 
responsive elements (DRE) which then blocks the formation of the ERα/Sp1 complex (Wang et al., 
2001). In 2000, Shang et al. showed that association of ERα with the proximal promoter of CTSD  
(-295 to -54) occurs in a cyclical manner with similar cycling times to that described for the pS2 
promoter (80 min).  
So far, studies have concentrated on the proximal promoter of CTSD neglecting the potential influence 
of distal ERα binding sites. Although ERα is recruited to these sites, it is still unclear whether these 
distal EREs can contribute to estrogen-induced activation of CTSD. It is noteworthy that cooperativity 
between widely spread weak binding sites for ERα binding and transactivation has been observed 
(reviewed in Sanchez et al., 2002). Therefore, the aim of a side project of this thesis was the 
evaluation of the regulatory potential of the 9 kb upstream binding site. For comparative reasons, the 
analysis was extended to the estrogen-induced genes GREB1 (gene regulated by estrogen in breast 
cancer protein) and the ELOVL2 (elongation of very long chain fatty acids protein 2) for which ERα 
binding sites were also identified using ChIP-on-Chip (our group and others, e.g. Bourdeau et al., 
2004; Carroll et al., 2006). 
 
 
 
 
 
Figure I8. Proximal promoter region of CTSD (modified from Wang et al., 1998). 
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7. The BASE gene – what is known  
The Breast cancer and salivary gland expression gene (BASE) was recently identified in a screen for 
membrane and secreted proteins that are present in prostate or breast cancers (Egland et al., 2003). 
The gene is located on chromosome 20q11.21 and consists of 9 exons. The 1203 bp transcript encodes 
a putative secreted 19,5 kDa protein. The secretion of the protein would potentially allow 
measurements of its levels in serum, plasma or even saliva. Remarkably, BASE expression seems to 
be restricted to breast cancer and salivary gland tissue as assayed using a commercially available 
tissue array. BASE expression was also detected in 5 out of 8 breast tumours and in the breast cancer 
cell lines MCF7, ZR-75, and SKBR3 (Egland et al., 2003). With its restricted expression pattern and 
the possible secretion, BASE has the potential to be an easily accessible and potent diagnostic marker 
for breast cancer. However, its reported expression profile remains to be further examined, especially 
in terms of differences in expression levels between primary and metastatic tumours.  
The BASE gene and protein have not been experimentally characterized previously. The protein has 
no predicted domains which could indicate its function. BASE does share sequence similarity with 
Latherin, a surfactant protein found in horse sweat. It is 42 % identical and 63 % similar to the first 
178 aa of Latherin (Beeley et al., 1986). BASE has been assigned to the PLUNC gene family which so 
far consists of 4 short (SPLUNC) and 6 long (LPLUNC) proteins expressed in the upper airways 
(reviewed in Bingle and Craven, 2004a). These proteins contain domains predicted to be structurally 
similar to one (SPLUNC) or both (LPLUNC) of the domains of BPI (bacterial/permeability-increasing 
protein) which plays an important role in the innate immune system. PLUNC proteins may function in 
host defence (Bingle et al., 2004b).  
In contrast to the other SPLUNC genes BASE contains a stop codon in exon 6 which removes the 
section containing a second conserved cyctein. This results in the loss of a disulphide bond essential 
for the correct folding of the PLUNC genes. The stop codon in Exon 6 was considered to be premature 
(Bingle et al., 2004b) which suggests that BASE mRNA could be subject of nonsense-mediated decay 
(NMD), a pathway leading to degradation of mRNAs containing premature stop codons (reviewed in 
Wagner and Lykke-Andersen, 2002). For its potential use as a diagnostic or prognostic marker it is 
essential to understand the mechanism underlying BASE expression. Since the gene has only been 
discovered recently, no studies have been carried out so far. However, genome wide expression 
analysis in the human breast cancer cell line MCF7 performed in our laboratory indicated a role for 
ERα in BASE regulation. In this analysis BASE mRNA levels were 6 fold down-regulated in response 
to estradiol. The aim of this thesis is to investigate the mechanism underlying BASE gene expression 
and to further analyse the role of the ERα in hormone induced gene repression. 
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RESULTS 
A Expression and regulation of the Breast Cancer and Salivary Gland Expressed gene  
1. Validation of microarray analysis with qRT-PCR 
BASE was identified as an estrogen responsive gene by Dr. Stefanie Denger in a comparative 
transcriptome analysis of untreated (EtOH) and estrogen-stimulated (E2, 10 nM) MCF7 cells using 
Amersham whole human genome 55 K array (Amersham, Freiburg, Germany). After 24 hour 
treatment, BASE mRNA levels were decreased about 6 fold while known E2 induced genes, like 
GREB1 and pS2 were up-regulated 6 and 2.9 fold, respectively. The first issue of this thesis was to 
validate the microarray data. For a number of genes that have been examined by real-time PCR for 
their regulation by E2 a high degree of correlation was observed with the microarray data (Fig. R1). 
 
A                                                                                                 B 
 
 
Figure R1. Comparative transcriptome profiling of MCF7 in absence and presence of E2. 
A. Microarray analysis presented as Scatter blot. MCF7 cells were serum starved for 3 days followed 
by a treatment with either EtOH or 10 nM E2 for 24 hours before cell harvest. mRNA from 3 
biological replicates, both for control and E2 treatment, was used to generate labeled cRNA which was 
then applied to individual Amersham Human 55 K arrays. Results are presented as scatter blot 
showing the average of the 3 replicates of control (EtOH) on the x-axis and average of E2 treatment on 
the y-axis.  
B. Real-time PCR validation of microarray (MA) data. Total RNA was prepared from 3 biological 
replicates of cells treated as for the microarray experiment. cDNA was generated and the relative 
levels of mRNA of selected genes were analysed by quantitative RT-PCR. Samples were analysed in 
triplicates and normalized to ßactin. Fold change of transcript levels after E2 treatment are listed in the 
table. 
 
2. BASE regulation is ERα-dependent 
The microarray analysis showed a highly significant repression of BASE expression in response to 
estradiol treatment. However, the long exposure to hormone does not rule out regulation through 
secondary, ERα independent, effects. In order to assess whether the effect of hormone treatment on 
BASE expression is mediated via ERα several approaches have been undertaken.  
Gene  MA RT-qPCR 
ßactin 0,89 1,00 +/- 0,00
GREB1 6,06 16,00 +/- 6,22
ELOVL2 1,40 2,76 +/- 1,90
pS2 2,88 6,93 +/- 4,57
CTSD 2,26 2,36 +/- 0,12
ERα 0,71 0,96 +/- 0,07
MSX2 0,62 0,62 +/- 0,09
BASE 0,14 0,08 +/- 0,02
DSCR1 0,48 0,29 +/- 0,06
BASE 
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2.1  BASE is rapidly down-regulated in response to E2 
The microarray analysis provided only a “snapshot” of BASE regulation induced by hormone. To 
assess the time-dependent regulation of the BASE gene expression by estrogen, a time course 
experiment was performed in which BASE transcript levels were determined at different time points 
up to 24 hours after treatment with 10 nM E2. RNA from triplicate samples at each time point was 
analyzed using quantitative RT-PCR. The repression of the BASE gene was found to be very rapid, 
showing about 30 % decrease in transcript levels after only one hour, which then constantly decreased 
further until the 24 hour time point (Fig. R2 A). This indicates that BASE down-regulation after 
hormone treatment is a direct rather than a secondary effect. Nevertheless, a mRNA degradation 
dependent mechanism can not be excluded. However, it also confirms that the 24 hour treatment is a 
valid time point for further investigations. Time course studies have also been performed for the pure 
anti-estrogen ICI182780. For these experiments cells were maintained in normal medium. As expected 
for an ERα-dependent repression, BASE mRNA levels rose after treatment with ICI182780. However, 
the induction was delayed compared to the repression in response to E2. An increase was only 
detectable after 6 to 12 hours. Opposite trends were observed for the well characterized E2-inducible 
pS2 gene which was included as positive control (Fig. R2 B). 
 
A BASE 
 
 
 
 
 
 
 
 
 
 
 
B  pS2 
 
 
 
 
 
 
    
 
 
 
Figure R2. Time course of BASE (A) and pS2 (B) expression in MCF7 cells.  
cDNA was prepared from 3 biological replicates of MCF7 cells after treatment with E2 (in stripped 
medium) or ICI182780 (in normal medium) for indicated times. Expression levels of BASE (A) and pS2 
(B) were determined with qPCR and normalized to ßactin.  
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predicted EREs
2.2  Knockdown of ERα induces BASE expression 
siRNA against ERα was used to investigate the effect of reduction of ERα receptor levels on BASE 
expression without additional treatment. Transcript levels of ERα and BASE were analysed 24 hours 
after transfection with ERα-siRNA. The receptor mRNA levels dropped to 30 % while BASE mRNA 
was increased to about 2.6 fold (Fig. R3). These results indicate that activation and degradation of 
ERα are the main reasons for BASE regulation in response to E2 and ICI182780, and not unidentified 
side effects of ICI182780. 
 
Figure R3. Knockdown of ERα leads to induction of the BASE 
gene. 
MCF7 cells were transfected with siRNA against ERα for 24 
hours. cDNA was analysed for BASE and ERα transcript 
levels. Expression levels were normalized to PPIA. 
 
 
 
 
 
 
 
3. Cloning and testing of reporter constructs  
To further investigate the regulation of BASE, luciferase reporter assays were chosen since this system 
would later allow rapid analyses of mutation effects. Based on the pGL3-basic vector (Promega) 
which lacks eukaryotic promoter and enhancer sequences, a reporter construct containing 2.4 kb of the 
BASE promoter upstream of luciferase gene was created (Fig. R4 A). In transient transfections in 
MCF7 cells, this reporter construct nicely recapitulates the regulation of the endogenous gene (Fig. R4 
B) – strong repression with estradiol while ICI182780 slightly induces BASE expression.  
 
A        B 
 
 
 
 
 
 
Figure R4. Regulation of BASE-luciferase reporter construct in MCF7 cells. 
A. Schematic view of the BASE promoter with bioinformatically predicted EREs and the generated 
luciferase reporter construct below (wt). B. Regulation of pS2 and BASE reporter constructs after 
transient transfection in MCF7 cell and treatment with either vehicle (EtOH), E2 (10 nM), or ICI182780 
(1 mM). The pS2 - luciferase reporter construct (-556 bp to +26 bp) has been generated in the group 
before. Relative luciferase units (RLU) were determined by normalization to Renilla luciferase.  
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4. BASE expression in different cell lines 
In a first study, no expression of the BASE gene was detected in normal tissue apart from salivary 
glands (Egland et al., 2003). Although BASE mRNA was undetectable in mammary gland samples, 
high expression was detected in different breast cancer cell lines and few breast tumour samples.  
To evaluate expression of BASE in cell lines used in our laboratory, cDNA was generated and 
analysed for the presence of BASE transcripts using semi-quantitative (end-point) PCR. To verify the 
quality of the cDNA templates, separate PCRs were performed for PPIA. Different breast cancer cell 
lines (ERα-positive: MCF7, ZR-75, T47D, ERα-negative: MDA-MB-231, SKBR3), the human 
cervical adenocarcinoma cell line HeLa, and the hepatocellular carcinoma cells line HepG2 (both 
ERα-negative) were tested. Furthermore, MDA-MB-231 stably expressing the full-length ERα66 
(MDA66) or the short isoform ERα46 (MDA46) were also included. As predicted from the previous 
study, BASE was undetectable in HeLa and HepG2 cells, while BASE mRNA was detected in all 
breast cancer cell lines but MDA-MB-231. Surprising was the high expression of BASE in the ERα-
negative cell line SKBR3 (Fig R5). 
 
MCF7    ZR-75    SKBR3   T47D      MDA     MDA46   MDA66    Hela      HepG2
BASE 
ERa
PPIA
 
Figure R5. BASE expression in different cell lines 
cDNA was prepared from different cell lines maintained in normal medium (for details see materials 
and methods). Expression of BASE, ERα, and PPIA was analysed with gene specific primers in end-
point PCR.  
 
 
After investigation of the endogenous gene expression levels, the 2.4 kb promoter fragment was 
assessed for its ability to drive expression in cell lines other than MCF7. In transient transfection 
assays using the luciferase reporter construct described before, the 2.4 kb proved to be sufficient for 
expression in the cell lines where endogenous BASE transcripts were detected (not all data shown). 
No luciferase activity was found in the MDA-MB-231, HeLa, and HepG2 cells (Fig. R6). 
Interestingly, although the BASE reporter construct was activated in ERα-negative SKBR3 cells, there 
was no regulation by either E2 or ICI182780. This suggests a role for ERα in BASE regulation rather 
than basal expression. It is therefore not surprising that re-introduction of ERα isoforms (ERα46 and 
ERα66) in MDA-MB-231 cells did not stimulate BASE expression. The high pS2 promoter activity in 
HepG2 cells in the transfection assay, although E2-unresponsive, is in contrast to the absence of 
endogenous pS2 transcripts in these cells. In summary, ERα is not sufficient for BASE expression 
since BASE transcripts were detected in the ERα-positive and the ERα- negative cell line SKBR3. 
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Figure R6. BASE promoter 
activity in different cell lines. 
Cells were stripped for 3 days, 
transiently transfected with wt 
BASE reporter construct and 
treated with either vehicle (EtOH), 
10-8 M E2 or 10-6 M ICI182780. 
Luciferase activity was determined 
24 hours later and normalized to 
Renilla luciferase activity. 
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5. BASE promoter analysis 
5.1 A 600 bp regulatory region  is essential for BASE expression  
After establishing the luciferase reporter construct as a functional system resembling the regulation of 
the endogenous gene, a series of deletion mutations was generated (Fig. R7) to identify regions that 
have a role in BASE expression and regulation by estrogen or anti-estrogen ICI182780. In this series, 
luciferase reporter constructs omitting different segments of the promoter were created from the  
2.4 kb-basic construct and tested in transient transfection assays. Deletion of the most upstream region 
I (-2419/ -2353, ΔI) had no effect compared to the full length reporter construct. In strong contrast, 
deletion of the region between -2352 and -1689 (segment II, ΔII) reduced gene expression to almost 
undetectable levels. Absence of segment IV (-916 /-179, ΔIV) also reduced expression strongly, while 
deletion of segment III (-1688 /-917, ΔIII) resulted in slightly increased expression indicating that this 
region might harbour weak repressive features. All constructs that were expressed also showed 
repression by E2 and induction by ICI182780 (data not shown). 
To summarize, promoter segment IV (-916/-179) contributes to BASE gene expression but is not 
necessary for regulation. The 600 bp region II is necessary for full expression of the BASE gene but 
whether in addition it plays a role in the repression by E2 could not be assessed with this approach due 
to the very low expression levels.  
 
Contribution of different promoter regions to BASE expression and regulation 
 
Figure R7. Identification of a 600 bp region essential for BASE expression that is located 2 kb 
upstream of the transcription start site. 
MCF7 cells were stripped for 2 days, then treated with either EtOH or 10-8 M E2 and transfected with 
a series of luciferase reporter constructs omitting different segments of the BASE promoter. Firefly 
luciferase activity was determined 24 hours later and normalized to Renilla luciferase activity. 
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5.2 Regulatory potential of the enhancer and identification of the core promoter 
To evaluate the role of region II in BASE regulation, promoter segments of increasing length have 
been subcloned into the pGL3-enhancer vector (Fig. R8). This vector is almost identical to the one 
used before but contains an additional SV40 enhancer which leads to increased basal expression and 
therefore allows to assess the regulation of constructs omitting the BASE enhancer region.  
MCF7 cells were transiently transfected with sequential 5’-deletion constructs and constructs either 
omitting or exclusively containing the enhancer region (Fig. R8). The region up to -917 bp (segment 
IV) was identified as core promoter (E2 and E7). It imparts basal activity and has been shown to 
contribute to full promoter activity in previous experiments (compare Fig. R7), but not to the response 
to E2 or ICI182780 (ICI data not shown). Regulation and further increased expression was observed only 
when segment II, which can also be considered as an enhancer, was included. Interestingly, disruption 
of the ERE surrounding the transcription start site reduced E2-induced repression (E10). In summary, 
the enhancer (segment II) is necessary and (together with the BASE transcription start site) sufficient 
to mediate the response to E2 and ICI182780. This is best illustrated by construct E9. 
 
Identification of BASE core promoter 
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Figure R8. Core promoter analysis.  
As series of promoter fragments of increasing length and omitting different promoter segments have 
been subcloned into the pGL3-enhancer construct (harboring an additional SV40 enhancer) and were 
tested for transcriptional activity in MCF7 cells 24 hours after transfection and treatment with either  
vehicle EtOH or 10-8 M E2. Values have been normalized to Renilla luciferase. 
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5.3 Impact of the transcription start site 
So far the identified minimal hormone-responsive region consists of the 600 bp enhancer enhancer 
(segment II) and the transcription start site. The enhancer is essential for expression and regulation, 
but the role of the transcription start site in BASE regulation remained to be elucidated. To assess this 
question the –2419/-179 promoter region (segments I to IV) and sequential 3’-deletions were 
subcloned upstream of the SV40 promoter and analysed in transient transfection assays (Fig. R9). 
Consistent with the results obtained before, all constructs containing the 600bp enhancer (region II) 
showed hormone responsiveness (P1, P2, P3), indicating, that the transcription start site is not essential 
for BASE gene regulation by E2. However, the enhancer alone was not sufficient to mediate the 
hormone response (P6). Only inclusion of segment I (P3) immediately upstream caused hormone 
sensitivity. Taken together with previous experiments, the minimal sequence required for hormone 
response consists of the 600 bp enhancer (segment II) and either segment V (about 200 bp including 
the transcription start site) or segment I (the small region directly upstream of the enhancer region). 
Thus, the results point towards a two component regulation – involving an interaction between the 
enhancer (II) and either the transcription start site (V) or a small region immediately upstream of the 
enhancer (I).  
 
The enhancer region is essential but not sufficient for E2-induced repression 
I     II            III              IV        V
 
 
Figure R9. The enhancer is necessary but not sufficient for regulation.  
BASE promoter segments of increasing length were subcloned upstream of the SV40 promoter and 
luciferase reporter. Transcriptional activity was analysed in MCF7 cells after transient transfections 
and treatment with either EtOH or 10-8 M E2 and normalized to Renilla activity.  
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5.4 Mutation of the EREs in enhancer and at transcription start site 
All three regions potentially involved in mediating the hormone response contain bioinformatically 
predicted EREs. The most proximal ERE is located in segment V, directly flanking the transcription 
start site. A conceivable mechanism could be that ERα, by binding to this site, interferes with 
assembly of an activation complex and thereby represses gene expression. To test this hypothesis, the 
ERE was disrupted (in the whole promoter context (2.4 kb)) while the ATG of the TSS was preserved. 
These mutations reduced the gene expression to about 50 % compared to wild type while not altering 
the estrogen- and ICI182780-dependent regulation. A similar result was obtained when the ERE in the 
enhancer region was mutated (Fig. R10 A to C). The complexity of promoters allows the combination 
of different signal pathways which makes assessment of single promoter features rather challenging. 
To minimize this problem further analysis was performed in a restricted background containing only 
the enhancer region (II) and the transcription start site (V). This combination is still able to confer the 
hormone response although to a slightly lower extent. In this background mutation of either one or 
both EREs also dropped expression while the regulation again was not dramatically affected (Fig. R10 
D to F). This indicates that direct binding to the predicted EREs is not required for the repression.   
  
Disruption of the EREs in the enhancer region and at the transcription start site (TSS) 
 
Figure R10. Mutation of EREs located in EH or at TSS affects expression levels but not regulation.  
A & D. Schematic display of reporter constructs. B & E. Luciferase assay. MCF7 cells have been 
cultured in stripped medium for 2 days before prior to treatment with either vehicle (EtOH) or 10-8 M 
E2 and transfection with reporter constructs containing the BASE promoter with disrupted EREs in the 
enhancer region or at the TSS. Firefly luciferase activity was determined 24 hours after transfection 
and normalized to Renilla activity. For C & F cells were maintained in normal medium containing E2 
and treated with either EtOH or ICI182780.   
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5.5 BASE expression and regulation can be separated 
The identified enhancer region encompasses about 600 bp which are essential for regulation. To better 
define the important region, reporter constructs each omitting only about 150 bp were generated and 
tested for their activation potential and hormone sensitivity (Fig. R11 A). Deletion of the region 
between -1990 and -1835 (segment C) reduced the expression levels to the same extent as the deletion 
of the whole enhancer, indicating important binding motifs in this region. Absence of the segments A, 
B and D had less impact. In the subsequent step, segment C was divided into 3 subparts, each 50 bp 
long. Corresponding reporter constructs were generated and again tested in MCF7 cells (Fig. R11 B). 
The result surprisingly showed that omitting only 50 bp (C2) reduced transcriptional activity 
dramatically, while again not abolishing the regulation. Therefore, BASE gene expression and gene 
regulation in response to hormone can be separated. These 50 bp were further investigated regarding 
putative transcription sites located within this region. 
 
A  Dividing the 600 bp enhancer in 150 bp segments 
 
  
B Omission of only 50 bp (C2) significantly reduces BASE expression 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure R11. Promoter deletion analysis.  
MCF7 cells were stripped for 2 days, then treated with either EtOH or E2 and transfected with a series 
of luciferase reporter constructs omitting different segments of the BASE promoter. Firefly luciferase 
activity was determined 24 hours later and normalized to Renilla luciferase activity. A. Deletion of 
150 bp (C) is sufficient to reduce expression significantly. B. Deletion of an only 50bp segment (C2) 
reduced BASE expression to about 12 % of the complete construct.   
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6.  ERα can bind the enhancer in vitro and in vivo 
All three regions (segments I, II (enhancer) and V) involved in mediating the hormone response 
contain bioinformatically predicted EREs. Since the enhancer region is required for hormone response, 
the ERE in the 600 bp enhancer region was the most promising candidate. To test whether ERα can 
bind to this region, electromobility shift assays (EMSAs) were performed, using in vitro translated 
ERα and [32P] labeled 50 bp oligos containing either the C1 segment, C2 segment or pS2 promoter 
sequence (Fig. R12 B). Binding of ERα was observed for the 50 bp of the pS2 promoter containing 
the ERE which functioned as positive control. In the C1 region, which contains a predicted ERE, only 
very weak ERα binding could be detected. To confirm the observed weak binding of ERα to the C1 
region a competition assay has been carried out. Oligos containing a perfect ERE were [32P] labeled 
and incubated with in vitro translated ERα while different cold oligos were used for competition (Fig. 
R12 C). Only the perfect ERE and the oligos covering region C1+C2 could compete for ERα binding, 
therefore confirming the ability of ERα to bind to the BASE promoter in the enhancer region.  
 
A        B                                                              C 
 
 
 
 
 
 
 
 
 
 
 
 
Figure R12. ERα can associate with BASE promoter in vitro.  
EMSAs were conducted by incubating recombinant human ERα with [32P] labeled oligos and the 
corresponding antibody (? protein bound, ? corresponding supershift). A. ERα can bind to the pS2 
promoter (positive control) and binds in the C1 region of the BASE promoter. B. Competition assay. 
Indicated oligos were tested for their ability to compete for ERα binding with the perfect ERE.  
   
 
Association of ERα with the BASE enhancer was also confirmed in vivo by ChIP-on-Chip analysis 
(Fig. R13). Chromatin from MCF7 cells grown in normal media was applied to the ChIP procedure 
using an ERα-antibody. The analysis, including fluorescent labeled labelling with Cy3 (input) and 
Cy5 (immunoprecipitated material), and hybridization to custom made promoter array, was carried out 
by Agilent Technologies (Canada). 
In the promoter region, ERα binding was observed in vicinity to the predicted ERα binding site in the 
identified enhancer region only. Although the enrichment is low (only about 2.7 fold) the extreme 
proximity of the probe with the highest enrichment and the predicted ERE strongly support the 
significance of this finding. Furthermore, preliminary conventional ChIP experiments also show ERα 
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association with the BASE promoter in this region (data not shown). However, whether ERα binds to 
the predicted ERE or whether it is recruited through protein-protein interaction remains to be 
determined. As a conclusion, ERα can bind to the BASE promoter in the enhancer region in vitro and 
in vivo. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure R13. ERα can bind BASE promoter in vivo - ChIP-on-Chip analysis (in collaboration with 
Agilent, Canada). 
MCF7 cells were crosslinked and submitted to the ChIP procedure using ERα antibody followed by 
hybridization on a custom made promoter Microarray. The fold enrichment of immunoprecipitated 
material vs input samples is displayed for the BASE promoter. The region of the most enriched probe 
matches the previously identified enhancer region.  
 
 
7. Bioinformatic analysis of segment C2 & identification of FoxA1 sites important for 
expression 
Sequence analysis of the enhancer using the transcription factor database TransFac (Matys et al., 
2003) indicated binding sites for FoxA1, Gata1 and the aryl hydrocarbon receptor (AhR) in the 
previously identified essential segment C2. To evaluate the potential of these binding sites we used 
site directed mutagenesis combined with luciferase reporter assays. Mutation of the AhR and the 
GATA1 site had mild effects on the expression but not on the estrogen-dependent regulation of BASE 
similar to the effect caused by disruption of the ERE. In contrast, disruption of the predicted FoxA1 
binding site strongly reduced the expression of the BASE gene (Fig. R14). Thus, FoxA1 might have 
an essential role in BASE expression while the repressive role of estrogen was not affected. 
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A            B 
 
 
 
 
Figure R14. FoxA1 sites are important for BASE expression.  
A. Schematic view of the promoter segments C1 and C2 of the enhancer region with putative 
transcription factor binding sites. B. Luciferase assay in MCF7. Luciferase reporter constructs 
containing mutations in different transcription factor binding sites were tested for their activity after 
treatment with either vehicle (EtOH) or 10-8 M E2.   
 
 
8. FoxA1 is essential for BASE expression 
ERE and FoxA1 binding sites located in close proximity are a common motif found in about 12% of 
direct ERα target gene promoters. For this subset, FoxA1 is required for recruitment of 
ERα (Laganiere et al., 2005). To evaluate the importance of FoxA1 in BASE expression several 
approaches have been undertaken.  
To confirm the ability of FoxA1 to bind in the BASE enhancer regions, EMSAs were performed, 
using again [32P] labeled 50 bp oligos containing either the C1 segment, C2 segment or pS2 promoter 
sequence. In vitro translated FoxA1 was able to bind to the C2 oligo (containing the BASE FoxA1 
binding sites) and could be supershifted with the corresponding antibody (Fig. R15 A). Preliminary 
data from ChIP experiments indicate association of FoxA1 with the BASE promoter in vivo (data not 
shown). These findings confirm the bioinformatic prediction of a FoxA1 binding site within C2.  
If FoxA1 is important for BASE expression, then it should be present in cells lines that express BASE. 
Therefore, as a next step, expression of FoxA1 was tested in different cell lines at mRNA (Fig. R15 B) 
and protein level (Fig. R15 C). Using quantitative RT-PCR, high FoxA1 mRNA levels were detected 
in the ERα-positive breast cancer cell lines MCF7, ZR-75 and T47D while in the ERα-negative breast 
cancer cell lines SKBR3 and MDA-MB-321 transcript levels were lower or not detectable. Low levels 
were also detected in HeLa and HepG2 cells. Presence of the FoxA1 protein was confirmed for the 
ERα-positive cell lines as well as for HeLa and HepG2 cells. For SKBR3, detection of FoxA1 protein 
depended on the antibody used. Therefore, the FoxA1 expression pattern underlines the importance of 
FoxA1 as a key factor for BASE expression, since FoxA1 protein was present in all breast cancer cell 
lines where BASE is expressed. However, FoxA1 itself is not sufficient as HepG2 and HeLa do not 
express BASE. It implies the requirement of additional factors that are cell specific.  
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To further analyse the contribution of FoxA1 to BASE basal and hormone-dependent expression 
overexpression and siRNA experiments have been conducted. While overexpression of FoxA1 protein 
in the FoxA1-positive cell line MCF7 had no effect (data not shown), the knockdown using siRNA 
against FoxA1 dramatically reduced BASE expression (Fig. R15 D). FoxA1 siRNA reduced transcript 
levels of FoxA1 to about 40 %. mRNA levels of BASE were dramatically decreased (about 90 %). 
These results strongly support a role of FoxA1 in BASE gene expression at least in cell lines that 
express FoxA1 protein.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure R15. FoxA1 is important for BASE expression.   
A. FoxA1 can bind to the C2 BASE promoter segment. EMSAs using [32P] labeled oligos and in vitro 
translated FoxA1 protein. The observed complex (? ) could be supershifted with an α-FoxA1 
antibody (T-20, Santa Cruz) (? ). B. Detection of FoxA1 mRNA in different cell lines using qRT-
PCR. ßactin levels are shown as loading control. C. FoxA1 protein levels detected by Western Blotting 
with FoxA1 antibody (upper part, M01, Abnova Corporation; lower part, T-20, Santa Cruz). D. 
Knockdown of FoxA1 using siRNA leads to reduction of BASE mRNA levels. MCF7 cells were 
reverse transfected with siRNA directed against FoxA1 (Dharmacon) and RNA isolation was 
performed 24 hours later. cDNA was generated and mRNA levels of FoxA1 and BASE were analysed 
with qPCR and normalized to PPIA transcript levels. Western blot analysis was used to test the 
efficiency of FoxA1 knockdown. GAPDH was used as loading control.   
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MCF7    ZR-75   SKBR3   T47D     MDA   MDA46  MDA66    HeLa    HepG2
BASE 
ERα
FoxA1
NFIL3
Oct-1
PPIA
NA NA NA NA
9. Bioinformatic analysis of the BASE promoter using MatInspector 
The FoxA1 binding motif in the enhancer region plays a key role in BASE expression. However, 
although FoxA1 can bind to this motif, the data obtained so far are not conclusive whether FoxA1 is 
the key factor for high BASE expression. To assess, if other transcription factors could also bind at 
this site, the sequence of segment C was re-analysed using the further developed programme 
MatInspector (Cartharius et al., 2005). This analysis revealed that the mutation of the previously 
identified FoxA1 site also affected putative binding sites of Oct-1 (octamer-binding transcription 
factor 1 (Pou2F1), NFIL3 (nuclear factor, interleukin 3-regulated, E4BP4), and IRF-3 (interferon 
regulatory factor 3).  
Expression of Oct-1 and NFIL3 was analysed in different cell lines using RT-PCR (Fig. R16 A) and 
Western blot (Fig. R16 B). Ubiquitous expression was observed for Oct-1, although relative levels of 
mRNA did not correlate with protein levels. The breast cancer cell lines MCF7 and T47D showed the 
highest Oct-1 protein levels. NFIL3 mRNA was found only at very low levels. This is in agreement 
with the microarray data which also indicate low transcript levels. Interestingly, the NFIL3 protein 
seems to be modified in the MDA46, MDA66 and the non-breast cancer cells HeLa and HepG2 – all 
cell lines which do not express BASE. However, expression or levels of Oct-1 and NFIL3 did not 
correlate with BASE expression.  
 
A 
 
 
 
 
 
 
 
 
B 
Figure R16. Expression in different cell lines.  
A. mRNA expression analysis of BASE and putative 
regulators in different cell lines. Total RNA was used 
to generate cDNA which was then analysed with 
exon spanning primers in qPCR. PPIA was included 
as reference. The data for BASE, ERα, FoxA1 and 
PPIA have been presented before (Fig. R5, R15).   
B. Western blot analysis in indicated cell lines.   
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10.  Validation of key roles for FoxA1 and ERα in BASE expression and regulation 
Based on the results presented distinct roles have been hypothesized for FoxA1 and ERα in BASE 
expression and hormone-dependent regulation. A possible role for Oct-1 was also suggested. To 
confirm these, siRNA experiments were performed in MCF7 cells in the presence and absence of 
hormone. The efficiency of the knockdown was controlled by Western blot, if possible, and RT-PCR. 
Application of siRNAs directed against FoxA1, ERα, and Oct-1, either alone or in combination 
significantly reduced the transcript and protein levels of their targets (no Western blot data for Oct-1 
protein).  
FoxA1 siRNA reduced FoxA1 transcripts to about 40 % and also affected Oct-1 and ERα levels. 
FoxA1 protein was significantly less abundant. The strongest impact at the transcript level was 
observed on BASE which expression dropped to almost undetectable levels. In contrast to the 
literature (Laganiere et al., 2005), pS2 gene expression and regulation by E2 was not affected. 
As expected, ERα siRNA decreased ERα mRNA levels to about 16 % and also reduced pS2 transcript 
levels. Two findings were surprising: firstly, induction of pS2 by E2 was not affected, and secondly, 
Oct-1 mRNA levels were decreased to about 60 %. FoxA1 mRNA levels remained unchanged. As 
predicted by the hypothesis, that ERα is mediating BASE repression in presence of E2, lower levels of 
ERα led to release of BASE repression by E2. Remarkably, in the Western blot analysis ERα-
antibody detected a protein at about 40 kDa only after treatment with E2. Whether the detected protein 
resembles an isoform or a degradation product of ERα remains to be analysed. Furthermore, it is 
unknown if this protein plays a role in BASE repression.  
Knockdown of Oct-1 had no effect on FoxA1, ERα or pS2 transcript levels and regulation. However, 
BASE mRNA levels dropped to about 60 %.  
Combination of FoxA1 siRNA with siRNA directed against ERα or Oct-1 did not reveal new insides. 
In conclusion, knockdown of FoxA1 protein abolished BASE expression while knockdown of ERα 
did not alter expression of BASE but significantly reduced E2-induced repression. These results 
confirm that FoxA1 is essential for BASE expression while E2-mediated repression is dependent upon 
ERα.  
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Figure R17. BASE expression depends on FoxA1 while repression in response to E2 is mediated by 
ERα. MCF7 cells were stripped for 36 hours and then reverse transfected with indicated siRNAs. 
Cells were then treated with either EtOH ( ) or 10-8 M E2 ( ). Total RNA and cDNA were prepared 
24 hours later. Gene expression was determined by qPCR and normalized to PPIA expression. 
Efficiency of knockdown was also analysed by Western blot.  
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11. Further putative factors involved in BASE regulation 
After identification of regions I, II and V as crucial segments for BASE regulation in response to E2 
and ICI182780, these sequences were bioinformatically analysed for common motifs. Using 
MatInspector software only 3 transcription factor binding sites were found to be present in all three 
segments: INSM1 (Zinc finger protein insulinoma-associated 1, IA-1), ZNF219 (Zinc finger protein 
219) and EF4 (Fig. R18). 
INSM1
E4F
ZNF219
I II VIII IV segment
 
 
Figure R18. Schematic view of the BASE promoter (2.4 kb) with the putative binding sites of INSM1, 
E4F and ZNF219 predicted by MatInspector (Genomatix, Munich, Germany). These are the only three 
transcription factors that have predicted binding sites in region I, II and V. The different segments 
used for previous truncation studies are indicated (I – V).  
 
 
E4F is an ubiquitinous expressed transcription factor which is E2-induced and ICI182780-repressed in 
vascular smooth muscle cells (VSMC; Nakamura et al., 2004). Nevertheless, in microarray analysis 
performed in MCF7 cells in our laboratory E4F was not detectable and examination of mRNA levels 
using qPCR showed a slight increase only in one out of 3 biological replicates after 24 hour treatment 
with estradiol (Fig. R19). The Zinc finger protein 219 was slightly upregulated by E2 in the 
microarray analysis of MCF7 cells, but this could not be confirmed with RT-PCR (Fig. R19).  
 
The INSM1 gene, also called Zinc finger protein insulinoma-associated 1 (IA-1), showed very low 
expression in the microarray and transcript levels were not modified in presence of hormone. 
However, a time course analysing INSM1 gene expression after hormone treatment a moderate 
increase of about 2.5 fold was observed between 6 and 12 hours (Fig. R19 A). To further investigate a 
possible role of INSM1 in BASE regulation, the expression of INSM1 at the transcript and protein 
level were tested (Fig. R19 A and B). mRNA abundance and protein levels did not correlate. While in 
ZR-75 high transcript levels were detected the protein level was lower than in T47D cells where the 
mRNA was less abundant. This discrepancy could be due to varying mRNA and protein half live or 
differences in translation efficiency. Notably, in SKBR3 in which BASE expression is not repressed 
after hormone treatment the INSM1 mRNA level was very low. And even more important the INSM1 
protein was undetectable.  
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Figure R19. Expression analysis of putative BASE regulators.  
A. Time course of gene expressions after E2 treatment in MCF7 cells for INSM1, ZNF219 and E4F. 
MCF7 cells were stripped for 3 days and then treated with E2 for indicated times. cDNA was prepared 
from 3 biological replicates and expression levels were determined and normalized to PPIA (left 
column). B. Gene expression levels were analysed in different cell lines and normalized to PPIA 
(single experiment, right column).  C. Western Blot analysis for INSM1 protein in different cell lines.  
 
M
C
F7
ZR
75
SK
B
R
3
T4
7D
M
D
A
M
D
A
46
M
D
A
66
H
eL
a
H
ep
G
2
INSM1
GAPDH
Results 
43 
12. Introduction of ERα in SKBR3 cells allows estrogen-induced regulation 
The ERα-negative cell line SKBR3 expresses relatively high levels of BASE but in luciferase reporter 
assays treatment with neither E2 nor ICI182780 changes BASE promoter activity (Fig. R20). If ERα is a 
key factor for BASE regulation then reintroduction of the receptor into these cells should repress 
BASE promoter activity in presence of estrogen. Through usage of the different isoforms (ERα66, 
ERα46) and a DNA-binding mutant it should be possible to assess the receptor feature important for 
hormone induced repression. Therefore, serum-starved SKBR3 cells were transfected with BASE 
reporter constructs (complete (2.4 kb), short (II + V), and short dm (with mutated EREs)) and 
expression constructs for either ERα66, ERα46, or ERα66mut. Cells were treated with either EtOH, 
E2 or ICI182780. Luciferase activity was determined 24 hours after transfection and normalized to 
Renilla luciferase activity (Fig. R20). 
Co-transfection of full length and truncated ERα resulted in E2-dependent reduction and ICI182780 
induced BASE promoter activity. Reduction of the promoter length and, even more important, 
mutation of the EREs reduced expression of BASE but it did not effect repression or induction after 
treatment. This indicates that direct binding of ERα to the BASE promoter is not necessary for 
hormone dependent regulation. Support for this hypothesis comes also from the ERα66 DNA binding 
mutant, which also has the ability to repress BASE in presence of E2. However, in the average of all 
experiments performed, the repressive potential of the DNA binding mutant is weaker than for the 
wild type. Also, ICI182780-stimulated induction of BASE expression was not observed in all 
experiments with the DNA binding mutant. The reduced expression of the “short” and “short dm” 
reporter constructs is independent of ERα presence (empty vector), indicating that other factors might 
bind these sites (e.g INSM1) and contribute to BASE expression.  
However, a significant difference was observed in the magnitude of regulation through ERα46 and 
ERα66. Both, E2-dependent repression and ICI182780-induced stimulation are much more pronounced 
in presence of ERα46 (5 fold increase with ICI182780 for ERα46 compared to less then 2 fold for 
ERα66). Again, the treatment dependent alterations in expression were not dependent on promoter 
length or intact EREs. Similar transfection experiments were also performed for ERß and ERRγ. ERß 
had the ability to repress BASE promoter activity in response to E2 while presence of ERRγ had no 
effect under these conditions (data not shown).  
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ERα causes E2-induced BASE repression 
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B  
 
 
 
 
Figure R20. Reintroduction of ERα induces BASE regulation in response to E2 and ICI182780. 
BASE reporter constructs (A) were cotransfected with expression constructs for ERα66, ERα46, and 
ERα66mut into serum-starved SKBR3 cells which were then treated with either vehicle (EtOH),      
10-8 M E2 or 10-6 M ICI182780 for 24 hours. Relative luciferase units were obtained by normalization to 
Renilla luciferase. 
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13. BASE main transcript is unlikely to be target of NMD 
The BASE gene consists of 9 exons (Fig. R21 A). Comparison with the PLUNC gene family which 
are predicted to share the same gene structure indicated that the BASE gene might contain a point 
mutation in exon 6 introducing a putative premature stop codon (Bingle et al., 2004b). Alignment of 
ESTs in the UCSC Genome, however, revealed that most ESTs end with exon 6, showing that the stop 
codon in exon 6 is not premature (Fig. R21 B). Thus, BASE mRNA is unlikely to be target of the 
nonsense-mediated decay (NMD) pathway. Since degradation of incorrect mRNAs depends on the 
translation, blockage of this process with cycloheximide would abolish the degradation leading to 
increasing transcript levels.  
However, BASE exon 3 has two slicing acceptor sites that give rise to 2 splicing variants differing in 
only 17 bp. The longer variant leads to a frame shift, generating stop codons already in exon 3. This 
transcript will be degraded and not lead to a protein. Using primers spanning exon 2 and 3 the ratio 
between these splicing variants was determined and the ‘nonsense’ transcript was found to be much 
less abundant than the transcript without frame shift (Fig. R21 C). Therefore, the majority of BASE 
transcripts are unlikely to be degraded due to NMD.  
A
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Figure R21. The BASE gene.  
A Schematic view.          UTR,           CDS,       splicing alternative,  ? RT primer, * stop codon in 
mouse.    B. BASE transcripts displayed in the UCSC Genome Browser. Almost all ESTs end with 
exon 6.   C. Alternative splice variants. cDNA from MCF7 cells was analysed with BASE RT primers 
spanning Exon 2 and Exon 3. Two splice variants of different lenght could be detected.    
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B. Patient studies 
 
So far, the expression of BASE has only been examined using a commercially available tissue array 
and selected tumour samples (Egland et al., 2003). To test whether BASE expression is restricted to 
breast tumour tissue, thereby harbouring the potential to act as a breast cancer marker, an additional 
study comparing normal and tumour tissue was initiated in collaboration with the University College 
Hospital (Galway, Ireland). All experiments and statistical analysis were performed by David Coyle 
and Dr. Nicola Miller in the laboratory of Dr. Michael J. Kerin (Dept. Surgery, National University of 
Ireland, Galway, Ireland). 
In total, 50 tumour samples, 4 benign and 4 normal samples were analysed by qPCR. BASE 
expression was detected in about 50 % of the samples tested (tumour: 26/50, benign 1/4, normal 2/4). 
The expression levels of BASE in normal tissue were 32 fold lower than in the tumour samples. Later 
on it turned out that the samples classified as “normal” were either benign tumour samples or were 
obtained as control biopsies from breast cancer patients and therefore do not represent good negative 
controls. Consequently, it is crucial that healthy breast tissue samples, e.g. from breast reduction 
surgery, will be tested. Nevertheless, BASE is expressed in the pathological samples. Through these 
findings, the potential of BASE as a putative marker for human breast cancer was confirmed and 
further studies are encouraged to increase the knowledge on the specificity of BASE expression. 
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C. The BASE protein – localization studies and antibody 
 
A secondary interest of this project was the analysis of the potential of the BASE protein to function as 
breast cancer marker on the basis of its restricted expression and the prediction that the protein would 
be secreted (Egland et al., 2003). To evaluate this possibility two peptide antibodies were generated 
(Eurogentec S.A., Belgium, Fig. R22). To obtain a positive control, the BASE coding sequence was 
cloned into different bacterial expression vectors (M80, M82, pET22b(+)) allowing expression and 
folding of the protein in different cell compartments. Since in the mature protein the predicted signal 
peptide would have been cleaved off, two variants of the BASE coding sequence were cloned – the 
full length and the short version missing the signal peptide. Production of the recombinant protein was 
accomplished by the Protein Expression and Purification Core Facility (Ario DeMarco) at the EMBL. 
The generated antibodies were tested on the recombinant bacterially expressed protein and in different 
cell lines. While both antibodies are able to detect the purified recombinant protein, specific 
endogenous BASE expression in cell lines could not be detected (Fig. R22). A commercially available 
antibody (CIM Antibody Core, Arizona State University) did not show a higher specificity (data not 
shown).  
 
A 
Base protein   179aa  signal sequence peptide 2peptide 1
ESTPQRKEATVQ KVQIRLEKNVGGRY  
 
B               C 
 
 
 
 
 
 
 
 
 
Figure R22. The BASE antibody. 
A. Schematic display of the BASE protein and localization of the peptides used for antibody 
generation by Eurogentec.  B Titration of recombinant BASE protein for detection with BASE-
antibody (rabbit 3). C. Application of BASE antibody on cell extracts from different cell lines. 
Antibody from a second rabbit was less sensitive. 
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Since BASE protein was predicted to be secreted the cell culture medium was also tested for the 
presence of the protein. But again, no specific band could be detected (data not shown). It is possible 
that the protein levels are below the detection level of about 1 µg protein as determined with the 
recombinant protein (Fig. R22). Therefore it is concluded that the antibodies used for these studies are 
not sensitive enough to detect BASE protein in a complex protein extract.  
To analyse the localization of the protein, BASE protein expression constructs for N- and C-terminal 
GFP fusion proteins were generated and transiently transfected into MCF7 cells. As expected, the C-
terminal tagged protein could not be detected, indicating that the signal peptide is cleaved off. The N-
terminal GFP-tagged protein could be detected. In MCF7, in co-transfections with RFP-tagged pSRß 
protein (kindly provided by J.Ellenberg), which localizes to the endoplasmatic reticulum, a co-
localization was observed, supporting the theory that the protein might be secreted (Fig. R23). 
However, in western blot analysis of the culture medium the tagged BASE protein could not be 
detected (data not shown).  
 
GFP              RFP             merge
BASEGFP
BASE GFP
GFP
BASE         pSRß-mRFP  
 
Figure R23. Localization studies of GFP-tagged BASE in MCF7 cells.  
Cells were transiently transfected with expression constructs for GFP-tagged and pSRß-mRFP 
(localizing to the endoplasmatic reticulum).  
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D. Cathepsin D 
 
1. Stimulation of CTSD expression upon E2 treatment  
Cathepsin D is a well known estrogen responsive gene. Nevertheless, before conducting further 
experiments, the extent of CTSD induction by E2 was examined in the MCF7 cells used in our 
laboratory. E2 treatment after 3 day serum-starvation resulted in a steady increase of CTSD mRNA, 
reaching a 2.3 fold increase after 24 hours (Fig. R24). These results are in very good agreement with 
the microarray analysis performed in our group which shows 2.3 fold increase in transcript levels after 
estrogen treatment for 24 hours.   
 
Figure R24. Time course of induction of 
CTSD expression by E2 in MCF7 cells. 
MCF7 cells stripped for 3 days were treated 
with hormone for indicated times. cDNA was 
prepared and transcript levels were determined 
by qPCR and normalized to ßactin expression.   
 
 
 
 
 
 
 
 
 
 
 
2. Distal estrogen receptor binding sites in the CTSD promoter 
Functional EREs have also been identified outside the proximal promoter, further upstream (about  
-9 kb and -33 kb; Bourdeau et al., 2004; Carroll et al., 2006). The ERE 9 kb upstream of the 
transcription start site differs from the consensus ERE in only 1 base pair (agGGTCAtggTGgCCcc). 
However, it is not known if binding of ERα to this almost perfect ERE can modulate CTSD gene 
expression. Therefore, luciferase-reporter constructs were generated (Fig. R25 A) containing either the 
distal ERE (-9446 to -8347, “distal”), the proximal promoter (-753 to +92, “proximal”), or both 
(“dis+prox”). Because these constructs were based on the pGL3-basic vector which does not contain a 
eukaryotic promoter, the expression of the “distal” construct was expected to be very low. To increase 
basal expression and allow better analysis of the regulatory potential, the “distal” sequence was 
subcloned into pGL3-promoter which contains the SV40 promoter upstream of the luciferase gene 
(“dis+SV40”). For further evaluation of the regulatory potential of the distal ERE this motif was also 
disrupted (“distal mut” and “distal mut+SV40”).  
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In transient transfection experiments in MCF7 cells using the above described reporter constructs, the 
proximal promoter showed basal expression but only a slight induction after 24 hour E2 treatment. In 
contrast, the distal ERE displayed a high E2 responsiveness, both, without basal promoter or upstream 
of the SV40 promoter. Combination of distal and proximal regions resulted in increased basal 
expression and significant E2-dependent induction. This induction was completely abolished by 
disruption of the ERE motif.  
In conclusion, the distal region, 9 kb upstream, confers significant higher estrogen responsiveness than 
the proximal promoter and is very likely to contribute to the estrogen induced upregulation of the 
CTSD gene.  
 
A       B 
ERE
-118
-753          +92
-8756
-9446       -8347
LUC
LUC
SV40
LUCproximal
LUCdistal
dis+SV40
dis+prox
CTSD promoter
LUC
SV40
dis_mut+SV40
LUCdistal mut
 
 
 
Figure R25. Promoter analysis of CTSD using luciferase reporter constructs. Schematic view of CTSD 
promoter and generated luciferase reporter constructs. MCF7 cells hormone deprived for 2 days were 
transfected with the indicated constructs and treated with either EtOH or E2. Luciferase activity was 
determined 24 hours later and normalized to Renilla luciferase. 
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3. ERα binds to the distal ERE in a cyclical manner 
To test the association of ERα and RNA Polymerase II with the CTSD promoter, ChIP experiments 
were performed (Fig. R26 A). ERα and PolII are preferentially recruited to the CTSD proximal 
promoter in presence of E2. ERα binding was also observed at the distal ERE. Interestingly, in 
presence of E2, PolII was detected as well, indicating that the distal enhancer might be in close 
proximity to the transcription start site through loop formation. This hypothesis could be tested 
through Chromatin-Conformation-Capturing (3C).  
In kinetic ChIP experiments, ERα cyclically associates with the distal ERE in the CTSD promoter 
with about 40 min periodicity (Fig. R26 B). The observed kinetics mirror the cycling times reported 
for the proximal promoter by Shang et al. (2000). Similar ERα cycling times have been observed at 
the pS2 promoter (Metivier et al., 2003).  
 
A                                                                        B 
 
 
 
 
 
 
Figure R26. ERα can associate with the distal ERE in vivo.  
A. Chromatin immunoprecipitation was performed for MCF7 cells (hormone deprived for 3 days and 
treated with either EtOH or E2 for 90 min). Chromatin was submitted to ChIP procedure using rabbit 
and mouse IgG, and antibodies against ERα and PolII. (TSS, transcription start site) 
B. Cyclical recruitment of ERα to the distal ERE in MCF7 cells. Cells were hormone deprived for 3 
days and then treated with E2. Samples were taken every 10 min from 0 to 140 min and then applied 
to ChIP procedure. Primers enclosing the distal ERE were used for PCR. 
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E. GREB1 & ELOVL2 – estrogen induced genes  
1. Estrogen stimulates GREB1 and ELOVL2 gene expression 
GREB1 (gene regulated in breast cancer 1) and ELOVL2 (elongation-of-very-long-chain-fatty-acids 
(family member 2)) are estrogen-induced genes. Stimulation by estrogen was also observed in our 
group in both, microarray analysis (performed by Dr. S. Denger) and RT-qPCR (Fig. R27). 
 
Figure R27. Estrogen induced GREB1 and 
ELOVL2 gene expression in MCF7 cells. MCF7 
cells were hormone deprived for 3 days and 
treated with estrogen for indicated times. Total 
RNA was extracted, cDNA was generated and 
expression levels of GREB1 and ELVOL2 were 
determined and normalized to PPIA expression. 
 
 
 
 
2. ERα associates with both promoters in vivo 
Customized promoter array (Agilent Technologies, Canada) covering the promoter region from -8 kb 
to 2 kb of selected genes, including GREB1 and ELOVL2, were used to identify estrogen receptor 
alpha binding sites. The outcome of this analysis is shown in figure R28 A. For the GREB1 promoter 
two of the identified ERα binding sites could correlate with predicted ERE 1 (-3400) and confirmed 
ERE 2 (-1560; Bourdeau et al., 2004), respectively. A third predicted ERE (ERE3, -670) is located 
within a repetitive sequence and therefore not covered by the array.  
Bioinformatic analysis of the ELOVL2 promoter identified 4 potential EREs within the 10 kb covered 
by the array (ERE1: -4130, ERE2: -2920, ERE3: -2260, ERE4: +90). However, significant enrichment 
was only observed for ERE 2 (14 fold over input) and a region at about -1.8 kb (about 4 fold). ERE1 
and ERE4 are again not covered by the array due to their location in repetitive sequences. It is of note, 
that a large number of EREs are found in these sequences.  
To confirm the results obtained by ChIP-on-Chip, conventional chromatin immunoprecipitation has 
been performed (Fig. R28 B). In agreement with the array, association of ERα with the GREB1 
promoter was observed in the region including ERE2. For ERE1 only a very low enrichment was 
detected, which cannot explain the strong signal obtained by ChIP-on-Chip. This indicates that ERα is 
recruited to sequences other than the predicted ERE 1. Whether ERα is bound directly or is recruited 
through protein-protein interactions remains to be determined.  
ChIP analysis also confirmed association of ERα with the ELOVL2 promoter in the region of ERE2, 
while no binding was detected for ERE1 and ERE3. Whether ERα is recruited to the predicted binding 
site at the transcription start site was not yet examined due to difficulties in primer design. FoxA1 was 
included in this analysis since ERE and FoxA1 sites are frequently found in close proximity and 
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important role has been assigned to FoxA1 in ERα-mediated gene regulation (e.g. at the pS2 
promoter, (Laganiere et al., 2005; Carroll et al., 2005). While FoxA1 was not present at high levels in 
the tested regions of the GREB1 promoter, strong recruitment was detected in proximity of ERE2 in 
the ELOVL2 promoter. Nevertheless, FoxA1 could be recruited in other regions of the GREB1 
promoter. Nevertheless, the results obtained so far indicates that GREB1 and ELVOL2 might belong 
to different subclasses of estrogen-responsive genes.  
 
A 
 
 
 
 
 
 
 
 
 
 
 
 
B 
 
 
 
 
 
 
 
 
Figure R28. ERα is recruited to GREB1 and ELOVL2 promoter. 
A. ERα association with the GREB1 and ELOVL2 promoters in MCF7 cells determined by ChIP-on-
Chip analysis (Agilent Technologies, Canada).  Predicted EREs are numbered. Vertical lines illustrate 
the localization of the predicted ERE in relation to the probes. B. Conventional ChIP analysis 
examining ERα presence at putative ERα binding sites in the promoters. 
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3. ERE2 is important for estrogen responsiveness of the ELOVL2 promoter 
Although ERα is present at the ELOVL2 promoter it is still unclear whether the predicted EREs are 
the sites of association and if they are important for E2-mediated regulation of ELOVL2 expression. 
To analyse this, reporter constructs containing either 2.4 kb or 4 kb of the ELOVL2 promoter 
upstream of the luciferase gene were generated and tested in MCF7 cells (Fig. R29). Consistent with 
the ChIP and ChIP-on-ChIP results, the first 2.4 kb showed only a weak induction (+1.4 ± 0.3) after 24 
hours E2 treatment and no repression with ICI182780 (1.1 ± 0.5). In contrast, E2 significantly induced 
luciferase activity from the 4.4 kb promoter fragment (4.5 ± 0.5) while ICI182780 repressed the activity 
(0.3 ± 0.1).  
These results indicate that the first 2.4 kb contain the proximal promoter while the estrogen-responsive 
motifs are located between 2.4 kb and 4.4 kb. Thus, ELOVL2 is another example for an estrogen-
induced gene for which estrogen response is mediated not by the proximal promoter but through 
regulatory region further upstream. Disruption of the EREs in the longer construct will reveal the 
contribution of ERE2 to estrogen-induced ELOVL2 expression.  
 
predicted ERE
-2260-4130 -2920
1 2 3
pGL3 basic LUC
+1
4
+90
2.4 kb LUC
4.4 kb LUC
 
 
Figure R29. The major estrogen-response is conferred by motifs located between 2 and 4 kb upstream.   
Schematic display of luciferase reporter constructs containing either 2.4 kb or 4.4 kb of the ELOVL2 
promoter. These constructs were tested in MCF7 cells (hormone deprived for 2 days) treated with 
either EtOH, 10-8M E2, or 10-6 M ICI182780. Luciferase activity was determined 24 hours later and 
normalized to Renilla activity.  
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DISCUSSION 
 
In women, breast cancer is the most common cancer and accounts for most cancer deaths. The decline 
in cancer mortality in the last years is mainly due to improvements in breast cancer treatment and early 
detection. If the tumour is detected at an early stage, the 5-year survival rate increases dramatically. It 
rises from about 26 % for a distant-stage disease (metastasized in distant organs), to 81 % for regional 
disease (spread to surrounding tissue) and to 98 % for local-disease (confined to the breast) (Atlanta: 
American Cancer Society, 2005). Therefore, much attention has been devoted to identification of 
markers indicating malignant phenotype, metastatic potential and tumour growth. These markers could 
help to detect and classify tumours in very early stages and select the most promising therapy. 
Unfortunately, only few tumour markers, including the ERα, HER-2 and CTSD, have been identified 
so far (reviewed in Murphy et al., 2005).  
A new potential tumour marker was identified recently - the Breast Cancer and Salivary Gland 
Expression gene (BASE). The gene, which encodes a putative secreted protein, shows a rather 
restricted expression to breast cancer cells and salivary gland, ideal for a breast cancer marker (Egland 
et al., 2003).  
Our group found BASE as a highly estrogen-repressed gene, indicating that the ERα, a recognized 
tumour marker, could be involved in BASE expression. This study aimed to understand the 
mechanisms underlying BASE expression and regulation in breast cancer cells.  
 
1. The BASE promoter 
This study identified the core promoter of the BASE gene and a 600 bp regulatory region about 2 kb 
upstream of the transcription start site. These 600 bp were demonstrated to be necessary but not 
sufficient for estrogen-induced regulation (Fig. R9). However, fractionation of this area in 150 bp 
fragments (A to D) abolished the effect on estrogen-mediated repression (Fig. R 11A), indicating that 
most likely at least two sites in the regulatory region contribute to the hormone response. A strong 
decrease in expression was observed when only region C was deleted. It is unlikely that these effects 
are caused by shifts in positioning of the nucleosomes since deletions of 150 bp should not interfere 
unless a nucleosome positioning signal was affected. And furthermore, absence of the segments A, B 
and D had significant less impact. Moreover, a similar decrease was observed even if only a small 
fragment of 50 bp (C2) was omitted in the context of the whole 2.4 kb reporter construct (Fig. R11B). 
Further characterization of C2 revealed a key role for FoxA1 binding sites as they were essential for 
BASE gene expression. Binding of FoxA1 to these sites in vitro and requirement for FoxA1 for BASE 
expression was confirmed (Fig. R15A & R17).  
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2. Distinct roles for FoxA1 and ERα in BASE expression and regulation 
Both, FoxA1 and ERα can bind to the BASE promoter in the regulatory region (Fig. R 12 & R15A). 
Whereas FoxA1 was essential for BASE expression it had no function in regulation in response to 
estrogen (Fig. R14 & R17). In contrast, presence of ERα was not required for BASE expression as 
shown by the ERα-negative but BASE-positive cell line SKBR3 (Fig. R5). However, ERα was crucial 
for estrogen-induced down-regulation (Fig. R17). As a conclusion, basal expression of the BASE gene 
and its regulation in response to hormone can be separated.  
As stated above, ERα has been assigned a key role in estrogen-induced BASE repression. Absence of 
ERα, either due to gene silencing, treatment with anti-estrogen ICI182780, or siRNA directed against 
ERα, abrogates repression in presence of hormone (Fig. R2, R3, R17). Binding of ERα to the 
regulatory region has been confirmed in vitro and in vivo (EMSA, ChIP, ChIP-on-ChIP, Fig. R12 & 
R13). However, ERα might not bind at the predicted ERE, as disruption of this motif did not alter 
repression in response to estrogen (Fig. R10). It is possible that ERα is recruited via protein-protein 
interaction to a nearby site. Furthermore, an indirect regulation through estrogen-regulated factors is 
conceivable. The very rapid repression of BASE in presence of estrogen (Fig. R2) argues against 
requirement of de novo protein synthesis. However, activation or inactivation through posttranslational 
modifications cannot be excluded. In this regard it is of note that estrogen can exert non-genomic 
activities which include rapid activation of signalling cascades like the MAPK pathway (reviewed in 
Song and Santen, 2006).   
 
The promoter study and siRNA experiments identified FoxA1 as one factor essential for BASE 
expression. This was further supported by the presence of FoxA1 protein in all breast cancer cell lines 
that express BASE (Fig. R16). The only FoxA1-negative cell line tested, MBD-MB-231, is also 
negative for BASE. Furthermore, stable expression of ERα in this cell line (MDAERα66, 
MDAERα46) did not lead to BASE expression, showing again that ERα is not required for BASE 
expression in contrast to FoxA1. However, FoxA1 cannot be the only transcription factor required. 
Although FoxA1 is present in HeLa and HepG2, no expression of BASE was detected in these cell 
lines. This result points towards the involvement of another, most likely breast specific or even breast 
cancer specific factor. Contradictory reports exist regarding FoxA1 regulation by estrogen. Whereas 
some groups report estrogen-induced down-regulation of FoxA1 (e.g Frasor et al., 2003), Langanier et 
al., (2005) observed up-regulation of FoxA1 within 4 hours after estrogen treatment. In the MCF7 
cells used in our group, FoxA1 mRNA levels did not change in response to exposure to estrogen (data 
not shown). Thus, reduction of FoxA1 levels is not the cause for down-regulation of BASE expression 
in presence of estrogen.  
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The clear separation of gene expression and hormone-dependent regulation was surprising. Although 
also expressed in ERα-negative tumours (Doane et al., 2006), FoxA1 expression is often associated 
with expression of ERα (Perou et al., 1999; 't Veer et al., 2002). Myles Browns group reported that 
about 50 % of ERα-binding sites are accompanied by Forkhead factor binding sites in close vicinity 
(Carroll et al., 2005; Carroll et al., 2006), and this applies for estrogen-stimulated and -repressed ERα 
target genes.  Furthermore, in this subset of genes, FoxA1 was required for recruitment of ERα and 
gene expression in MCF7 cells. pS2 belongs to this reported subset. However, in contrast to the 
findings reported by Laganiere et al. (2005), in this study knockdown of FoxA1 in MCF7 cells had 
only a mild effect on pS2 expression (Fig. R17). This is in agreement with previous studies from our 
group where reintroduction of ERα into the ERα- and FoxA1-negative cell line MDA-MB-231 lead to 
expression and estrogen-dependent regulation of the pS2 gene, which is silenced otherwise (Metivier 
et al., 2004). This effect is not due to induction of FoxA1, which itself is an ERα target gene 
(Laganiere et al., 2005), as confirmed by RT-PCR and Western blot analysis performed on MDA-MB-
231 and derived cell lines stably expressing ERα.  
 
3. Other factors binding the FoxA1 motif  
In addition to FoxA1 and ERα, several other factors might be involved in BASE expression and 
regulation. For example, the binding site of Oct-1 (octamer-binding transcription factor 1) overlaps 
with the FoxA1 motif and is affected by disruption of the FoxA1 motif in mutation studies. Oct-1 
might cooperate or compete with FoxA1 for DNA binding and thereby modulate BASE expression. 
   
Oct-1 has an important role in expression of the small breast epithelial mucin gene (SBEM). This gene 
shares several similarities with BASE including salivary and breast specific expression (Miksicek et 
al., 2002). Although Oct-1 is ubiquitously expressed it has been shown to play a role in regulation of 
tissue-specific genes (e.g. Dong and Zhao, 2007). Moreover, Oct-1 is involved in repression of the 
mouse gonadotropin-releasing hormone (GnRH) gene expression by glucocorticoids in cooperation 
with the glucocorticoid receptor GR (Chandran et al., 1999; Cheng et al., 2002). Although knockdown 
of Oct-1 reduced BASE expression (Fig. R17), the role of Oct-1 was not further evaluated due to time 
limitations. In addition, Oct-1 might not be the only relevant octamer-binding transcription factor 
involved in BASE expression. Jin et al. (1999) found Oct-1 (Pou2F1), Oct-2 (Pou2F2), Oct-3 
(POU5F1) and Oct-11 (POU2F3) in the breast cancer cell line MCF7. The embryonic transcription 
factor Oct-3 was found to be expressed in breast cancer cell lines and tumours, while absent in normal 
breast tissue. Therefore, extended studies on recruitment of octamer-binding factors to the BASE 
promoter and there impact on BASE expression should also include Oct-3 and Oct-11.  
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Another factor which can bind in very close proximity to the FoxA1 motif is NFIL3 (nuclear factor, 
interleukin 3-regulated, E4BP4). It has been hypothesized that NFIL3 is involved in anti-inflammatory 
response, regulation of the circadian rhythm, as well as cell survival (Cowell, 2002). Furthermore, 
NFIL3 has been suggested to play a role in parathyroid hormone- and glucocorticoid induced gene 
repression (Wallace et al., 1997; Ozkurt and Tetradis, 2003). In contrast, at the human Interleukin-3 
promoter in T-cells it functions as a transcriptional activator (Zhang et al., 1995). NFIL3 was present 
in all cell lines tested in this study (Fig. R17). However, in cell lines where BASE is not expressed, 
bands of higher molecular weight were detected. It could be hypothesized that these display 
posttranslational modifications, which might alter the activity or the DNA binding ability of NFIL3. A 
more speculative suggestion is that different posttranslational modifications might influence whether 
NFIL3 functions as activator or repressor of gene expression. NFIL3 can be induced by elevated Ca2+ 
levels (Nishimura and Tanaka, 2001; Priceman et al., 2006) and cAMP (Ozkurt et al., 2004). These 
secondary messengers can be triggered through non-genomic actions of estrogen. This could be a link 
between NFIL3 and estrogen-mediated repression. Furthermore, NFIL3 (E4BP4) is transcriptionally 
regulated by GATA-1 (Yu et al., 2005) whose transactivation ability can be inhibited by estrogen-
activated ERα (Blobel and Orkin, 1996). 
 
4. ERα partners in BASE regulation   
Contradictory to the simple model that ERα binds the ERE and recruits corepressors, mutation of 
predicted and confirmed EREs did not affect the hormone-induced repression (Fig. R10). Therefore, 
ERα likely cooperates with other factors or even might regulate BASE only indirectly. Three regions 
in the promoter were important in hormone response – the essential enhancer (region II) and either a 
small region immediately upstream of the enhancer (region I) or an approximately 200 bp segment 
including the transcription start site (region V) (Fig. R8, R9, additional results). Although it is not 
necessary that factors mediating BASE regulation in these segments are identical it was worthwhile to 
bioinformatically analyse and compare these sequences for common motifs. Only for three 
transcription factors binding sites were predicted in all three segments: INSM1, E4F, and ZNF219 
(Fig. R18). 
 
A promising candidate is INSM1, also called Zinc finger protein insulinoma-associated 1 (IA-1). 
INSM1 protein was detected in all cell lines tested except for SKBR3 (Fig. R19). In this cell line, 
BASE is expressed but not repressed in presence of estrogen. This opens the possibility that if BASE 
is expressed, INSM1 could contribute to estrogen-mediated repression. In keep with this hypothesis, it 
is noted that INSM1 has been shown to repress the neuroD/beta2 gene in conjunction with cyclinD1, a 
well known ERα target, by recruiting HDACs (Liu et al., 2006). Furthermore, expression of INSM1 is 
associated with cancer. It is re-expressed in neuroendocrine tumours (Pedersen et al., 2006) and 
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(Taniwaki et al., 2006) showed that the expression is altered in small-cell lung cancer (SCLC). It is of 
note, that the predicted INSM1 binding site slightly overlaps with the confirmed ERE in the enhancer 
region of the BASE promoter. An overlap of binding sites also exists for INSM1 and ZNF219. The 
localization of these motifs opens the possibility for an “exchange/interactive” mechanism. A 
conceivable approach to evaluate whether INSM1 is involved in BASE regulation would be re-
expression of INSM1 in SKBR3 cells and analysis of BASE expression in presence and absence of 
E2. Alternatively, since transient expression of ERα is sufficient to induce repression of BASE by 
estrogen, ERα could be expressed in SKBR3 cells and expression and regulation of both, INSM1 and 
BASE could be monitored.    
 
Another factor of potential interest is E4F, an ubiquitously expressed transcription factor which is 
synthesized in two variants, the full-length 120 kDa protein (p120E4F) and a 50 kDA NH2-terminal 
fragment (p50E4F) created by proteolytic cleavage. Both variants recognize the same DNA motifs in 
vitro, but regulate gene expression differentially in vivo (Fernandes and Rooney, 1997). While p50E4F 
transactivates adenoviral E4 gene expression (Raychaudhuri et al., 1987; Raychaudhuri et al., 1989), 
p120E4F likely plays a role in mammalian cell cycle control (Fajas et al., 2001). Interestingly, E4F 
was identified as highly estrogen-induced and ICI182780-repressed gene in vascular smooth muscle cells 
(VSMC; Nakamura et al., 2004). However, no response to hormone was observed in MCF7 cells in 
our laboratory.  
Not much information is available for the Zinc finger protein 219, which was isolated and 
characterized by H. Maeda (Sakai et al., 2000). The same group identified the consensus binding site 
(CCCCC). Furthermore, they showed that ZNF219 functions as a transcriptional repressor of the 
HMGN1 promoter (Sakai et al., 2003). Thus, both factors could have the potential to mediate 
estrogen-induced repression. However, a possible role for E4F and ZNF219 in BASE regulation was 
not addressed in this study due to time limitations. 
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5. ERα features important for BASE regulation 
Expression of BASE in the ERα-negative cell line SKBR3 presented an opportunity to dissect the 
ERα domains required for BASE repression. In absence of ERα and presence of E2 no repression was 
observed. Introduction of estrogen receptor alpha variants in the ERα-negative cell line SKBR3 
confirmed the necessity of ERα for BASE repression. Interestingly, a significant difference was 
observed between the potential of the truncated ERα46 and the full-length receptor ERα66 in BASE 
regulation. Estrogen-stimulated repression as well as ICI182780-mediated de-repression were more 
pronounced for ERα46. A possible explanation for these results is that ICI182780 renders both receptor 
isoforms inactive, but whereas hERα66 is rapidly degraded, ERα46 stability is only slightly 
decreased. Also, in presence of estrogen, levels of the full-length ERα decrease while levels of ERα46 
even increase (our data, Valley et al., 2005). Therefore, when both isoforms are expressed, the ratio 
between the two isoforms is altered in response to estrogen or anti-estrogen. At least in absence of 
estrogen, ERα46 and ERα66 associate with distinct cofactors (Metivier et al., 2004). Thus, in the case 
that BASE repression would be based on sequestering of required factors, the ratio between ERα46 
and ERα66 may have an influence. However, reduction of ERα levels in absence of E2 had no effect 
on BASE expression level (Fig. R17), indicating that apo-ERα does not affect BASE expression. In 
concludion, BASE expression levels are only modulated by the estrogen-activated ERα while apo-
ERα has no impact. 
 
Compared to ERα66, ERα46 lacks the A/B domain which harbours the transactivation function 1 
(AF-1). This domain is subject of frequent phosphorylation, which can activate the receptor in an 
estrogen-independent manner (reviewed in Lannigan, 2003). Thus, ERα46 can only be activated in a 
ligand-dependent manner. Furthermore, since ligand-activated ERα46 represses BASE this function is 
not dependent on AF-1, but seems to be exclusively based on AF-2. Metivier et al. (2002) proposed a 
model in which the A domain competes which helix 12 and the nuclear receptor corepressor (NCoR) 
for a hydrophobic cleft. This dynamic competition with the A domain is absent in ERα46 allowing 
unhampered interaction with cofactors. This might result in higher magnitudes of regulation. 
 
Comparison of the repressive potential of ERα66 and a DNA binding mutant ERα66mut revealed that 
BASE repression does not require direct binding of ERα to DNA (Fig. R20). This result is in 
agreement with mutation studies where disruption of the EREs did not alter BASE regulation. 
Nevertheless, ERα is present at the BASE promoter (Fig. R13). This indicates either recruitment of 
ERα via protein-protein interactions or, in addition, indirect mechanisms such as regulation of a 
second gene or squelching of other factors. Repression by ERα without direct DNA binding has been 
reported for the TNFα gene (Cvoro et al., 2006). TNFα gene is induced by TNFα which results in 
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recruitment of AP-1 and NFκB. In a subsequent step, recruited unliganded ERα then potentiates the 
activation. In presence of estrogen, ERα was dismissed from the promoter, GRIP1 was recruited and 
TNFα expression was reduced.  
In conclusion, apo-ERα does not contribute to BASE expression. And in presence of E2, BASE 
repression is mediated through AF-2 in a DNA binding-independent way.  
 
6. Restricted expression of BASE to breast cancer and salivary gland?  
BASE is a predicted member of the PLUNC gene family, which is expressed in the upper airways 
(Bingle et al., 2004a). However, in a commercially available tissue array, no BASE expression was 
observed in lung. In fact, BASE expression was restricted to salivary gland and breast cancer cells 
(Egland et al., 2003). The group also tested few breast cancer samples and found about  
50 % of them BASE positive.  
To complement this thesis a more comprehensive study was performed in collaboration with the group 
of Prof. Michael Kerin (Galway, Ireland). Within this study, 50 primary breast tumour samples were 
analysed for BASE expression so far. In agreement with the initial report by Egland et al. (2003), 
about 50 % (26/50) samples were positive for BASE expression in qPCR.  
The as “normal” classified samples, of which 2 expressed BASE at very low levels, were obtained 
from either benign tumours or from control biopsies from breast cancer patients. They therefore do not 
represent valid controls and it is crucial that healthy tissue, e.g from breast reduction surgery, will be 
tested. In conclusion, BASE seems to be overexpressed in the pathological condition and could still 
function as breast cancer marker. However, BASE expression was not correlated with tumour stage, 
grade, ERα status, tumour size or histological subtype of breast cancer. Based on the results obtained 
in this thesis, it could be speculated that BASE expression might correlate with the FoxA1 status. 
Also, BASE was found to be more frequently expressed in ERα-positive tumours. This is in 
agreement with the positive correlation between ERα and FoxA1 expression (reviewed in Nakshatri 
and Badve, 2007). Nevertheless, an obvious question remaining is which changes occur during the 
transition from a normal to a malignant cell that induces BASE expression. A link between salivary 
gland, or more precise salivary gland tumour, and breast cancer has been reported. Female patients 
with a salivary gland tumour have a 2.5 times increased risk to develop breast cancer (In der Maur et 
al., 2005). However, reports in the literature are contradictory, ranging from no increased risk to up to 
8-fold increase (e.g. Berg et al., 1968; Moertel and Elveback, 1969).  
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BASE is not the only gene with preferential expression in these tissues. The small breast epithelial 
mucin (SBEM) also shows a breast- and salivary gland-specific expression. However, in contrast to 
BASE, very low expression of SBEM was detected in some normal tissues including lung and breast 
(Miksicek et al., 2002; Hube et al., 2004). Nevertheless, SBEM mRNA has been detected in more than 
90% of breast tumours (e.g. Miksicek et al., 2002; Colpitts et al., 2002). Also like BASE, SBEM has 
been detected in the well-differentiated breast cancer cell lines MCF7, ZR-75 and T47D but was 
undetectable in the poorly differentiated MDA-MB-231 cell line, HeLa and HepG2 cells (Miksicek et 
al., 2002). The transcription factor Oct-1 was suggested to contribute to the strong expression of 
SBEM in breast tissue (Hube et al., 2006). Interestingly, an Oct-1/FoxA1 binding site is also essential 
for BASE expression. And furthermore, knockdown of Oct-1 also decreased BASE expression in 
MCF7 cells (Fig. R17). Therefore, it is possible that Oct-1, and in case of BASE also FoxA1, are 
essential for the breast-specific expression. In bioinformatic analyses of the first 3 kb of the SBEM 
promoter using MatInspector binding sites for ERα, estrogen-related receptors (ERRs) and NFIL3 
(E4BP4) were predicted. All three transcription factors could also play a role in BASE expression. 
However, in contrast to BASE, SBEM is not regulated by estrogen or anti-estrogen ICI182780. Both, 
SBEM and BASE are putative secreted proteins that have a salivary gland and breast specific 
expression pattern. As stated by (Miksicek et al., 2002) for SBEM, the expression in salivary gland 
tissue does not undermine the potential use as breast cancer marker since salivary gland tumours can 
be easily distinguished. This is also underlined by the use of SBEM as breast cancer marker (Lacroix, 
2006).   
 
The potential diagnostic relevance of BASE is substantiated by the predicted secretion of the protein. 
BASE protein has not been detected yet, most likely due to the lack of specific antibodies. Although, 
expression in salivary gland has not been further investigated, it is possible that expression of BASE in 
breast cancer and salivary gland are linked. BASE was not found in a screen for proteins in human 
whole saliva (Vitorino et al., 2004). However, only 100 out of more than 200 protein spots on 2D-gel 
were tested and not all resulted in identifiable sequences (55%). Therefore, BASE could be present at 
low levels. Even more important, the analysed saliva sample was obtained from a healthy 25 year old 
man. The absence of BASE protein under these circumstances is expected. Therefore, this report does 
not undermine the potential of BASE determination in saliva as the previous study could not address 
this question. Furthermore, the possibility to detect breast cancer markers in saliva has been shown for 
HER2/neu (c-ERBB-2) whose levels in saliva strongly correlated with breast cancer in women (e.g. 
Bigler et al., 2002). Similar results have been reported for the Her2/neu protein in nipple aspirates 
(Kuerer et al., 2003). Detection of breast cancer markers in saliva or nipple aspirates opens the 
possibility of a non-invasive and inexpensive diagnostic tool for early detection and treatment 
response.  
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7. Conceivable mechanisms of BASE repression 
A key finding of this thesis is the clear separation between basal expression of the BASE gene and the 
repression induced by estrogen. There is strong evidence that FoxA1 is a key factor in BASE 
expression while ERα is involved in the repression.  
 
BASE basal expression 
Exclusion of FoxA1 from the BASE promoter either by siRNA against FoxA1 or by mutation of the 
FoxA1 binding site greatly decreased transcription of the gene (Fig. R14 & R15). FoxA1 is a pioneer 
factor that can bind compact chromatin and initiate chromatin opening events (Cirillo et al., 2002) 
which has been shown to support ERα-mediated transcription. Thus, FoxA1 might allow BASE 
expression by increasing the accessibility of the chromatin and thereby facilitate binding of other 
transcription factors including a breast and salivary gland specific factor (BSSF) (Fig. D1, I). Another 
possibility is that FoxA1 can displace a repressor binding the same DNA sequence (Fig. D1, II). A 
possible candidate is the transcriptional repressor NFIL3/E4BP4. This factor can bind in the same 
region as FoxA1. The model is supported by the fact that knockdown of Oct-1, another factor able to 
bind this site, has repressive effects on BASE expression (Fig. R17). However, it is also possible that 
FoxA1 and Oct-1 cooperate in BASE activation.  
 
 
Figure D1. Schematic view of proposed mechanisms for activation of BASE gene basal transcription  
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BASE regulation 
Repression of BASE in response to E2 requires ERα but no direct interaction with DNA. However, 
ERα can bind to the enhancer region in vitro and is present in the same region in vivo (Fig. R12 & 
R13). It is conceivable that ERα is recruited via protein-protein interactions, which are then stabilized 
by a direct binding to the half ERE. This hypothesis is able to explain the slight but reproducible 
difference between the repressive potential of the wild type and the DNA binding mutant of ERα. 
Nevertheless, whether presence of ERα is required for repression could not be conclusively defined.  
 
Several mechanisms of repression have been outlined in the introduction (Fig.I6). The proposed 
models from the introduction will be discussed based on the results obtained in this study. 
 
Model A has already been described for the repression of GATA-1 target genes. Ligand-activated 
ERα binds to GATA-1 preventing its binding to DNA and thereby activation of target gene promoters 
(Blobel et al., 1995; Blobel et al., 1996). The model is compatible with the results obtained in this 
study. Direct binding of ERα to DNA is not required since the ERα DNA binding mutant can also 
repress BASE in transient transfection assays (Fig. R20). Furthermore, reduction of ERα through 
siRNA in presence of E2 increases BASE transcript levels (Fig. R3). Also the delayed induction of 
BASE expression after treatment with ICI182780 (Fig. R2), which inactivates ERα and accelerates its 
degradation, suggests a mechanism of de-repression rather than active induction. The only point 
undermining this model is the presence of ERα in the enhancer region of the BASE promoter (Fig. 
R13). However, whether this is required for repression remains unknown. 
 
The second model suggested that ERα influences BASE expression by displacement of another 
transcription factor important for BASE activation from the promoter (“allosteric hindrance”). 
However, experiments with the ERα DNA binding mutant indicated that this is not the mechanism, 
since DNA binding is not required for repression (Fig. R20). Nevertheless, it is conceivable that ERα 
does not block a DNA sequence but rather a protein-protein interaction site.  
 
Model C was based on the idea that liganded ERα would compete for coactivators, sequester them, 
and thereby decrease BASE expression. Such pronounced effects are unlikely caused by sequestering 
due to the redundancy in the transcription machinery and the shared usage of cofactors between 
transcription factors. In addition, ERα is present at the BASE promoter (Fig. R13). The opposite 
mechanism, in which apo-ERα sequesters repressive cofactors, is also not conceivable. If apo-ERα 
would titrate repressive factors away from the BASE promoter then knockdown of ERα by siRNA in 
absence of E2 would result in reduction of BASE expression, which was not observed (Fig. R17).   
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Model D proposed that apo-ERα would be absent from the active BASE promoter. In the presence of 
estrogen, ERα and subsequent repressors (e.g. HDACs) should be recruited, resulting in the 
inactivation of the BASE gene. This model is in agreement with the results if DNA binding is not the 
major requirement. It is possible that ERα is recruited through both, protein-protein interactions and 
direct DNA binding, and that these two modes act together to assure a stable association of ERα. In 
the absence of ERα, no repression would be observed. Furthermore, the observed difference in BASE 
activation by ICI182780 in the presence of ERα46 and ERα66 could be due to varying cofactor binding 
for the two isoforms. Whereas apo-ERα46 preferentially associates with corepressors, apo-ERα66 
rather binds to coactivators (Metivier et al., 2004). The A domain of ERα competes with helix H12 
and corepressors for the same binding surface at the receptor (Metivier et al., 2002). ERα46 lacks this 
domain and is more open for corepressor binding.  
 
Model E was based on the theory that the sequence of the ERE induces changes in the ERα 
conformation which then determine whether binding sites for coactivators or corepressors are exposed. 
This scenario is highly unlikely since disruption of the ERE motif did not affect BASE repression in 
presence of E2 (Fig. R10) and even the DNA binding mutant could transmit the repression (Fig. R20). 
 
Model F proposed that unliganded ERα contributes to BASE expression in the absence of hormone 
and is dismissed in presence of E2. In this case, knockdown of ERα with siRNA should reduce BASE 
expression levels. The contrary was observed, BASE levels in stripped medium were not affected, but 
the repression in presence of E2 was greatly diminished when ERα levels were reduced (Fig. R17). 
Therefore, the unliganded ERα is unlikely to contribute to basal BASE expression. This conclusion is 
further supported through experiments in the BASE expressing ERα-negative cell line SKBR3. Taken 
together, this model can also be neglected.  
 
In another hypothesis, BASE repression was due to secondary effects. In this model, E2 would 
regulate expression of a second gene, whose product would then either repress or activate transcription 
of the BASE gene. A common method to distinguish between direct and indirect target genes of a 
transcription factor is the blockage of translation by cycloheximide. If the changes of expression in 
response to drugs are direct, meaning no additional protein synthesis is required, then the regulation 
should also be detectable in presence of cycloheximide, whereas secondary effects would be blocked. 
Unfortunately, two almost identical splicing variants of BASE exist. The less abundant form generates 
a nonsense-mRNA and is most likely target of NMD. Therefore, interference with translation led to 
increased levels of BASE transcripts even in presence of E2 (data not shown) since this second form 
was no longer degraded via the NMD pathway. However, down-regulation of BASE within 1 hour 
after exposure to E2 argues against this model (Fig. R2). Nevertheless, the rapid decrease in BASE 
transcripts could be due to blocked transcription and/or enhanced degradation of BASE mRNA. In 
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view of the weaker repression observed in luciferase reporter assays as compared to mRNA level, it is 
possible that mRNA destabilization might also contribute. A tempting hypothesis is that BASE mRNA 
is regulated through micro RNAs. In this context it is interesting that BASE is a predicted target for 
several micro RNAs (miRBASE, http://microrna.sanger.ac.uk). It is of note that this software only 
analyses the 3’UTR of the longest transcript which includes all 9 exons. However, analysis of the 
ESTs of BASE showed that most transcripts only include exons 2 to 6. Thus, the analysis does not 
include the majority of the transcripts.  
 
In conclusion, the following models for BASE expression and regulation are proposed (Fig. D1). The 
pioneer factor FoxA1 binds to the inactive promoter and converts the chromatin structure into an 
active state (I) and/or replaces a repressor (II, e.g. NFIL3) which then allows recruitment of breast and 
salivary gland specifc factors and subsequent BASE expression. A cooperative role for Oct-1 is 
possible. However, which specific factors are recruited subsequently and whether FoxA1 is dismissed 
from the promoter in presence of hormone remains to be determined. 
 
The level of expression of the active gene is then regulated by ERα in the presence of E2. In the 
proposed models (Fig. D2), ERα is only associated with the BASE promoter in presence of estrogen. 
In model III, ERα forms a complex with INSM1 and cyclin D1 and recruits co-repressors. A 
repressive mechanism involving INSM1, cyclin D1 and HDACs has been shown for the neuroD/beta2 
gene (Liu et al., 2006). The data obtained in this thesis support this model at several points. Firstly, 
BASE gene repression only occurs in presence of the estrogen-activated ERα (Fig. R17 & R20). 
Secondly, ERα can bind to the BASE promoter in vitro and in vivo (Fig. R12 & R13). Thirdly, INSM1 
is expressed in cell lines where BASE is regulated by estrogen but not in SKBR3 cells where BASE is 
not regulated (Fig. R19). Fourthly, putative INSM1 binding sites have been identified in all three 
regions important for BASE regulation (Fig. R18). And finally, mutation of the ERE in the enhancer 
only slightly alters the INSM1 binding sites. All highly conserved bases are maintained and only non 
conserved bases are changed. This could explain the retention of regulation by E2 even if the ERE is 
disrupted.  
There are further indications from the literature which might argue in favour of this model. Cyclin D1 
is a well known estrogen-induced gene. Cyclin D1 can bind liganded and unliganded ERα and 
stimulates its transactivation ability (Neuman et al., 1997; Lamb et al., 2000). Zwijsen et al. (1997) 
reported a direct interaction between cyclin D1 and the LBD of ERα, and that this interaction is not 
affected by the pure-antiestrogen ICI164384. In contrast, ICI182780 was reported to interfere with 
transactivation at ERE elements (Neuman et al., 1997). However, interaction of ERα and cyclin D1 
have not been studied in the context of estrogen-repressed promoters. Nevertheless it is of note, that 
cyclin D1 is overexpressed in about 50% of breast cancer tumours (Gillett et al., 1996). Interestingly, 
BASE expression is also detected in about 50 % of tumours. It remains to be determined if a 
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correlation (positive or negative) between expression of cyclin D1 and BASE exists. An altered 
expression in some types of cancer has also been reported for INSM1. For example, it is re-expressed 
in neuroendocrine tumours (Pedersen et al., 2006) and its expression is increased in small-cell lung 
cancer (SCLC, Taniwaki et al., 2006). However, no link between INSM1 expression and breast cancer 
tumours has been reported so far.  
 
 
Figure D2. Schematic view of possible mechanisms of estrogen-induced repression of the BASE gene. 
 
Model IV is also based on the requirement of FoxA1, and perhaps Oct-1, for BASE expression. The 
model proposes that the liganded ERα associates with the BASE promoter where it then interacts with 
a second factor (e.g SHP) which subsequently recruits co-repressors. The short heterodimer partner 
(SHP) binds via the LXXLL-related motif directly to estrogen-bound ERα (Johansson et al., 2000). 
SHP has also been shown to directly interact with the DNA binding domain of FoxA1, thereby 
preventing its binding to DNA (Kim et al., 2004). Moreover, SHP acts as a repressor by recruiting 
HDACs, in particular HDAC1 (Gobinet et al., 2005).   
For the second transcription factor involved, Oct-1, it is of note, that Oct-1 DNA binding is inhibited 
by phosphorylation through PKA (Segil et al., 1991). Interestingly, PKA can indirectly be activated by 
E2 via the second messenger pathways (Doolan et al., 2000).  
To summarize, in presence of E2 both factors important for BASE expression would be prevented 
from binding to the promoter and therewith from activating the gene. As a result, BASE expression 
would be decreased.  
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8. Concluding remarks and future perspectives for BASE 
This thesis investigated the regulation of the breast cancer and salivary expression gene (BASE) in 
breast cancer cell lines, predominantly in the well-differentiated estrogen receptor alpha positive cell 
line MCF7. BASE fulfilled the main criteria of a model gene for studies on repression of gene 
expression by E2: strong E2- dependent down-regulation and a compact promoter region that contains 
major elements contributing to expression and regulation of the gene. Additionally, the restricted 
expression pattern of the only recently discovered gene BASE implies biomedical relevance as BASE 
is potentially a new breast cancer marker.   
 
One of the major findings of this study is the clear separation between gene expression and gene 
regulation in response to estrogen, with key roles for FoxA1 in expression and ERα in repression. 
Based on the data obtained, two models are favoured (Fig. D2). However, to distinguish between these 
and to refine the model, additional experiments would have to be conducted. These include chromatin 
immunoprecipitations to analyse presence of the pivotal factors (ERα, FoxA1, INSM1, cyclinD1, 
HDACs, SHP) at the BASE promoter in absence and presence of estrogen. Furthermore, transfection 
of SKBR3 cells with variants of ERα to induce regulation of BASE would be an excellent way to 
define the molecular basis of the control of the gene. If INSM1, which is not expressed in SKBR3, has 
a major role then it should be re-expressed under these conditions. Additionally, the application of 
HDAC inhibitors could clarify whether HDAC are involved in the process.  
 
Primary studies of BASE expression in breast cancer samples conducted in collaboration with Prof. 
Michael Kerins group in Galway, Ireland, indicate that about 50 % of breast tumours are positive for 
BASE while normal breast samples were negative. This expression rate is higher than for the accepted 
breast cancer marker HER2, which is overexpressed in only 30 % of breast and ovarian cancers 
(reviewed in Nicolini et al., 2006). This promising result should be the basis for more comprehensive 
studies analysing BASE expression in normal human tissues, especially salivary gland, and different 
breast cancer types. To evaluate the potential of BASE as breast cancer marker, it is important to 
analyse whether its expression can be correlated with breast cancer subtypes, stage or prognosis.  
Further studies should also focus on the BASE protein. The recombinant protein has been generated 
and an antibody will be raised against the full BASE protein. A BASE antibody would allow an 
immunohistochemical approach to investigate which in breast cell population expresses BASE. 
Furthermore, to address the function of BASE, the protein should be overexpressed and knocked down 
using siRNA. If the secreted protein could be detected, the value of BASE as a marker would even 
increase. Tests for BASE could then be performed in an inexpensive and non-invasive way by 
analysing the nipple aspirate fluid or maybe even saliva.  
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9. A distal enhancer of the cathepsin D gene 
Cathepsin D (CTSD) is a lysosomal aspartyl protease that is overexpressed in aggressive human breast 
cancer cells where it is associated with poor clinical outcome. Whereas CTSD is constitutively 
expressed in ERα-negative cells, its expression is induced by estrogen in ERα-positive cells (Liaudet-
Coopman et al., 2006). Transcription of CTSD is initiated at five sites located between -72 and -20 bp 
upstream from the initiation codon (Cavailles et al., 1993). Estrogen only induces transcription from 
the start site of at -20. This induction requires the promoter fragment -365 to -122. This region 
includes binding sites for ER (half EREs), and SP1 which cooperate in expression and the estrogen-
dependent regulation of the CTSD gene (Krishnan et al., 1994; Wang et al., 1998; Wang et al., 2001 
and references therein). However, no canonical ERE has been identified. In contrast, the distal ERα 
binding site (GGTCAtggTGGCC), identified by S. Mader and co-workers (Bourdeau et al., 2004), 
contains only one mismatch compared to the consensus motif and has been shown by ChIP to bind 
ERα in vivo.  
This study now shows the ability of the distal enhancer to induce estrogen-dependent activation in 
reporter gene assays. The distal enhancer caused significantly stronger estrogen stimulation than the 
proximal promoter (Fig. R25). Disruption of the ERE abolished this induction. Interestingly, the 
proximal promoter part showed only very weak estrogen-responsiveness. However, the proximal 
segment tested contained the core promoter and could drive transcription of the reporter gene, while 
only very low expression was seen with the enhancer alone. It is of note, that the proximal segment 
was slightly longer than the ones used in the previous studies that were mentioned. It therefore could 
include elements that attenuate the response to E2.  
 
The general importance of distal enhancers has been accepted. Three general models of action to 
describe how distal elements can communicate with the proximal promoter have been discussed 
(reviewed in Bondarenko et al., 2003).  
A. The looping model. Key transcription factors and coactivators or co-repressors assemble on the 
distal enhancer, which then contacts the transcription start site. The intervening chromatin loops out. 
This physical interaction leads to transcriptional activation or repression. Whether this is due to 
protein transfer between enhancer and the proximal promoter, or whether these factors only modify the 
promoter to set up a transcriptional permissive environment, is most likely dependent on the gene 
context. This mechanism has been reported for example for the monocyte chemoattractant protein 1 
gene (MCP-1). There, upon stimulation by TNF, NFκB binds to a distal regulatory region and recruits 
factors with HAT activity. Subsequent direct interaction between the distal region and the promoter 
induced histone modifications that allow binding of other transcription factors and gene activation 
(Teferedegne et al., 2006).  
B. The tracking model. In this model, again key factors assemble on the distal enhancer. From there, 
they track along the DNA to the proximal promoter. This mechanism has been shown for the prostate 
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specific antigen (PSA) promoter, where the introduction of an insulator between the enhancer and the 
transcription start site blocked tracking of PolII and thereby inhibited transcription (Wang et al., 
2005a). 
C. The spreading-looping model suggests formation of a series of small DNA loops by polymerisation 
of a special protein through which the enhancer and promoter move in close vicinity. The protein-
protein interaction is initialized at the enhancer and moves as a wave towards the promoter. Thereby 
the polymerizing protein can either interact with different factors bound to DNA or directly bind to 
multiple specific DNA binding sites between the enhancer and the promoter. This model is not 
suitable for transactivation over large distances.  
 
Figure D3.  
Proposed mechanisms for 
communication between distal 
enhancer and promoter (from 
(Bondarenko et al., 2003). For 
model description see text 
above. 
 
 
 
 
 
 
 
 
 
 
 
 
It is very likely that different mechanisms and combinations apply depending on the promoter context. 
Enhancer motifs may be located tens or hundreds of kilobases upstream the gene (Kleinjan and van, V, 
2005; Carroll et al., 2006). In these cases, the tracking model and the spreading-looping model are 
rather implausible. In contrast, for enhancers that are only 4 kb upstream it is conceivable that PolII 
tracks along the DNA to the promoter.  
For the CTSD, the enhancer is located 9 kb upstream. Therefore, the looping model is the more likely 
one (Fig. D4). Estrogen-dependent association of ERα and PolII with the enhancer has been shown in 
this study (Fig. R26), by Bourdeau et al. (2004) and very recently by Carroll et al. (2006). However, it 
remains to be investigated whether the looping model applies with the enhancer physically contacting 
the proximal promoter. Two approaches will be necessary to answer this question. The physical 
contact should be observed in a chromatin conformation capturing assay (3C) and using chromatin 
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immunoprecipitations PolII should be detected at the enhancer and the transcription start site but not 
on sequences in between. Furthermore, it has been shown that ERα associates with the proximal 
promoter in a cyclical manner (Shang et al., 2000). Preliminary data in this thesis indicated that ERα 
also cycles on the distal enhancer. It would be very interesting to test, whether these dynamics are 
synchronized.  These studies should also include another ERα binding site about 33 kb upstream of 
the transcription start site (Bourdeau et al., 2004). The potential and importance of this binding site 
also remains to be analysed in further studies.  
 
Figure D4. Looping model for 
induction of CTSD expression 
in response to estrogen 
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MATERIALS AND METHODS 
 
1. Reagents and antibodies 
α-amanitin, estradiol (E2), 4-hydroxytamoxifen (Tam), 12-O-Tetradecanoylphorbol 13-acetate (TPA), 
cycloheximide were purchased from Sigma (Taufkirchen, Germany). ICI182780 (ICI) was ordered from 
TOCRIS (Ellisville, MO). Protease inhibitor cocktail “complete (EDTA-free), T4 DNA ligase and 
selected restriction endonucleases were purchased from Roche Diagnostics GmbH (Mannheim, 
Germany). Protein A SepharoseTM CL-4B (Ge Healthcare Bio-Sciences AB, Uppsala, Sweden). 
Selected restriction endonucleases were also obtained from New England Biolabs (Frankfurt am Main, 
Germany) and Fermentas GmbH (St.Leon-Rot, Germany). Primers were synthesized by Sigma-
Aldrich Chemie GmbH (Munich, Germany).  
 
Table M1. Antibodies used in this study. (WB – Western blot, ChIP – chromatin immunoprecipitation, 
IF – immunofluorescence, EMSA – electromobility shift assay) 
 
Antigen name host company application 
α-BASE (R3) R3 rabbit Eurogentec S.A., Belgium WB 
α-BASE (R4) R4 rabbit Eurogentec S.A., Belgium WB 
α-BASE  A0406 rabbit CIM Antibody Core, 
Arizona State University 
WB 
α-E4BP4 H-300 rabbit Santa Cruz, Heidelberg ChIP, WB 
α-ERα HC-20 rabbit Santa Cruz, Heidelberg WB,ChIP, IF, EMSA 
α-ERα H-184 rabbit Santa Cruz, Heidelberg ChIP 
α-FoxA1 T-20 goat Santa Cruz, Heidelberg ChIP, WB, EMSA 
α-FoxA1 M01 mouse Abnova Corporation, 
Heidelberg 
WB 
α-GAPDH 6C5 mouse Santa Cruz, Heidelberg WB 
α-GFP FL rabiit Santa Cruz, Heidelberg WB, IF 
α-INSM1 1800342133 rabbit GenWay, San Diego,USA ChIP, WB 
α-Oct-1 C-21 rabbit Santa Cruz, Heidelberg ChIP 
α-PolII N-20 rabbit Santa Cruz, Heidelberg ChIP 
α-ßactin I-19 rabbit Santa Cruz, Heidelberg WB 
α-goat-IgG-HRP   Santa Cruz, Heidelberg WB 
α-rabbit IgG HRP    GE Healthcare, UK WB 
α-mouse IgG HRP   Dianova, Hamburg. WB 
α-P-PolII CTD4H8 mouse Upstate, NY, USA ChIP 
normal mouse IgG sc-2025 mouse Santa Cruz, Heidelberg ChIP 
normal rabbit IgG sc-2027 rabbit Santa Cruz, Heidelberg ChIP 
normal goat IgG sc-2028 goat Santa Cruz, Heidelberg ChIP 
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2. Cell lines, cell culture and analysis  
ERα-positive cell lines used were mammary epithelial adenocarcinoma cell line MCF7, human 
mammary gland ductal carcinoma cell lines T47D and ZR75, ERα-negative cell lines were mammary 
adenocarcinoma cell lines SKBR3 and MDA-MB-231, human cervical adenocarcinoma cell line 
HeLa, hepatocellular carcinoma cells line HepG2. Most cell lines were maintained in Dulbecco’s 
Modified Eagle’s Medium (DMEM, Sigma) supplemented with 10 % fetal calf serum (FCS, Sigma), 
2mM L-glutamine (Invitrogen), penicillin (100 units/ml, Invitrogen), and Streptomycin (100 µg/ml, 
Invitrogen) (“normal medium”) at 37 °C under 5 % CO2. ZR75 cells were cultured in RPMI 1640 
medium containing the same supplements as DMEM. Cell lines stably expressing ERα (ERα46 or 
ERα66) derived from ERα-negative cell line MDA-MB231 were previously described (Reid et al., 
2003) and maintained in DMEM under hygromycin selection (0.8 mg/ml). When hormone deprivation 
was required, cells were cultured in phenol red free DMEM (Gibco) containing 2.5 % charcol-dextran 
stripped serum and antibiotics (“stripped medium”) for 2 to 3 days before treatment.  To evaluate 
direct effects on BASE regulation, cells were cultured in 6-well plates and treated with the protein 
synthesis inhibitor cycloheximide (1 µg/ml) alone and in conjunction with E2 and ICI182780 for 6 h,  
4 h, 2 h, 1 h, and 0 h. Cells were harvested at the same time through lyses in 1 ml TriZol and 
subsequent storage at –80 °C until RNA was extracted.  
 
3. General PCR protocol 
In all PCR reactions performed FastStart Taq DNA polymerase (Roche Diagnostics, Mannheim, 
Germany) was used. For each primer pair PCR conditions were optimised by varying annealing 
temperature, extension time, MgCl2 and DMSO concentration. A standard PCR reaction was setup as 
follows: 
  
Table M2: Standard PCR reaction setup 
component volume used final concentration (in 25 µl) 
template      x µl 100 ng (plasmid) 2 µg (genomic DNA)
10X buffer w/ MgCL2 2.50 µl 1x 
dNTPs (25 mM) 0.25 µl 250 µM 
forward Primer (10 µM) 1.00 µl 400 nM 
reverse Primer (10 µM) 1.00 µl 400 nM 
FastStart Taq DNA polymerase (10 U/µl) 0.20 µl 2 U 
DMSO 1.25 µl 5 % 
MgCl2 (25 mM) 1.25 µl 1.25 mM    
Nuclease-free water Add up to 25µl  
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4. Expression constructs 
Expression constructs for human ERα66 (pcDNA3.1-hERα66, Metivier et al., 2004), ERα46 
(pcDNA3.1-hERα46, Metivier et al., 2004), ERα66 with mutated DNA binding domain (pcDNA3.1-
hERα66mut, unpublished) and ERß (pSG5-hERβ) had been previously generated in the laboratory. 
The FoxA1 expression construct, containing the FoxA1 coding sequence as BamH1 and Xho1 
fragment in pcDNA3.1/hygro, was generated by Heike Brand. Expression constructs for INSM1 and 
E4BP4 (NFIL3) were kindly provided by Dr. Michael Lan (The Research Institute for Children, New 
Orleans, USA) and Dr. Sotiri Tetradis (UCLA School Dept Dentistry, Los Angeles, USA). 
 
4.1 BASE protein expression constructs 
The bacterial expression vectors M80, M82, and pET22b(+) were kindly provided by the Protein 
Expression and Purification Core Facility EMBL. The pcDNA3.1/hygro vector was obtained from 
Invitrogen Corporation (Carlsbad, CA) and the EGFP-N1 and EGFP-C1 vectors were purchased from 
Clontech Laboratories Inc. (Palo Alto, CA). The BASE coding sequence was obtained from the 
ENSEMBL genome browser and primers were designed accordingly. The BASE coding sequence was 
then amplified from MCF7 cDNA using FastSart DNA Polymerase (Roche). Different primer pairs 
(see table below) introducing various restriction sites were used to obtain suitable products for cloning 
into the expression vectors pEGFP-N1 (for C-terminal tagging) and pGFP-C1 (for N-terminal 
tagging), and the vectors M80, M82, p22b(+) for bacterial expression. Since the first 20 aa of BASE 
are predicted to be a signalling peptide, marking BASE for secretion, the sequence for the full length 
and the truncated protein, omitting the signal peptide, were generated. The GFP-tagged BASE was 
excised using Nhe1 and Not1 for the C-terminal GFP-tagging and Nhe1 and HindIII for the N-
terminal tagging and subcloned into the pcDNA3.1hygro vector.  
 
C-terminal tagging (pEGFP-N1, pcDNA3.1 hygro) 
fwd2: gcg gctagc gcc atg ctg aat gtc tcc ggc  (clamp Nhe1 Kozak ATG) 
rev2: aattc agatct gtttgccacaacaaattttg (clamp BglII CDS BASE) 
 
N-terminal tagging (pEGFP-C1, pcDNA3.1 hygro) 
fwd3:  at agatct atg ctg aat gtc tcc ggc (BglII- ATG) 
rev3: ca aagctt cta tgtttgccacaacaaattttg (HindIII- TAG) 
 
HA-tagging (pcDNA3.1+) 
HA_fwd4: agcg gctagc gccacc atg ctg aat gtc tcc ggc (clamp Nhe1 Kozak ATG) 
HA_rev4: gcca gaattc cta agcgtaatctggaacatcgtatgggta tccgcc tgtttgccacaacaaattttg 
                                                                (clamp EcoR1-TAG-HAGlyGlyCDS)
Expression constructs (M80, M82, p22b(+)) 
fwd L-Nco1: cgcat ccatg gtg aat gtc tcc ggc (Nco1- ATG-whole protein) 
fwd S-Nco1: cgcat ccatg gca cag gag gtc ctg gct (Nco1-ATG-w/o signal. peptide) 
CDS rev:           cgtcat ggt acc cta tgt ttg cca caa caa att ttg (Asp718- TAG) 
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5. In vitro transcription and translation 
In vitro transcription and translation were mainly accomplished with the TNT T7 Quick Coupled 
Reticulocyte Lysate system from Promega Corp. (Madison, WI) following the manufacturer’s 
protocol. In short, 40 µl master mix were combined with 1 µg DNA, 1 mM Methionine and 9 µl dH2O 
containing 1 µg template DNA and incubated for 90 min at 30 °C. The expression vectors 
pcDNA3.1hygro-hERα66, pcDNA3.1hygro-hERα46 and pcDNA3.1hygro-FoxA1 were used as 
templates for transcription with T7 RNA polymerase followed by translation to generate human 
ERα66, ERα46 and FoxA1 proteins. 
For non-radioactive EMSA experiments in vitro transcription/translation was also carried out using the 
RTS 100 Wheat Germ CECF Kit following the manufacturer’s protocol. The reaction is set up on a 
microtiter plate consisting of feeding and reaction modules which are separated by a semi-permeable 
membrane. To obtain in vitro translated proteins 900 µl feeding mix, 80 µl amino acids and 20 ml 
methionine were combined in the feeding compartment. The reaction solution, containing 15 µl 
reaction mix, 4 µl amino acids, 1 µl methionine, 15 µl wheat germ lysate and 15 ml sterile water 
containing 2 µg plasmid, was placed into the reaction compartment. The modules were closed with 
adhesive film and incubated at 30 °C for 24 hours. After incubation the reaction mix was transferred to 
a fresh tube and stored at –80 °C until use. Production of protein was confirmed by Western blot. 
  
6. Transient transfections and luciferase assays 
Before transfection, cells were plated in 24-well plates and cultured over night in normal medium, or 
when hormone deprivation was required, maintained in stripped medium for 2 days. Transfections 
were carried out at 70 % confluency with Fugene6 Transfection Reagent (Roche) for MDA and 
derived cell lines and with ExGeneTM500 (Fermentas) for all other cell lines used. DNA mixture per 
well consisted of 1 µg reporter constructs, 100 ng phRL-TK Vector (Renilla luciferase, Promega), and 
for cotransfection experiments, 200 ng expression plasmids for either ERα66, ERα46, ERα66mut, 
FoxA1, Gata1, or ERRγ. Empty expression vector was used to adjust the final amount of DNA. Cells 
were treated immediately after transfection as indicated with either vehicle (EtOH), 10-8 M E2, 10-6 M 
ICI182780, 10-7 M OH-Tam, 50 ng/ml TPA. After 24 h incubation, cells were harvested and cellular 
extracts were analysed for luciferase activity using the Dual-luciferase reporter system (Promega). The 
firefly luciferase reporter activities were normalized by Renilla luciferase activities and shown as 
relative light units (RLU). The data are the mean ± SD from a minimum of three independent 
experiments with triplicates for each experiment.  
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7. Generation of stable cell lines 
MCF7 cells were seeded in 9cm plates and at 50 % confluency transfected with either carboxy-
terminal GFP-tagged BASE (pcDNA3.1-BASE-GFP), N-terminal GFP-tagged BASE (pcDNA3.1-
GFP-BASE), of C-terminal HA-tagged BASE (pcDNA3.1-BASE-HA). The pcDNA3.1 vector confers 
hygromycin resistance and drives expression of BASE under the control of a cytomegalovirus (CMV) 
promoter. 24 hours after transfection cells were set under hygromycin selection (0.8 mg/ml). Cell 
colonies were isolated and screened for tagged-BASE expression by Western blot analysis with GFP-
antibody.  
 
8. Identification of putative transcription factor binding sites 
Identification of transcription factor binding sites was performed with Dragon ERE Finder (version 2) 
and MatInspector v.2.2 (Cartharius et al., 2005) software bases on the TransFac database (Matys et al., 
2003). All three databases are available online (Dragon ERE Finder: sdmc.lit.org.sg/promoter, 
MatInspector: www.genomatix.de, TransFac: www.gene-regulation.com). All parameters were set as 
default except for matrix group (vertebrates). 
 
9. Preparation of genomic DNA 
Cells maintained in normal medium were washed twice with PBS, lysed Vo ml lysis buffer (3.6 M 
GTCI (Guanidine Thiocyanate/Isobutyl), 50 mM Tris-HCl (pH 8), 0.05 % SDS) and then transferred 
into a new tube (polypropylene). To extract the DNA Vo ml of phenol/chloroform/isoamyl alcohol 
(25:24:1; AppliChem GmbH, Darmstadt, Germany), mixed rigorously, and centrifuged at 2000 xg or  
5 min. The aqueous phase was transferred to a fresh tube and the phenol/chloroform extraction was 
repeated until the aqueous phase was clear. After 2 washing steps using chloroform only, the DNA 
was precipitated by adding 1/10 of Vo 5 M NaCl and Vo of Isopropanol. DNA was pelleted through 
centrifugation at maximal speed for 10 min and then washed with 70 % EtOH. Genomic DNA was 
resuspended in 10 mM Tris (pH 8.0) and stored at 4 °C. 
 
10. Measurement of DNA/RNA  concentration 
The light absorption-maximum of nucleic acids is at 260 nm (UV-light) while proteins absorb 
maximal at 280 nm. To determine the nucleic acid concentration and the impurity (contamination with 
proteins) the absorption was measured at both wavelengths and the ratio of A260/280 was calculated. 
dsDNA at the concentration of 50 µg/ml has an OD260 of 1. Ratios of A260/280 below 1.8 were 
considered impure and discarded or purified using EtOH-precipitation. 
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11. DNA purification/concentration through EtOH-precipitation 
To purify or to concentrate the DNA it was precipitated by adding 1/10 volume of 3 M Na-acetate and 
3 volumes of EtOH and incubation for at least 20 min @ -80 °C. DNA was pelleted by centrifugation 
at 14,000 rpm for 15 min (at 4 °C). After washing with 70 % EtOH and air drying for 10 min, DNA 
was resuspended in TE buffer (10 mM Tris-Cl, 1 mM EDTA (pH 8.0)) or dH2O. 
 
12. Basic luciferase reporter constructs - cloning of the 5’ upstream region  
12.1 Basic 2.4 kb construct and first deletion series 
2.4 kb of the 5’ region upstream of the BASE gene were amplified from 2 µg genomic DNA from 
MCF7 cells using FastStart Polymerase (Roche). Primers were designed to introduce Kpn1 and Xho1 
restriction sites at the end of the PCR product (2.4 kb fwd: gcg ggtacc tacatgactccaggctgtgg; start rev 
gcg ctcgag tgtgctgtcaagacactctgg). Using these restriction sites the BASE promoter region from -2418 
to +23 was cloned into the multi cloning site of the pGL3-basic (Promega) reporter construct upstream 
of the luciferase reporter gene.  
The ßactin promoter region (–1109 bp to +36 bp) was also amplified from 2 µg genomic DNA from 
MCF7 cells (forward primer: gcg ggtacc tgacaaggacagggtcttcc; reverse primer: gcg agatct 
caaaggcgaggctctgtg) and subcloned into the pGL3-basic vector using the restriction enzymes Kpn1 
and BglII. The sequence was verified by DNA sequencing at the Genomics Core Facility using RV-
primer3 (ctagcaaaataggctgtccc) and GL2 primer (ctttatgtttttggcgtcttcca). The Renilla-reporter vector 
(phRL-TK Vector) was purchased from (Promega) and the pS2-luciferase construct (containing the 
pS2 promoter from -556 to +26) was previously generated in the laboratory.  
 
12.2 Modification of promoter region using digests  
To identify the promoter regions important for expression and regulation of the BASE gene a series of 
deletion mutations (series 1) was created (constructs A to H). Construct ‘A’ was generated by PCR 
using the 2.4 kb construct as template and the following primers (2.2 fwd: gcg ggtacc 
ggagggagagggacacctac, start rev: gcg ctcgag tgtgctgtcaagacactctgg) introducing Kpn1 and Xho1 sites 
for cloning. The remaining constructs (B-H) were generated by digestion with different combinations 
of blunt cutting restriction enzymes (Tab. M3) and subsequent internal vector re-ligation. 
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Table M3: Information for generation of deletion constructs of BASE promoter 
construct  restriction enzymes sequence omitted 
Δ I A PCR -2419/ -2353 
Δ II B Msc1, PvuII, 4+BSA -2352 /-1689 
Δ II/III* C Msc1, Pml1,  1+BSA -2352 /-917 
Δ II/III/IV* D Msc1, Sma1, 4+BSA  -2352 /-179 
Δ III E PvuII, Pml1,  1+BSA -1688 /-917 
Δ IV F Pml1, Sma1,  4+BSA  -916 /-179 
Δ III//IV* G PvuII, Sma1, 4+BSA -1688 /-179 
Δ /IV* H Msc1, PvuII, 4+BSA ; Pml1, Sma1, 4+BSA -2352/-1689 and -916 /-179 
* Constructs are not represented in results 
 
12.3 Modification of the promoter region using site-directed mutagenesis 
To evaluate the significance of specific transcription factor binding sites (EREs, FoxA1, Gata1, AhR, 
AP-1, Oct-1) point mutations were introduced using site-directed mutagenesis by overlap extension 
(Fig. M1). Two primer pairs were designed to amplify two overlapping DNA fragments (A & B) 
which harbour the mutation site in the overlapping region. The forward primer (primer 1) of set 1 
contains a restriction site for subsequent subcloning while the reverse primer (mut primer 1) contains 
the mutation. In the second primer set the forward primer (mut primer 2) includes the mutation and the 
reverse primer (primer 2) does introduce an restriction site for cloning. If convenient restriction sites 
were present in the promoter the outside primers were not extended with additional restriction sites. 
All primers used are listed below. In the first step the fragments A & B were generated in separate 
amplifications using the primers described. The PCR products were analysed by electrophoresis and 
purified using the Qiagen Gel Purification kit. The two overlapping fragments function as templates in 
a second PCR reaction where they are first extended to form the full-length mutant DNA, and then 
amplified using only the outside primers (primer 1 and primer 2). The mutated DNA was also gel 
purified and subsequent digested with the appropriate restriction enzymes. The corresponding DNA 
fragment was excised from the original reporter construct (e.g. pGL3-BASE 2.4 kb) using the same 
enzymes. In the last step, the mutated sequence was ligated into the vector backbone substituting the 
wild type DNA sequence. For mutations close to the transcription start site, only one primer pair was 
used in which the reverse primer contained the mutation and a restriction site for cloning. A similar 
amplification and cloning strategy was applied for the generation for the deletion mutants omitting 
only 50 bp to 150 bp. Primers are listed below in tables M4 and M5. 
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Figure M1. Schematic 
display of the mutation 
strategy. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table M4: Primers used for further deletion mutations.  
construct  primer sequence segment omitted 
Δ A fwd miss A gacccactgaagactgatgt ctcaactctagtacaggctc -2351 / -2099 
 rev  miss A gagcctgtactagagttgag acatcagtcttcagtgggtc  
Δ B fwd miss B gttatccagagagtaaagca gataacatttcaggatcca  -2098 / -1984 
 rev  miss B tggatcctgaaatgttatc tgctttactctctggataac    
Δ C fwd miss C ttcaggatccaaattgttaa atatttgctctgtgaatggg -1983 / -1836 
 rev  miss C cccattcacagagcaaatat ttaacaatttggatcctgaa  
Δ D fwd miss D gatggaaacctttattgtaa agctgggtgggaatac -1835 / -1684 
 rev  miss D gtattcccacccagct ttacaataaaggtttccatc  
Δ AB* fwd miss AB gacccactgaagactgatgt gataacatttcaggatcca -2351 / -1984 
 rev  miss AB tggatcctgaaatgttatca catcagtcttcagtgggtc   
Δ BC* fwd miss BC gttatccagagagtaaagca atatttgctctgtgaatggg -2098 / -1836 
 rev  miss BC cccattcacagagcaaatat tgctttactctctggataac  
Δ CD* fwd miss CD ttcaggatccaaattgttaa agctgggtgggaatac  -1983 / -1684 
 rev  miss CD gtattcccacccagctttaa caatttggatcctgaa  
Δ C1 fwd miss C1   aggataacatttcaggatcc aatatttaccaaactggatc  -1984 / -1930 
 rev  miss C1   gatccagtttggtaaatatt ggatcctgaaatgttatcct  
Δ C2 fwd miss C2  accccaggaacacatcacga catatttcactacatctttg -1930 / -1881 
 rev  miss C2   caaagatgtagtgaaatatg tcgtgatgtgttcctggggt  
Δ C3 fwd miss C3  cattacaatgatagcgtgta ttgctctgtgaatgggaata -1880 / -1831 
 rev  miss C3   tattcccattcacagagcaa tacacgctatcattgtaatg  
 fwd 2.4 kb gcg ggtacc tacatgactccaggctgtgg  
 rev  enhancer   tggagaggcactgcttaggt  
With * marked constructs are not shown in results.  
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Table M5: Primers used for generation of point mutations. Mutated bases are shown in capital letters. 
Restriction enzymes used for cloning are shown in regular, while restriction sites introduced for 
screening are shown in italic.  
 
primer 
 
sequence restriction 
enzyme 
mutations at the transcription start site  
out fwd primer   
680 bp fwd1        gcg ggtacc ggaccttgggcaagatttgt Kpn1 
600 bp fwd2         gcg ggtacc ggagagacggagaccatgaa Kpn1 
mut rev primer   
mERE TSS rev1 gctctcgagacTctActAgTctctgtaggttga Xho1, Spe1 
   
mutations in the BASE enhancer region  
out fwd primer   
fwd 2.4 kb gcg ggtacc tacatgactccaggctgtgg Kpn1 
out rev primer   
rev enhancer       tggagaggcactgcttaggt  
mut fwd & mut rev primer   
mERE EH fwd aaattgttaactctatgcct tAACacGtttAAACGccccaggaacacatc Pme1  
mERE EH rev gatgtgttcctggggCGTTTaaaCgtGTTaaggcatagagttaacaattt Pme1 
mFoxA1 EH fwd  accccaggaacacatcacgaaaAaGCtTccaaactggatctttcATGCta 
cattacaatg 
HindIII  
mFoxA1 EH rev tacacgctatcattgtaatgtaGCATgaaagatccagtttggAaGCtTtt 
tcgtgatgtg 
HindIII 
mGata1 EH fwd tttctgtttacattacaGAATtCgcgtgtacatatttcac  EcoR1  
mGata1 EH rev gtgaaatatgtacacgcGaATTCtgtaatg taaacagaaa EcoR1 
mAhR EH fwd tttctgtttacattacaatgatagGCCTtacatatttcac Stu1  
mAhR EH rev gtgaaatatgtaAGGCctatcattgtaatgtaaacagaaa Stu1  
mERE EH perf fwd ctctatgccttAACGGTCACtgtgaccccaggaacacatc         
mERE EH perf rev gatgtgttcctggggtcacaGTGACCGTTa                        
mOct1 EH perf fwd ggatctttACgtttaGattacaatgatagcgtgta  
mOct1 EH perf rev tacacgctatcattgtaatCtaaacGTaaagatcc    
mOct1 EH rev fwd ggatctttACATTTGTCttacaatgatagcgtgta  
mOct1 EH rev rev tacacgctatcattgtaaGACAAATGTaaagatcc    
mFoxA1 EH 1 fwd aaAaGCtTccaaactggatctttctg left site only
mFoxA1 EH 1 rev gatccagtttggAaGCtTtttcgtgatgtgttcctggggt left site only
With * marked constructs are not shown in results. 
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12.4 Subclonings into pGL3-enhancer and pGL3-promoter constructs 
To assess the role of the transcription start site and other promoter segments different promoter 
fragments were subcloned either in the pGL3-promoter vector or the pGL3-enhancer vector (both 
purchase from Promega). These vectors are almost identical to pGL3-basic but contain either an 
additional SV40 promoter or a SV40 enhancer. All constructs were generated by digestion and ligation 
using the original 2.4 kb reporter construct as template. The used restriction enzymes are listed in the 
table.  
 
Table M6. Restriction enzymes used for subclonings into pGL3-promoter and pGL3-enhancer 
construct 
name     
internal 
number 
template enzymes  
  pGL3- promoter Kpn1/ Sma1  
P1 1760 1236 Kpn1/ Sma1  
P2 1764 1236 Kpn1/ Pml1  
P3 1769 1236 Kpn1/ PvuII  
P4 2555 1236 Kpn1/ Msc1  
P5 1776 1282 Kpn1/ Sma1  
P6 1828 1793 Kpn1/ PvuII  
  pGL3- enhancer Sma1/ Xho1  
E1 1782 1236 Sma1/ Xho1  
E2 1787 1236 Pml1/ Xho1  
E3 1788 1236 PvuII/ Xho1  
E4 1793 1236 Msc1/ Xho1  
  pGL3- enhancer Kpn1/ Xho1  
E5 1797 1282 Kpn1/ Xho1  
E6 1800 1291 Kpn1/ Xho1  
E7 1805 1294 Kpn1/ Xho1  
E8 1808 1322 Kpn1/ Xho1  
E9 1834 1793 PvuII/Sma1  
E10 1917 1793, 1327 Sma1/Xho1  
 
13. Heat shock transformation and plasmid DNA preparation  
Chemical competent DH5α cells were thawed and incubated with 5 µl ligation for 30 min on ice. Cells 
were then heat shocked for 45 s at 42 °C and kept on ice for 2 min before addition of 250 µl SOC 
medium (SOC medium: 0.5 % Yeast extract, 2.0 % tryptone, 10 mM NaCl, 2.5 mM KCl, 10 mM 
MgCl2 , 20 mM MgSO4, 20 mM glucose). After incubation for 1 h at 37 °C cells were plated on LB 
agar plates containing the appropriate antibiotic, which corresponds to the resistance gene of the 
introduced plasmid, and incubated at 37 °C overnight. Next day 2 ml LB medium aliquots containing 
the appropriate antibiotic were inoculated with single colonies and cultured for at least 8 hours at  
37 °C. The cultures were then used to inoculate bigger cultures (maxiprep) or to isolate DNA 
(miniprep). For minipreps and maxipreps DNA was purified using Qiagen spin-miniprep kits or 
maxiprep kits according to manufacture instructions. 
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14. RT-PCR and quantitative real-time PCR  
RNA was extracted from cells in 1 ml TriZol reagent (Invitrogen) followed by a phenol-chloroform 
phase extraction and isopropanol precipitation. cDNA reverse-transcription using poly-dT oligos 
(SigmaAldrich) was then performed on 3 µg total RNA using Expand Reverse Transcriptase (Roche) 
according to manufacturer’s instructions.  
2 µl cDNA were used in the subsequent real-time quantitative PCR containing 1x SYBR Green PCR 
Master Mix (Applied Biosystems) and 0.4 µM gene specific primers (synthesized by SigmaAldrich, 
listed below). PCR was performed on an ABIprism7500 (Applied Biosystems) with 40 cycles of two-
step amplification (1x 2 min 50 °C, 1x 10 min 95 °C, 40 x 15 sec 95 °C, 1 min 60 °C measurement). 
The fold change of expression was calculated using either βactin or PPIA as an internal reference gene 
and the expression level was determined relative to the vehicle treated control. 
 
Table M7: Primers used for RT-qPCR  
Primer name sequence Product size  
RT ßactin fwd GTCTTCCCCTCCATCGTG 256  
RT ßactin rev GGGTACTTCAGGGTGAGGATG   
RT PPIA fwd AGGGTTCCTGCTTTCACAGA 83  
RT PPIA rev CTTGCCACCAGTGCCATTAT   
RT pS2 fwd CACCATGGAGAACAAGGTGA 134  
RT pS2 rev TGACACCAGGAAAACCACAA   
RT BASE (2/3) fwd GGAGTTTCTTCCCAGCTCCT 135  
RT BASE (2/3) rev GATGTCCAGGAGGCCTGATA   
RT BASE (5/6) fwd GGAGTTTCTTCCCAGCTCCT 176  
RT BASE (5/6) rev GATGTCCAGGAGGCCTGATA   
RT ERα fwd  CATGATCAGGTCCACCTTCT 170  
RT ERα rev  AGCAGCATGTCGAAGATCTC   
RT ERRα fwd (1) TCGCTGTCTGACCAGATGTC 502  
RT ERRα rev (1) CCTCGAGCATCTCCAAGAAC   
RT ERRß fwd (1) CCCCTACCTGAGCTTACAGATTT 486  
RT ERRß rev (1) TACATTGAATCTGAGTTGGCAAG   
RT ERRγ fwd (1) ACCATGAATGGCCATCAGAA 470  
RT ERRγ rev (1) ACCAGCTGAGGGTTCAGGTAT   
RT ERß fwd (1) TGAAAAGGAAGGTTAGTGGGAACC 528  
RT ERß rev (1) TGGTCAGGGACATCATCATGG   
RT E4F fwd 2 CTGCTGGAGGTGGAGGAGTT 113  
RT E4F rev 2  TCAGCTACCACGGACGAGAA   
RT INSM1 fwd 1 TTGGAACCCCCACTTTTACG 112  
RT INSM1 rev 1   TTCCAACCACGAGACAAACG   
RT ZNF219 fwd 2 CTTTCCGCTCAGCACATCAC 82  
RT ZNF219 rev 1  TAGTCGCAGTGCGGACACTT   
RT IRF3 fwd 1    CAAGAGGCTCGTGATGGTCA 142  
RT IRF3 rev 2 GTCGGAGGTGAGGGAGAGTG   
RT FoxF2 fwd  1  CGCTGGAGCAGAGCTACTTG   
RT FoxF2 rev 1 CCCATTGAAGTTGAGGACGA 122  
RT FoxF2 rev 2  CGCTAGCTGAGGGATGGAAA 150  
RT ATF2 fwd  1  AACCGCCATGCAGAAGAAAT 123  
(1) primer published by (Cheung et al., 2005) 
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Table M7: Primers used for RT-qPCR (continued) 
Primer name sequence Product size  
RT ATF2 rev  1 TTGGATGTGCTGACCGAACT   
RT FoxA1 fwd 1 GAAGATGGAAGGGCATGAAA 97  
RT FoxA1 rev 1 GCCTGAGTTCATGTTGCTGA   
RT CTSD (5/6) fwd 1 CAGAAGCTGGTGGACCAGAAC 139  
RT CTSD (5/6) rev 1  TGCGGGTGACATTCAGGTAG   
RT E4BP4 fwd 1          GCGCTCGGAACTGACCTACT   
RT E4BP4 rev 1        CCACATTGCTACTGGCATCA 117  
RT E4BP4 rev 2 ACCATCATCTTGTCCACATTGC 130  
 
15. siRNA experiments 
siRNAs against FoxA1 and INSM1 were purchased from Dharmacon (SMARTpool siRNA) and 
StealthTM  siRNA against ERα, E4BP4, and Oct-1 were ordered from Invitrogen. MCF7 cells were 
transfected (in 6-well plates) with siRNA at a final concentration of 100 nM using reverse-transfection 
with Lipofectamine2000 (Invitrogen). The next day, cells were treated and 24 hours later harvested for 
RNA isolation or analysis by Western blot. When hormone deprivation was required, cells were set E2 
free 24 hours prior transfection.  
 
16. Antibody generation 
BASE antibodies raised in two rabbits against two peptides (ESTPQRKEATVQ and 
KVQIRLEKNVGGRY) of the BASE protein were generated and purified by Eurogentec S.A. 
(Belgium). The antibodies were tested in Western Blot analysis using recombinant BASE protein 
produced by the Protein Expression and Purification Core Facility (Ario DeMarco) at the EMBL using 
the pET22b(+)-BASE short construct described above. 
 
17. Western blotting  
Cells were washed twice with phosphate buffered saline (PBS) and directly lysed in Lämmli buffer 
(4x: 250 mM Tris pH 6.8, 8 % SDS, 40 % glycerol, 150 mM DTT, bromphenol blue). Samples were 
sonicated to reduce the viscosity and proteins were resolved on a 10 % SDS-PAGE gel at 200 V in 
SDS/Page running buffer (5x: 25 mM Tris, 192 mM glycine, 0.1 % (w/v) SDS). Proteins were then 
transferred onto PVDF membranes (Millipore Corporation, Bedford, MA, USA) using wet transfer 
over night (50 V, 4 °C) (transfer buffer: 0.02 M Tris, 0.15 M glycine, 20 % MetOH). 
.  
Membranes were blocked for 1 h in 3 % milk + 0.05 % Tween®20 (Sigma-Aldrich,St. Louis, MO, 
USA), incubated 1 h with primary antibodies (Table M1), washed and incubated for another 1 h with 
corresponding horseradish peroxidase-conjugated secondary antibodies (1:10000), and developed 
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using ECLTM Western Blotting Detection reagents (PerkinElmer Life Sciences, Boston, MA, USA) 
and Kodak Biomax MR films. To reprobe the membranes these were stripped for 20 min in stripping 
buffer (0.1 M glycin (pH 2.8)), washed with PBS and reprobed with the desired primary antibody. 
For protein analysis in the cell culture medium (for secreted proteins) samples were prepared through 
“Wessel-Flugge precipitation” (Wessel and Flugge, 1984). In short, 1 ml of medium was combined 
with 4 ml of MetOH and mixed well. After addition of 1 ml Chloroform, sample was vortexed again 
before 3 ml dH2O were added to increase the volume. Following another vortexing step samples were 
centrifuged for 10 min at 14,000 xg at 4°C. The aqueous phase was removed and 3 ml MetOH were 
added. Proteins were collected by centrifugation at 4 °C for 30 min at 14,000 xg. The pellet was 
washed ones with 50 % MetOH, dried and resuspended in 1x Lämmli buffer. 
 
Table M8: Western blot gel compositions 
component separation gel (10 %, 50 ml) stacking gel (5 %, 10 ml) 
30 % acrylamide 
1.5 M Tris (pH 8.8)  
1.0 M Tris (pH 6.8) 
10 %SDS 
10 % ammonium persulfate 
TEMED (Sigma) 
dH2O 
16.7 ml 
12.5 ml 
 
 0.5 ml 
 0.5 ml 
0.02 ml 
19.8 ml 
1.7 ml 
 
1.25 ml 
0.1 ml 
0.1 ml 
0.01 ml 
6.8 ml 
 
18. Immuostaining and Microscopy 
For localization studies MCF7 cells were seeded in 6 cm plates containing sterile round cover slips 
and allowed to settle over night at 37 °C, 5 % CO2. Using ExGeneTM500 cells were transiently 
transfected with either pcDNA3.1hygro-BASE-GFP, pcDNA3.1hygro-GFP-BASE, or 
pcDNA3.1hygro-GFP, and where indicated co-transfected with pSRß-mRFP, encoding red-
fluorescent-protein (RFP) with a leading sequence which targets it to the endoplasmaic reticulum. The 
pSRß-mRFP plasmid was kindly provided by J. Ellenberg, EMBL, Heidelberg. 
24-48 hours after transfection, cells were washed twice with PBS and fixed with ice cold MetOH for 
5-10 min. Cell nuclei were stained with DAPI, washed, and cells were mounted in Moviol containing 
the radical scavenger DABCO and then examined using a Zeiss Axioscope fluorescent microscope 
(Carl Zeiss, Jena, Germany) using the x63 objective. 
 
Moviol was prepared according to Osborn und Weber (1982).  
2.4 g Mowiol 4-88 (Hoechst, Frankfurt), 6 g Glycerol and 6 ml ddH2O were stirred for 3 h at room 
temperature. To dissolve the Moviol 12 ml of 0.2 M Tris-HCL (pH 8.5) were added followed by a  
10 min incubation at 50 °C with occasional stirring. After centrifugation for 15 min at 5000 xg the 
supernatant was aliquoted and stored at –20 °C. 
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19. Electrophoretic mobility shift assay (EMSA) - radioactive and non-radioactive 
Radioactive and non-radioactive EMSAs differ in 2 steps – the probe preparation and based on this the 
detection method.  
Oligos (see table below) were ordered from SigmaAldrich either unmodified or for non-radioactive 
EMSAs with 5’-end biotinylation. The oligos were annealed by heating sense and antisense oligos in 
1x annealing buffer (10x: 100 µl 1 M Tris (pH 8.0), 200 µl 5 M NaCl, 120 µl 0.5 M EDTA, 690 µl 
dH2O) up to 100 °C and slow cooling to room temperature. Efficiency of annealing was analysed in a 
12 % native gel. For radioactive EMSAs 2 µg dsoligos were end labelled in a 20 µl reaction in 1x 
PNK buffer with 1.5 µl T4 polynucleotide kinase (PNK, New England Biolabs) and 1 µl [γ-32P]ATP 
(3,000 Ci/mM; PerkinElmer Life Sciences). After 90 min incubation at 37 °C probes were purified 
using Chromaspin columns (Clontech, USA). The columns were prepared by centrifugation at 2000 xg 
for 5 min. Probe volume was increased to 100 µl with TE buffer and applied to the columns. Probe 
was recovered by centrifugation for 5 min at 2000 xg. 1 µl was used for analysis in the scintillation 
counter. 
In vitro translated proteins or extracts of MCF7 cells were pre-incubated in binding buffer (10 mM 
Tris-HCl (pH 8.0), 1 mM EDTA, 3 mM MgCl2, 100 µg/ml BSA, 12 % glycerol, 1 mM DTT, 100 mM 
KCl, if mentioned hormone) with 1 µg of poly (dI/dC) for 5 min at room temperature. The samples 
were then incubated for 30 min at room temperature with 1 ng of radioactive oligonucleotide probe (1-
6*104 cpm) or non-radioactive Biotin labelled probes (SigmaAldrich). For competition assays 10 to 
100x of unlabeled oligonucleotide was used. For supershift experiments, specific antibodies (1 mg/ml) 
were added 5 min after initial start of incubation. Protein-DNA complexes were then separated from 
free probe by non-denaturing electrophoresis on 4 % or 6 % polyacrylamide gels in 1x TBE (45 mM 
Tris/borate, 1 mM EDTA). The gels were pre-run at 4 °C for 30 min followed by electrophoresis for  
2 h at 200 V.  
For radioactive EMSAs gels were dried and subsequently exposed to Kodak Biomax film (Eastman 
Kodak Co., Rochester, NY). Non-radioactive gels applied to Western blot procedure using peroxidise-
conjugated Streptavidin antibody (Jackson ImmunoResearch) to detect the Biotin-labeled oligos. 
 
Table M9: Gel composition for EMSAs  
 30 % acrylamide 
(BioRad) 
10x TBE 10 % ammonium 
persulfate 
TEMED 
(Sigma) 
dH20 
4 % 6,7 ml 2,5 ml 0,5 ml 0,03 ml 40,3 ml 
6 % 10 ml 2,5 ml 0,5 ml 0,03 ml 37 ml 
12 % 20 ml 2,5 ml 0,5 ml 0,03 ml 27 ml 
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Table M10: Oligos used in EMSAs  
Oligo name Sequence 
BASE_EH_I_sense -1994ttcaggatccaaattgttaactctatgccttggaacattttgTGACCcca-1944 
BASE_EH_II_sense -1954tgTGACCccaggaacacatcacgaaatatttaccaaactggatctttctg-1904 
BASE_EH_III_sense -1914gatctttctgtttacattacaatgatagcgtgtacatatttcactacatc-1864 
BASE_EH_IV_sense -1874tcactacatctttgccagcagatggaaacctttattgtaaatatttgctc-1824 
BASE C2_sense -1930aatatttaccaaactggatctttctgtttacattacaatgatagcgtgta-1880 
BASE C2_anti-sense -1880tacacgctatcattgtaatgtaaacagaaagatccagtttggtaaatatt-1930 
BASE C1*_sense -1970atgccttggaacattttgtgaccccaggaacacatcacgaaatatttacc-1920 
BASE C1*_anti-sense -1920ggtaaatatttcgtgatgtgttcctggggtcacaaaatgttccaaggcat-1970 
BASE random _sense atcagtctagaactacaactaatctgtgttcatacaagttatagtttcta 
BASE random_anti-sense tagaaactataacttgtatgaacacagattagttgtagttctagactgat 
BASE EH 100_sense -1970atgccttggaacattttgtgaccccaggaacacatcacgaaatatttaccaaactggatctttctg 
tttacattacaatgatagcgtgtacatatttcac-1870 
BASE EH 100_anti-sense -1870gtgaaatatgtacacgctatcattgtaatgtaaacagaaagatccagtttggtaaatatttcgtg 
atgtgttcctggggtcacaaaatgttccaaggcat-1970 
positiv controlle pS2_sense -414ccttcccttccccctgcaaggtcacggtggccaccccgtgagccactgtt-364 
ERE1_sense         (control) taatggaaGGTCAgtcTGACCtgagcacag 
ERE1u_anti-sense    (control) ctgtgctcaGGTCAgacTGACCttccatta 
EREmut_sense         (control) taatggaagcacagtctgtcctgagcacag 
EREmutu_anti-sense(control) ctgtgctcaggacagactgtgcttccatta 
 
20. Chromatin immunoprecipitation (ChIP) assay 
Cells were grown in 10 cm plates when necessary deprived of hormone for 3 days before stimulation 
with either vehicle (EtOH), 10-8 M E2 or 10-6M ICI182,780 for indicated times. Cells were crosslinked 
with 1 % formaldehyde for 15 min at room temperature. The reaction was stopped by addition of 
gylcin to the final concentration of 0.125 M. After two washes with cold PBS cells were scraped in  
1 ml collection buffer (10 mM Tris-HCl, (pH 8.0), 150 mM NaCl, 1 mM EDTA) and collected for 5 
min at 3000 xg. Cell pellet was resuspended in 400 µl lysis buffer (1 % SDS, 10 mM EDTA, 50 mM 
Tris-HCl (pH 8.0), 10 mM ß-glycerophosphate, 1 mM Na3VO4, proteinase inhibitors). Chromatin was 
sonicated to about 500 bp fragment size and cell debris was sedimented by centrifugation at 14,000 xg 
for 10 min.The supernatant was saved and diluted to 10 ml with ChIP dilution buffer (0.01 % SDS,  
1.1 % Triton X-100, 1.2 mM EDTA, 16.7 mM Tris-HCl, pH 8.0, 167 mM NaCl, 10 mM ß-
glycerophosphate, 1 mM Na3VO4, proteinase inhibitors). Chromatin was either frozen at –80 °C for 
later use or processed immediately. 100 µl chromatin were incubated with 0.4 µg antibody or IgG (or 
nothing for input samples) for 4h or over night. To recover the protein-DNA-complexes 50 µl 50 % 
Protein A slurry (for goat antibodies Protein G was used) pre-absorbed with sheared salmon sperm 
DNA were added, and incubated for 2-3 h rotating at 4 °C. For the subsequent washing steps BioRad 
mini columns were prepared by adding 500 µl dilution solution. After transfer of the 
immunoprecipitations to the columns the tubes were rinsed with 500 µl dilution solution to ensure 
complete transfer of the beads. Subsequent washing steps were as follows: 2x with 1 ml TSEI (0.1 % 
SDS, 1 % Triton X-100, 2 mM EDTA, 20 mM Tris-HCl (pH 8.0), 150 mM NaCl), 2x with 1 ml TSEII 
(0.1 % SDS, 1 % Triton X-100, 2 mM EDTA, 20 mM Tris-HCl (pH 8.0), 500 mM NaCl), 2x with 
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TSEIII (1 mM EDTA, 10 mM Tris-HCl (pH 8.0), 1 % NP-40, 1 % sodium deoxycholate, 0.25 M 
LiCl), and 3x with 1 ml TE buffer (10 mM Tris (pH 8.0), 1 mM EDTA).  
For DNA recovering the bottom of the mini columns were capped and beads were resupended in  
400 µl TE buffer and transferred to fresh tubes. Additional 500 µl of TE buffer were used to rinse the 
columns and transferred to the same tubes. After centrifugation at 3,000 xg for 2 min supernatant was 
aspirated and 100 µl of 10 % Chelex (in water) added. Beads were vortexed and incubated at 95 °C for 
10 min to reverse the crosslinking. To release DNA and digest the proteins 2 µl Proteinase K solution 
(Invitrogen) was added and incubate at 55 °C for 30 min and then inactivated at 95 °C for 10 min. 
Supernatant was cleared by centrifugation for 2 min at full speed and transferred to a fresh tube. 
Remaining beads were washed with 100 µl water, sedimented again and supernatant was transferred to 
the same tube as in previous step. 2-5 µl were used as template in subsequent PCRs. 
 
Table M11: Primers used for ChIP  
Primer name sequence product size (bp)  
BASE -575 rev ccatctgctggcaaagatgtagtga 184  
BASE w2 fwd  gatctttccaatgtttgcctga   
CTSD distal fwd cctcctcaactgctcttgca 172  
CTSD distal rev gcggctgagatgctgagtca   
CTSD TSS fwd accggtccgggtgcaaacacg 189  
CTSD TSS rev ctgaggcttcacctgacgagc   
CTSD unspecific fwd cctcacaggtgcgtatctca 117  
CTSD unspecific rev agcaaggggtgaaagatggt   
 
21. ChIP-on-Chip 
ChIP-on-ChIP experiments were performed by Agilent Technologies including Chromatin 
immunoprecipitation, fluorescent labelling with Cy3 (input) and Cy5 (immunoprecipitated material), 
hybridiziation to custom made promoter array provided by Agilent. Chromatin from MCF7 cells 
grown in normal media was provided by Heike Brand (EMBL, Gannon laboratorium). The array 
covered promoter regions of selected genes from -8 kb to +2 kb with 60 bp probes in 200 bp intervals. 
Repetitive sequences were omitted.  
 
22. Expression analysis of BASE in human breast cancer tissues  
(Department of Surgery, National University of Ireland, Galway, Ireland; D. Coyle, N. Miller, RE Mc 
Neill, MJ. Kerin) 
Primary breast tumours were obtained from the Department of Surgery Biobank (Dept. of Surgery, 
University College Hospital, Galway) and divided into 6 groups of age-matched patients. The groups 
are summarized in table M12.  
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Table M12: Summary of patient groups 
Patient Group Progression of breast cancer at 5 year follow-up 
Metastasis-free (n=11) No metastasis of breast cancer detected 
Bone Metastasis (n=8) Bone metastasis only 
Bone and Visceral Metastasis (n=9) Metastasis to both bone and viscera 
Visceral metastasis (n=2) Metastasis to viscera only 
Benign Non-applicable, no follow-up required 
Normal Non-applicable, no follow-up required 
 
Total RNA was isolated and cDNA was synthesized using Superscript III reverse transcriptase 
(Invitrogen) according to manufacturers instruction. BASE expression was analysed in end-point 
PCRs using Amplitaq Gold® DNA polymerase (Applied Biosystems, Warrington, UK) or in 
quantitative RT-PCR using Taqman Universal Master mix (Applied Biosystems, Warrington, UK). 
BASE expression levels were normalized against the endogenous control PPIA gene expression levels 
by subtracting the average PPIA cycle threshold (Ct) from the average BASE Ct for each cDNA 
sample, yielding a level of mRNA expression for the target molecule relative to the endogenous RNA 
reference gene (ΔCT). The ΔCT for our calibrator sample, the breast cancer cell line T47D, was 
subtracted from the ΔCT values for all cDNA samples to yield mRNA expression relative to the 
calibrator sample (ΔΔCT). The relative quantity of gene expression for each sample was calculated 
using the formula 2-ΔΔCT (Livak & Schmittgen, 2001). 
 
23. Generation of CTSD reporter constructs 
Two sections of the CTSD promoter were amplified using FastStart Taq Polymerase (Roche) and the 
primers listed below. The first primer pair (distal) flanks the -9698 to -8725 bp segment containing a 
putative enhancer while the second pair (proximal) amplifies the -753 to +96 segment containing the 
transcription start site and the proximal promoter. The PCR products were cloned into pGL3-basic 
vector both separate and combined using the restriction sites introduced by the primers.  
To mutate the almost perfect ERE in the distal part the mut dERE primers, which introduce an EcoR1 
site for easier screening, were used. All constructs were verified by sequencing. 
 
Table M13: CTSD cloning and mutation primer. Introduced restriction sites for cloning are indicated 
in italic. Mutated bases are displayed as capital letters.  
 
Primer name sequence product size  
luc distal fwd     (Nhe1) at gctagc atttgtgatcctggaaggtcaggt 973 bp  
luc distal rev      (BglII)  gt agatct cctcctcttagggctgagtcactg   
luc prox fwd     (BglII) gt agatct gagttgacgtgagtggacaaaagg 849 bp  
luc prox rev      (HindIII) ac aagctt gtgcgcttatagccgggatgac   
mut dERE fwd  (EcoR1)       tCCg gAATTCggtTgccc cagctctgagagtg   
mut dERE rev (EcoR1)       gggcAaccGAATTc cggaagagaaagggggctgcg   
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24. Summary of constructs 
 
 
pGL3-basic- promoter deletions 
 
 
pGL3- basic - enhancer deletions 1 
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pGL3- basic - enhancer deletions 2 
 
 
pGL3-enhancer constructs - core promoter identification 
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pGL3-promoter constructs - to test enhancer competence 
 
 
pGL3- basic – constructs containing mutations 
 
 
pGL3- basic - mutations in restricted background 
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ABBREVIATIONS 
 
 
3C chromatin-conformation-capturing 
AF-1 / 2 activation function 1 / 2 
AhR aryl hydrocarbon receptor 
AI aromatase inhibitors 
ATP adenosine triphosphate 
BASE breast cancer and salivary gland expression gene 
BPI bacterial/permeability-increasing protein 
BRCA1/2 breast cancer 1 gene/ breast cancer 2 gene 
BSA bovine serum albumin 
cAMP cyclical adenosine monophosphate 
cDNA  complementary DNA 
CDS coding sequence 
ChIP chromatin immunoprecipitation 
CHX cycloheximide 
C-terminus carboxy-terminus 
CTSD cathepsin D 
DAPI 4,6-diamino-2-phenylindole 
DBD DNA binding domain 
dNTP deoxy nucleotide triphosphate 
dsDNA double-stranded DNA 
E2 17ß-estradiol 
E4BP4 E4 binding protein 
EGFR epidermal growth factor receptor (HER-1, Neu) 
EH enhancer 
ELOVL2 elongation of very long chain fatty acids protein 2 
EMSA electromobility shift assays  
ERα estrogen receptor alpha 
ERE estrogen response element 
ERR estrogen-related receptor  
ERß estrogen receptor beta 
EST expressed sequence tag 
EtOH ethanol 
FCS fetal bovine serum 
FoxA1 forkhead factor A1 
GAPDH glyceraldehyde-3-phosphate dehydrogenase 
Gata-1 GATA-binding protein 1, erythroid transcription factor 1 (ERYF1)  
GFP green fluorescent protein 
GnRH gonadotropin-releasing hormone 
GR glucocorticoid receptor 
GRE glucocorticoid response element 
GREB1 gene regulated by estrogen in breast cancer protein 
HAT histone acetyl transferases 
HDAC histone deacetylase 
HER-1 EGFR, Neu 
HER-2 ErbB2 (((erythroblastic leukaemia viral oncogene homolog????????))) 
HMT histone methyl transferases 
IgG immunoglobulin G 
IL-6 interleukin 6 
INSM1 zinc finger protein insulinoma-associated 1, IA-1 
IRF-3 interferon regulatory factor 3 
kDa kilo Dalton 
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LBD ligand binding domain 
LBP ligand binding pocket 
Luc luciferase 
Lys lysin 
MAPK mitogen-activated protein kinase 
mRNA messenger RNA 
NCoR nuclear receptor corepressor 
NFIL3 nuclear factor, interleukin 3-regulated, E4BP4 
NMD nonsense-mediated mRNA decay 
N-terminus amino-terminus 
NURD nucleosome remodelling and deacetylating complex 
Oct-1 octamer-binding transcription factor 1 (Pou2F1) 
PCR polymerase chain reaction 
PI3K phosphatidyl-inositol-3-kinase 
PLUNC palate, lung, and nasal epithelium carcinoma-associated protein 
PPIA peptidyl-prolyl isomerase 
pS2 TFF1, trefoil factor 1 
qPCR quantitative PCR 
RFP red fluorescent protein 
RLU relative luciferase units 
RT reverse transcriptase 
SBEM small breast epithelial mucin 
SCLC small-cell lung cancer 
Ser serin 
SERM selective estrogen receptor modulator 
SHP short heterodimer partner 
siRNA small interference RNA 
SUMO small ubiquitin-like modifier 
Tam Tamoxifen 
TERP1/2 truncated estrogen receptor product 1/2 
TNF tumor necrosis factor 
TR thyroid hormone 
TSS transcription start site 
UTR untranslated region 
ZNF219 zinc finger protein 219 
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